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ABBREVIATION INDEX 
ADMA  Asymmetric dimethylarginine 
ALS   Amyotrophic lateral sclerosis 
EWS   Ewing sarcoma 
FTD  Frontotemporal dementia 
FUS  Fused in sarcoma (also TLS) 
G3BP1  Ras GTPase activating protein (SH3 domain) binding protein 1                
(also G3BP stress granule assembly factor 1) 
hnRNP  Heterogeneous ribonucleoprotein 
HSP  Heat shock protein 
IDP  Intrinsically disordered protein 
LC   Low complexity 
LLPS  Liquid-liquid phase separation 
MAPT  Microtubule-associated binding protein Tau 
MMA  Monomethyl arginine 
NLS  Nuclear localization signal 
PRMT  Protein arginine methyltransferase 
PTM  Post-translational modification 
PY-NLS  Proline (P) -tyrosine (Y) -NLS 
RAN   GTP-binding nuclear protein Ran or repeat associated non-ATG (translation) 
RBP  RNA-binding protein 
RGG/RG Arginine (R) – glycine (G) -glycine (G) / arginine (R) – glycine (G) 
RNP   Ribonucleoprotein 
SAM  S-adenosylmethionine 
SDMA  Symmetric dimethylarginine 
SG  Stress granule 
TAF15   TATA binding protein-associated factor 15 
TIA1  T-cell-restricted intracellular antigen 1 
TDP-43  TAR DNA-binding protein of 43 kDa 
TNPO1  Transportin 1 (also Karyopherin β2) 
UMA  Unmethylated arginine 
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ABSTRACT 
Nuclear depletion and cytosolic aggregation of the RNA-binding protein FUS are pathological 
hallmarks in a subset of patients suffering from frontotemporal dementia (FTD) and amyotrophic 
lateral sclerosis (ALS). Defective nuclear import of FUS by its nuclear import receptor Transportin 
(TNPO1) is a major pathomechanism contributing to the pathogenesis of ALS and FTD with FUS 
pathology (ALS-FUS, FTD-FUS). Mutations in the nuclear localization signal (NLS) of FUS that disrupt 
binding to TNPO1 are associated with ALS-FUS. In FTD-FUS patients, no such NLS mutations have been 
identified so far, but TNPO1 is aggregated and arginine methylation of FUS, which regulates FUS-
TNPO1 interaction, is lost. Defective nuclear import of FUS causes an accumulation of FUS in the 
cytoplasm and, upon cellular stress, favors recruitment of FUS into stress granules (SGs), which have 
been proposed to be condensation sites for aberrant phase separation and aggregation of FUS. It is 
not clear which factors suppress phase separation and aggregation in healthy brains. Furthermore, it 
remains also ambiguous whether the loss of arginine methylation is involved in the aggregation 
process and which physiological roles arginine methylation of FUS plays. Thus, these questions were 
addressed in this Ph.D. thesis.    
I could show that TNPO1 has a dual function towards FUS, namely it not only mediates nuclear import 
of FUS, but also acts as a FUS chaperone in the cytoplasm and thereby suppresses RGG/RG-driven 
liquid-liquid phase separation (LLPS), SG association and aggregation of FUS. The chaperone activity is 
specific to TNPO1, since other FUS RGG/RG domain interacting proteins or other importins are not 
able to suppress phase separation of FUS. ALS-associated FUS-NLS mutations impairing nuclear import 
of FUS furthermore reduce the chaperone activity of TNPO1. Moreover, I could demonstrate that 
arginine methylation also has a suppressive effect on LLPS and SG partitioning of FUS. Loss of arginine 
methylation, as seen in FTD-FUS patients, enhances phase separation and promotes SG recruitment 
of FUS. These data reveal two novel regulatory mechanisms of liquid phase homeostasis that suppress 
phase separation and SG recruitment of FUS and are impaired in ALS-FUS and FTD-FUS, respectively. 
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1 INTRODUCTION 
1.1 ALS and FTD: late-onset neurodegenerative diseases 
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are fatal, late-onset 
neurodegenerative diseases for which no curative treatments are available. ALS, also known as Lou 
Gehrig´s or Charcot´s disease, is the most common adult motor neuron disease caused by a 
progressive degeneration of upper and lower motor neurons. The neuronal death causes muscle 
weakness, atrophy and spasticity progressively affecting the patient´s moving, swallowing, speaking 
and breathing abilities (Rothstein, 2009). Eventually, patients die of respiratory failure within 1-5 years 
of disease onset (Kiernan et al., 2011). While most ALS cases are considered sporadic (sALS), 5-10% of 
cases are familial (fALS), showing an autosomal dominant pattern of inheritance (Da Cruz and 
Cleveland, 2011).  
After Alzheimer´s disease (AD), FTD is the second most prevalent form of dementia in patients younger 
than 65 years. Hallmarks of the disease are selective degeneration of the frontal and temporal lobes 
hence the term FTLD (frontotemporal lobar degeneration) is commonly used to describe the 
neuropathology in FTD. Clinical characteristics of FTD are severe and progressive alterations in 
personality, behavior and/or language difficulties (Neumann et al., 2012; Rademakers et al., 2012). 
Clinically, FTD cases can be subdivided into behavioral variant FTD (bvFTD) and two forms of primary 
progressive aphasia: progressive non-fluent aphasia and semantic dementia (Gorno-Tempini et al., 
2011; Rascovsky et al., 2011). In contrast to AD, memory is relatively well preserved at early stages of 
FTD, but with disease progression patients suffer from severe cognitive and physical decline and 
eventually die within 3-10 years of disease onset. Around 25-50% of all cases are classified as familial 
FTD (Rademakers et al., 2012; Rohrer et al., 2009; Seelaar et al., 2008). 
ALS and FTD have been shown to have a large clinical overlap, since up to 15-20% of FTD cases exhibit 
clinical criteria for ALS and vice versa. While up to a third of FTD patients show motor neuron 
dysfunction, 30-50% of ALS patients suffer from cognitive defects (Lomen-Hoerth et al., 2002; Murphy 
et al., 2007; Wheaton et al., 2007). 
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1.2 Genetic and neuropathological overlap of ALS and FTD 
Due to extensive studies in genetics and neuropathology of ALS and FTD, the molecular culprits for 
the clinical disease continuum have been largely uncovered (Ling et al., 2013; Van Langenhove et al., 
2012). These studies have revealed that the clinical overlaps of ALS and FTD is also reflected in a 
genetic and neuropathological overlap:  
The most common genetic cause of ALS and FTD is an abnormal GGGGCC hexanucleotide repeat 
expansion in a non-coding region of the C9orf72 gene (DeJesus-Hernandez et al., 2011; Mackenzie and 
Neumann, 2016; Renton et al., 2011) (Fig. 1A). While healthy individuals typically carry 2-22 
hexanucleotide repeats in the C9orf72 gene, ALS/FTD patients can have hundreds or even thousands 
of repeats (DeJesus-Hernandez et al., 2011; Renton et al., 2011; van Blitterswijk et al., 2012).  
Another genetic cause for ALS are mutations in the TARDBP gene (encoding for the TDP-43 protein) 
which have been associated with 4% of familial and 1.5% of sporadic ALS cases. So far,  more than 38 
ALS-linked TARDBP mutations have been identified (Mackenzie et al., 2010). Notably, most of the 
disease-linked mutations in TDP-43 have been identified in the prion-like C-terminal domain (Cushman 
et al., 2010; Fuentealba et al., 2010; Hock and Polymenidou, 2016; Lagier-Tourenne et al., 2010; Ling 
et al., 2013). In addition to mutations in TDP-43, cases with C9orf72 repeat expansions also show TDP-
43 pathology (Mackenzie et al., 2013). Other genetic causes for TDP-43-positive inclusion in FTD are 
mutations in the granulin gene (GRN) and in the valosin containing protein gene (VCP) (Mackenzie and 
Neumann, 2016) (Fig. 1A) which is implicated in autophagy (Ju et al., 2009). Based on the anatomical 
distribution, morphology and composition of inclusion, pathology in FTD-TDP is subdivided in four 
different patterns (type 1-4) (Mackenzie et al., 2010). Mutations in FTD seem to be quite rare, since 
only three different TARDBP mutations have been identified in patients so far (Mackenzie and 
Neumann, 2016; Mackenzie et al., 2010). 
In 2009, mutations in FUS (Fused in sarcoma) have been identified in a subset of familial ALS (fALS) 
patients that are predominantly clustered in the C-terminal RGG3-PY domain (Kwiatkowski et al., 
2009; Vance et al., 2009). Unlike in ALS-FUS patients, no FUS mutations in clinical FTD have been 
confirmed (Neumann et al., 2009; Rohrer et al., 2009; Snowden et al., 2011; Urwin et al., 2010) (Fig. 
1A). The majority of cases with proven FTD-FUS pathology are sporadic (Urwin et al., 2010).   
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Figure 1: Disease continuum of ALS and FTD. A) ALS and FTD are the extreme ends of an overlapping disease 
spectrum sharing clinical symptoms (ALS in red and FTD in purple). Major genetic risk factors are delineated 
according to the likelihood of identified mutations to cause ALS or FTD. B) Distribution of the major accumulating 
protein in pathological inclusion in ALS and FTD. Inclusions of TDP-43 and FUS in ALS and FTD represent the 
neuropathological overlap of the two diseases. Figure reproduced from (Ling et al., 2013) with permission from 
Elsevier. 
 
The molecular pathology of ALS and FTD is characterized by a nuclear depletion, cytosolic 
mislocalization and aggregation of RBPs in neurons and glia cells (Fig. 2). In 97% of all ALS cases and 
almost 50 % of FTD patients, pathological inclusions positive for TDP-43 have been identified (Arai et 
al., 2006; Neumann et al., 2006) (Fig. 1B). In addition to the above mentioned TDP-43 pathology, three 
different, not mutually exclusive, pathomechanisms have been proposed for C9orf72 repeat 
expansions, (Gitler and Tsuiji, 2016): First, patients carrying C9orf72 repeat expansions display repeat 
RNA foci that sequester RNA-binding proteins to the nucleus (Haeusler et al., 2014; Lee et al., 2013; 
Mori et al., 2013b), most likely leading to disturbances in RNA metabolism (Kwon et al., 2014). Second, 
both sense (GGGGCC) and antisense (GGCCCC) repeat RNA transcripts can be translated by 
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unconventional repeat associated non-ATG-initiated (RAN) translation, giving rise to five different 
dipeptide repeat (DPR) proteins, namely glycine-arginine (GR), proline-arginine (PR), glycine-alanine 
(GA), glycine-proline (GP) and proline-alanine (PA) (Ash et al., 2013; Gendron et al., 2013; Mori et al., 
2013a; Mori et al., 2013b; Zu et al., 2013). Third, haploinsufficiency leading to reduced expression of 
C9orf72 gene product is considered as a third possible mechanism how hexanucleotide repeat 
expansions in the C9orf72 gene contribute to pathogenesis (Gitler and Tsuiji, 2016).  In addition, a 
subset of ALS and FTD cases are characterized by cytoplasmic aggregation of FUS. ALS cases with FUS 
pathology are usually associated with FUS mutations which account for ~ 4% of familial and <1 % of 
sporadic ALS cases (Kwiatkowski et al., 2009; Mackenzie and Neumann, 2016; Vance et al., 2009). 
Pathological inclusions containing FUS were found in 5-10% of all FTD cases (Neumann et al., 2009) 
(Fig. 1B). FTD-FUS includes three distinct neuropathological subgroups: atypical FTLD with ubiquitin-
positive inclusions (aFTLD-U), neuronal intermediate filament inclusion disease (NIFID) (Neumann et 
al., 2009) and basophilic inclusion body disease (BIBD) (Munoz et al., 2009). In very rare ALS cases, 
other RBPs, e.g. hnRNP-A1 and hnRNP-A2, have also been identified in pathological aggregates (Kim 
et al., 2013). 
 
 
Figure 2: TDP-43 and FUS pathology in ALS/FTD. In healthy brains, FUS and TDP-43 are mainly localized in the 
nucleus (normal, left). Immunohistochemistry of TDP-43 and FUS showing characteristic depletion of diffuse 
nuclear localization and accumulation in cytosolic and rarely nuclear inclusions in post mortem brains of ALS and 
FTD patients (right, ALS/FTD pathology). Figure reproduced from (Ederle and Dormann, 2017) with permission 
from John Wiley and Sons.  
 
Besides the above-mentioned characteristic nuclear depletion and cytosolic aggregation of the 
specific RBPs (Fig. 2), TDP-43 and FUS cases in ALS and FTD share other pathological features. First, 
TDP-43 inclusions have been reported to be positive for p62 and ubiquitin and TDP-43 is 
hyperphosphorylated (Arai et al., 2006; Neumann et al., 2006). Similarly, immunoreactivity for 
ubiquitin and p62 in inclusions is also a common hallmark of ALS-FUS and FTD-FUS (Baumer et al., 
2010; Neumann et al., 2009; Seelaar et al., 2010). p62 facilitates autophagic degradation of 
12 
 
ubiquitinated proteins (Pankiv et al., 2007) and its aggregation may impair the ubiquitin-proteosome 
system (UPS) (Korolchuk et al., 2010). Second, pathological TDP-43 and FUS inclusion in ALS and FTD 
were shown to co-localize with various stress granule (SG) marker proteins, respectively. While co-
localization of TIA1, PABP-1 and Staufen was found in TDP-43-positive inclusion in ALS patients, TDP-
43 inclusion in FTD cases were shown to contain PABP-1 and eIF3 (Bentmann et al., 2013). Inclusions 
in both ALS-FUS and FTD-FUS have been demonstrated to be positive for PABP-1 and eIF4G (Baumer 
et al., 2010; Dormann et al., 2010), but cytoplasmic FUS aggregates immunoreactive for TIA1 have 
been found only in FTD-FUS patients (Fujita et al., 2008). 
In addition to several pathological commonalities, there are also slight differences between ALS and 
FTD associated with the same RBP. In the cortex of FTD-TDP patients, TDP-43 is, in addition, 
proteolytically cleaved to C-terminal fragments that are highly aggregation-prone and co-deposited 
with the full-length TDP-43 protein (Arai et al., 2006; Neumann et al., 2006). Notably, in pathological 
inclusions in the cortex and hippocampus of FTD-TDP patients, full-length TDP-43 is less abundant 
than phosphorylated C-terminal TDP-43 fragments, whereas inclusions in the spinal cord of ALS-TDP 
patients contain mainly phosphorylated full-length TDP-43 (Hock and Polymenidou, 2016; Igaz et al., 
2008). Moreover, co-labeling of FTD-TDP inclusions with the SG marker PABP-1 was only 
demonstrated in presence of full-length TDP-43 in spinal cord but not in hippocampal and cortex 
indicating that these converging observations may emerge from the fact that different brain regions 
have different TDP-43 species (Bentmann et al., 2013). Although pathological inclusions in both ALS-
FUS and FTD-FUS patients contain FUS, the inclusions are characterized by a distinct protein 
composition (Dormann et al., 2012; Neumann et al., 2011; Neumann et al., 2012) (see section 1.4 for 
further details). In contrast to ALS with FUS mutations, co-deposition of two closely related proteins, 
namely Ewing sarcoma protein (EWS) and TATA-binding protein-associated factor 15 (TAF15), has 
been discovered only in FTD-FUS cases (Davidson et al., 2013; Neumann et al., 2011). Furthermore, 
the characteristic pattern of arginine methylation of FUS is lost (Dormann et al., 2012; Suarez-Calvet 
et al., 2016) and the nuclear import receptor Transportin (TNPO1) co-aggregates (Brelstaff et al., 2011; 
Davidson et al., 2013; Neumann et al., 2012; Troakes et al., 2013). These differences between ALS and 
FTD with FUS pathology indicate that both diseases develop from different pathomechanisms 
(Dormann and Haass, 2013). 
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1.3 FUS and other FET family proteins 
FUS is a member of the FET protein family that also includes two other members, Ewing sarcoma 
protein (EWS) and TATA binding protein-associated factor 15 (TAF15) (Tan and Manley, 2009). The FET 
proteins have a homologous domain structure with an N-terminal transcriptional activation domain, 
several nucleic acid-binding motifs as well as a C-terminal PY-NLS (Fig. 3).  
FUS, also known as translocated in liposarcoma (TLS), is a ubiquitously expressed DNA/RNA-binding 
protein with a length of 526 amino acids. FUS contains an N-terminal serine-tyrosine-glycine-
glutamine-rich (SYGQ) domain which is commonly referred to as low-complexity (LC) domain due to 
its low-amino acid complexity. It is also termed “prion-like domain” due to its similarity to yeast prions 
(Alberti et al., 2009; Cushman et al., 2010). The SYGQ-rich domain is thought to mediate FUS 
aggregation (Burke et al., 2015; Kato et al., 2012; Murakami et al., 2015; Patel et al., 2015; Sun et al., 
2011) and self-assembly of FUS (Yang et al., 2014) and is involved in transcriptional activation (Crozat 
et al., 1993; Rabbitts et al., 1993). The finding that translocation of the SYGQ-rich domain resulting in 
fusion to transcription factors, such as CHOP, gives rise to fusion oncogenes in human myxoid 
liposarcomas demonstrates its involvement in transcriptional activation.  
Moreover, FUS harbors multiple domains with nucleic acid binding motifs that mediate both protein-
RNA as well as protein-protein interactions. The first arginine-glycine-glycine rich domain (RGG1) is 
followed by a highly conserved RNA recognition motif (RRM) and two more RGG domains (RGG2 and 
RGG3) that flank a zinc finger (ZnF).  
In addition, FUS contains a C-terminal non-classical NLS, composed of a proline-tyrosine NLS (PY-NLS) 
(Lee et al., 2006) and the preceding RGG3 domain (Dormann et al., 2012). The nuclear import receptor 
TNPO1, also known as Karyopherin β2, binds to the NLS and mediates the import of PY-NLS-containing 
proteins from the cytoplasm into the nucleus (Lee et al., 2006). 
14 
 
 
Figure 3: Domain structure and disease-associated mutations of FUS. FUS harbors a N-terminal prion-like 
serine-tyrosine-glycine-glutamine (SYGQ)-rich domain, three arginine-glycine-glycine (RGG)-rich domains, an 
RNA recognition motif (RRM), and a zinc-finger (ZnF) and a non-classical PY-nuclear localization signal (PY-NLS). 
The RGG3 domain together with the PY-NLS function as the protein´s NLS, recognized by the nuclear import 
receptor Transportin (TNPO1). A number of dominant mutations in FUS have been identified in ALS (black) and 
rare FTD (blue) cases (including missense, deletions (del), insertions (ins), frameshifts (fs), and truncations (X).  
Most disease-linked mutations cluster in the C-terminal NLS. Figure reproduced from (Dormann and Haass, 
2013) with permission from Elsevier. 
 
 
1.4 Nuclear import defects as a key pathomechanism in ALS and FTD 
The pathology of a subset of ALS and FTD patients is characterized by a sequestration of RBPs, such as 
TDP-43 and FUS, from the nucleus into cytoplasmic inclusions in neurons and glia cells indicating 
nuclear import defects (Fig. 2). 
Nuclear import of FUS is mediated by interaction of its C-terminal NLS with TNPO1 that translocates 
FUS across the nuclear pore complex into the nucleus. The FUS-NLS is composed of the PY-NLS and 
the neighboring RGG3 domain (Dormann et al., 2012). Cargo binding of TNPO1 in the cytoplasm and 
cargo release in the nucleus is regulated by the small GTPase Ran and its proteins regulating its GTP-
bound state (Gorlich et al., 1996). In the cytoplasm, low levels of RanGTP allow tight binding of TNPO1 
to cargoes containing a PY-NLS. In the nucleus, RanGTP binds TNPO1 with high affinity and mediates 
dissociation of the import complex (Lee et al., 2006).  
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1.4.1 Nuclear import defects in fALS-FUS 
FUS mutations have been identified to cause familial ALS with FUS pathology. These ALS-associated 
mutations are mostly missense, nonsense or frameshift mutations in the C-terminal RGG3-PY domain  
(Dormann and Haass, 2013; Kwiatkowski et al., 2009; Vance et al., 2009) (Fig. 3). Cell culture studies 
showed that fALS-associated point mutations in the PY-NLS, e.g. R521G, R522G, R524S, P525L, show 
varying degrees of cytosolic mislocalization, ranging from slightly mislocalized for the R521G and 
R524S mutations (16 and 21% cytosolic, respectively) over an intermediate mislocalization for R522G 
(45%) to a very severe phenotype for P525L (65 %) (Dormann et al., 2010). With an early disease onset 
in the mid-twenties and a rapid disease progression, the P525L mutation causes an extremely 
aggressive form of fALS (Chio et al., 2009; Kwiatkowski et al., 2009). Hence, there is a correlation 
between the degree of cytosolic mislocalization of FUS with clinical symptoms, i.e. the more FUS is 
mislocalized the earlier and more severe the disease progresses (Dormann et al., 2010). Dormann and 
colleagues demonstrated that ALS-associated mutations in the NLS or complete deletion of the signal 
sequence drastically impair or disrupt TNPO1-mediated  nuclear import of FUS (Dormann et al., 2012; 
Dormann et al., 2010). Mouse models carrying ALS-associated mutations or deletions of the NLS of 
FUS exhibit age-dependent degeneration of motor neurons (Devoy et al., 2017; Scekic-Zahirovic et al., 
2017; Sharma et al., 2016), demonstrating that impaired nuclear import of FUS indeed causes motor 
neuron degeneration. Together, these studies provide strong evidence that defective nuclear import 
of FUS is a key pathomechanism of ALS-FUS.  
 
1.4.2 Observed defects in FTD-FUS 
In contrast to fALS-FUS, no mutations have been identified in FTD-FUS cases so far (Neumann et al., 
2009; Rohrer et al., 2009; Snowden et al., 2011; Urwin et al., 2010). Although pathological inclusions 
in both ALS-FUS and FTD-FUS patients are FUS-positive, they are completely distinct in protein 
composition (Dormann et al., 2012; Neumann et al., 2011; Neumann et al., 2012). Different from ALS-
FUS, cytoplasmic inclusion in FTD-FUS do not only contain FUS, but also the other two members of the 
FET protein family, EWS and TAF15 (Neumann et al., 2011). Interestingly, the nuclear import receptor 
TNPO1 also shows nuclear depletion and co-aggregation in post mortem brains of FTD-FUS patients 
(Brelstaff et al., 2011; Davidson et al., 2013; Neumann et al., 2012; Troakes et al., 2013). This indicates 
that TNPO1-mediated nuclear import could be impaired in these patients, although a general defect 
in the TNPO1 import machinery seems unlikely as other PY-NLS containing TNPO1 cargoes, such as 
hnRNP-A1, are not altered. This points to further defects specifically affecting the FET family proteins 
(Neumann et al., 2011) (for details see section 1.7). 
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1.4.3 Nuclear import defects in TDP-43 proteinopathies and C9orf72-ALS/FTD 
Nuclear import defects seem not to be exclusive for cases with FUS aggregates, but may also play an 
important role in ALS/FTD cases with TDP-43 pathology. TDP-43 is imported into the nucleus by the 
heterodimeric nuclear import receptor Importin α/Importin β1, also known as karyopherin α/β1 
(Nishimura et al., 2010; Winton et al., 2008). A study of Nishimura and colleagues showed that 
knockdown of Importin β1 and cellular apoptosis susceptibility protein (CAS, member of the 
karyopherin β family, also known as exportin-2), which recycles karyopherin αs back to the cytoplasm, 
results in cytoplasmic accumulation of TDP-43. Additionally, CAS and Importin α2 levels are reduced 
in spinal cord and cortex of FTD patients showing TDP-43 pathology (Nishimura et al., 2010). Notably, 
aggregated TDP-43 sequesters components of the nucleocytoplasmic transport machinery, such as 
the nucleoporins Nup98, Nup214, and Nup358, and impairs nuclear protein import as well as mRNA 
export (Chou et al., 2018). Moreover, Kinoshita and colleagues showed that also in sporadic and SOD1-
linked ALS cases nuclear importin β is significantly reduced (Kinoshita et al., 2009). Several recent 
studies in yeast and flies have linked the C9orf72 repeat expansion with dysregulated nuclear 
transport (Boeynaems et al., 2016; Freibaum et al., 2015; Jovicic et al., 2015; Zhang et al., 2015). 
Unbiased genetic screens to identify modifiers of C9orf72 toxicity revealed several factors implicated 
in nucleocytoplasmic shuttling as major toxicity modulators. Zhang et al. reported that Ran GTPase-
activating protein 1 (RanGAP1) overexpression rescues C9orf72 repeat expansion-induced toxicity 
while RNAi-mediated knockdown of RanGAP1 enhances toxicity. Furthermore, upregulation of 
importins rescues eye degeneration (Zhang et al., 2015). Concordantly, Boeynaems and colleagues 
demonstrated enhancement of degenerative eye phenotypes in Drosophila caused by poly-PR toxicity 
upon RanGAP1 downregulation (Boeynaems et al., 2016). Homologues of human TNPO1 (Kap104 in 
yeast, Trn in fly) were identified in these genetic screens. While overexpression of Kap104 was shown 
to suppress DPR toxicity in yeast (Jovicic et al., 2016), deletion of Trn in Drosophila increased eye 
degeneration (Boeynaems et al., 2016; Freibaum et al., 2015). In all, these studies provide strong 
evidence that dysregulation of nucleocytoplasmic transport may play a crucial role in disease 
initiation, causing nuclear loss of function and cytoplasmic gain of function of RBPs in ALS/FTD 
(Boeynaems et al., 2016). 
 
1.5 Nuclear functions of FUS 
FUS is a mostly nuclear RBP with multiple functions in DNA/RNA processing at the transcriptional and 
post-transcriptional level both in the nucleus and in the cytoplasm. Due to this plethora of functions, 
it seems obvious that its sequestration from the nucleus to cytoplasmic protein inclusions leads to 
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detrimental RNA processing defects and thus may contribute to the pathogenesis of ALS and FTD 
(Ederle and Dormann, 2017). 
Originally identified as fusion oncogene, FUS was shown to be a potent transcriptional activator 
(Crozat et al., 1993; Rabbitts et al., 1993). The SYGQ-rich domain mediates FUS dimerization and 
subsequently binds transcriptionally active chromatin and thus regulates transcriptional initiation 
(Ratti and Buratti, 2016; Yang et al., 2014). Further studies revealed interactions with RNA polymerase 
II (RNAP II) and the TFIID complex, both components of the pre-initiation complex (PIC). FUS binds to 
and controls phosphorylation of the catalytic domain (CTD) of RNAP II on Serine 2 (Ser2) and thus 
regulates the activity of RNAP II (Bertolotti et al., 1996; Schwartz et al., 2012). Furthermore, FUS 
binding to ssDNA gene promotors also regulates gene expression (Tan et al., 2012). Importantly, ALS-
associated mutations of FUS were reported to reduce transcriptional regulation by reduced binding 
to chromatin and RNAPII (Schwartz et al., 2014; Yang et al., 2014). 
FUS is furthermore involved in splicing, not only by directly binding nascent pre-mRNAs, but also by 
interacting with essential components of the splicing machinery. One well-studied splice target of FUS 
is the pre-mRNA of the neuronal microtubule-associated binding protein Tau (MAPT) which has a 
complex alternative splicing regulation resulting in six different isoforms (Goedert and Spillantini, 
2011). Multiple studies demonstrated that loss of FUS causes an increase in inclusion of exons 2, 3, 
and 10, respectively (Lagier-Tourenne et al., 2012; Orozco and Edbauer, 2013; Orozco et al., 2012; 
Rogelj et al., 2012). Since Tau-pathology is associated with FTD and other neurodegenerative diseases 
(Goedert and Spillantini, 2011), aberrant splicing of MAPT may contribute to neurodegeneration in 
cases with FUS pathology (Orozco and Edbauer, 2013). Importantly, FUS also binds to its own pre-
mRNA and thus autoregulates its own expression, by repression of exon 7 splicing and subsequent 
degradation of the exon 7-skipped splice variant by nonsense-mediated decay (NMD) (Lagier-
Tourenne et al., 2012; Zhou et al., 2013). FUS has been reported to be essential for assembly of 
spliceosomes by interacting with components of the spliceosome machinery, namely SMN proteins, 
U1 small nuclear ribonucleoprotein (snRNP) and the Sm-snRNP complex (Gerbino et al., 2013; Ratti 
and Buratti, 2016; Yamazaki et al., 2012). ALS-associated FUS mutations cause a dramatic reduction of 
nuclear Gems, severe splicing impairment, and reduce FUS binding to U1-snRNP (Ratti and Buratti, 
2016; Sun et al., 2015; Tsuiji et al., 2013; Yamazaki et al., 2012; Yu et al., 2015). Since FUS interacts 
with both RNAP II and U1-snRNP, it is likely that FUS couples transcription and splicing (Yu and Reed, 
2015). 
In 1999, Baechtold and colleagues provided evidence that FUS is in involved in DNA damage repair by 
demonstrating that FUS promotes D-loop formation and homologous recombination in the repair of 
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DNA double strand breaks (DSBs) (Baechtold et al., 1999; Ratti and Buratti, 2016). FUS knock-out mice 
were shown to have defective B-lymphocyte development, high genomic instability, elevated 
radiation sensitivity as well as defects in spermatogenesis (Hicks et al., 2000; Kuroda et al., 2000). 
Furthermore, interaction of FUS with factors involved in DNA damage repair, namely Poly-ADP-ribose 
polymerase 1 (PARP-1) and HDAC1, at sites of DNA damage is required for proper DNA damage 
response (Mastrocola et al., 2013; Ratti and Buratti, 2016; Rulten et al., 2014; Wang et al., 2013). 
Consequently, FUS depletion or FUS mutations causing reduced binding to PARP-1 and HDAC1 were 
shown to cause defects in DNA repair. 
In addition, FUS also regulates processing of microRNAs (miRNAs) and long noncoding RNAs (lncRNAs). 
FUS, together with TDP-43, associates with the Drosha complex (Gregory et al., 2004). FUS binds to a 
precursor of miRNAs (pri-miRNAs) at sites of active chromatin and also recruits Drosha to these loci to 
stimulate pri-miRNA biogenesis (Morlando et al., 2012). Furthermore, FUS depletion causes reduced 
Drosha recruitment to sites of active transcription and thereby reduces biogenesis of miRNAs essential 
for neuronal functions, differentiation and synaptogenesis, e.g. of miR-9, miR-125b, and miR-132 
(Morlando et al., 2012). Importantly, FUS also regulates biogenesis of miR141 and miR200a which in 
turn bind the 3’UTR of FUS mRNA and thus downregulate FUS protein synthesis (Dini Modigliani et al., 
2014; Ederle and Dormann, 2017). The presence of ALS-linked mutations, e.g. a guanine-to-adenine 
substitution (G48A), in the 3’UTR seed sequence disrupt this auto-regulatory feed-forward loop (Dini 
Modigliani 2014). In addition to miRNAs, FUS is also interacting with diverse lncRNAs, such as NEAT1, 
which is necessary for paraspeckle formation. FUS regulates NEAT1 levels and, together with TDP-43, 
is essential for proper paraspeckle assembly (Nishimoto et al., 2013; Ratti and Buratti, 2016; 
Shelkovnikova et al., 2013; Shelkovnikova et al., 2014). ALS-linked FUS mutations have been reported 
to sequester other paraspeckle proteins to cytosolic aggregates and disrupt paraspeckle assembly, 
suggesting a contribution to pathogenesis in ALS/FTD (Shelkovnikova et al., 2013). 
 
1.6 Physiological functions of FUS in the cytoplasm 
Although FUS is a mostly nuclear RBP with multiple nuclear functions, several studies reported that 
FUS also fulfills numerous tasks of mRNA regulation in the cytoplasm, including mRNA stability, 
trafficking, and mRNA translation (Bowden and Dormann, 2016; Ratti and Buratti, 2016). FUS was 
shown to interact with the 3’UTRs of various mRNA targets (Colombrita et al., 2012; Hoell et al., 2011; 
Lagier-Tourenne et al., 2012; Rogelj et al., 2012), although FUS knockdown had no effect on mRNA 
stability for bound targets like Vps54, Taf15, and Nvl in murine motoneuronal-like cells  (Colombrita 
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et al., 2012; Ratti and Buratti, 2016). Recently, Udagawa and colleagues demonstrate that GluA1, a 
subunit of AMPA receptors, is downregulated due to decreased mRNA stability in FUS-depleted 
primary cortical neurons (Udagawa et al., 2015). 
In 2005, two studies reported that FUS is localized in RNA granules that are transported to dendrites 
and presynapses of hippocampal neurons (Belly et al., 2005; Fujii et al., 2005). Upon mGluR5 
stimulation, FUS was shown to enable mRNA transport into dendritic spines and to regulate spine 
morphology by transporting mRNAs encoding for β-actin and the actin-stabilizing factor Nd1-L (Fujii 
et al., 2005; Fujii and Takumi, 2005). Evidence for an involvement of FUS in local mRNA translation 
was provided when Yasuda and colleagues showed FUS co-localization with the tumor suppressor 
protein adenomatous polyposis coli (APC) in RNP complexes at cell protrusions and promotion of 
translation of APC-associated mRNA transcripts like Kank2 and Pkp4 (Yasuda et al., 2013). Remarkably, 
overexpressed or mutant FUS protein carrying ALS-linked mutations preferentially recruits APC-RNPs 
to cytosolic granules that are translationally active, showing that translation can take place in stress 
granule-like structures (Yasuda et al., 2013). 
 
1.7 Protein arginine methylation 
The three FET family members (FUS, EWS, TAF15) have been shown to undergo extensive asymmetric 
dimethylation at arginine residues in the RGG domains (Araya et al., 2005; Belyanskaya et al., 2001; 
Du et al., 2011; Hung et al., 2009; Jobert et al., 2009; Ong et al., 2004; Pahlich et al., 2005; Rappsilber 
et al., 2003). A remarkable difference in FTD-FUS pathology compared to ALS-FUS is that the state of 
arginine methylation of FUS is altered. Asymmetric dimethylation of FUS in healthy individuals and 
ALS-FUS patients is lost in FTD-FUS inclusions (Dormann et al., 2012; Suarez-Calvet et al., 2016) 
(detailed explanation of arginine methylation below). However, gene analysis of the responsible 
protein arginine methyltransferases (PRMTs) did not reveal any mutations or altered gene expression 
levels (Ravenscroft et al., 2013). Notably, inhibition of arginine methylation of FUS in HeLa cells and 
motor neurons rescues cytosolic mislocalization of ALS-associated FUS mutations (Dormann et al., 
2012; Suarez-Calvet et al., 2016; Tradewell et al., 2012). Surprisingly, loss of arginine methylation of 
FUS, as seen in FTD-FUS patients, enhances binding affinity of FUS to TNPO1 in vitro (Dormann et al., 
2012). Furthermore, TNPO1 co-aggregates in FTD-FUS inclusions, indicating that FUS binding to TNPO1 
itself is not impaired (Jovicic et al., 2016). 
Arginine methylation is a common post-translational modification (PTM) in mammals (Larsen et al., 
2016) and is carried out by different members of the protein arginine methyltransferase (PRMT) family 
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(Bedford and Clarke, 2009). In addition to the PRMT family, there are other putative arginine 
methyltransferases like NDUFAF7 (Zurita Rendon et al., 2014). PRMTs catalyze the transfer of a methyl 
group from the methyl group donor S-adenosylmethionine (SAM) to the guanidino nitrogen atoms of 
arginine, resulting in methylarginine and S-adenosylhomocysteine (Fig. 4). In eukaryotes three forms 
of methylarginines have been identified, namely monomethylarginine (MMA), symmetric 
dimethylarginine (SDMA), and asymmetric dimethylarginine (ADMA) (Fig. 4). The nine members of the 
PRMT family can be subdivided into three groups according to the type of methylation mark they 
establish. Type I (PRMT1, PRMT2, PRMT3, PRMT4/CARM1, PRMT6, and PRMT8) and type II (PRMT5 
and PRMT9) enzymes first establish the intermediate MMA and subsequently carry out the formation 
of ADMA or SDMA, respectively (Yang and Bedford, 2013) (Fig. 4). While for ADMA two methyl groups 
are added to one terminal nitrogen atom of the guanidine group, for SDMA the two methyl groups 
are added to one nitrogen atom each. PRMT7 is categorized as type III enzyme that only establishes 
MMA (Feng et al., 2013). Addition of a methyl group to an arginine residue eliminates one out of five 
potential hydrogen bond donors and causes a conformational change. Since arginine methylation 
increases bulkiness and hydrophobicity of a protein, protein-protein interactions can be affected both 
negatively and positively (Bedford and Clarke, 2009; Fuhrmann et al., 2015; Pahlich et al., 2006; 
Tripsianes et al., 2011; Yang and Bedford, 2013). Notably, the positive charge of arginine residues is 
not altered by the addition of methyl groups (Tripsianes et al., 2011). RGG/RG-rich motifs often play 
an important role in protein-protein interactions and nucleic acid binding and are the most common 
target motif for PRMTs (Guo et al., 2014; Thandapani et al., 2013; Wooderchak et al., 2008). 
Importantly, glycines next to arginines are supposed to facilitate the accessibility of arginines to the 
active site of PRMTs by increasing conformational flexibility (Blanc and Richard, 2017). In contrast to 
most other PRMTs, PRMT7 has been reported to favor RxR motifs neighboring lysines (Feng et al., 
2013), and PRMT4 preferentially targets arginines in an proline-glycine-methionine (PGM)-rich 
surrounding (Yang and Bedford, 2013). Type I and II PRMTs harbor a central cavity and two opposing 
active sites forming head-to-tail homodimers (Zhang and Cheng, 2003). A highly conserved SAM 
binding pocket embedded in these active sites includes an E-loop essential for substrate recognition 
and methylation (Antonysamy et al., 2012). Remarkably, type III PRMT7 acts as a homodimer-like  
structure with two catalytic domains (Debler et al., 2016; Jain et al., 2016a). 
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Figure 4: Different patterns of arginine methylation. Type I, II, and III protein arginine methyltransferases 
(PRMTs) are able to convert arginine to monomethylarginine (MMA) by transferring a methyl-group from S-
adenosylmethionine (SAM) to one of the equivalent, terminal guanidine nitrogen atoms. Type II enzymes can 
subsequently catalyze the generation of symmetric dimethylarginine (SDMA) at different nitrogen atoms. The 
production of asymmetric dimethylarginine (ADMA) is catalyzed by type I enzymes where the two methyl groups 
are added to the same nitrogen atom of the guanidine group. 
 
 
1.7.1 Protein arginine demethylation 
For a long time, methylation of nitrogen atoms (N-methylation) was considered to be a very stable, 
irreversible post-translational modification. While the oxygen-dependent reversal of lysine 
methylation is well demonstrated by now, the existence of real arginine demethylases is still discussed 
controversially (Blanc and Richard, 2017; Yang and Bedford, 2013). In 2007, Jumonji C domain-
containing protein 6 (JMJD6) was reported to be the first putative arginine demethylase (Chang et al., 
2007). Two years later, JMJD6 was shown to be a lysine hydroxylase (Webby et al., 2009). Recently, 
JMJD6 was shown to demethylate the stress granule protein G3BP1 and thereby regulate stress 
granule (SG) dynamics by promoting SG formation (Tsai et al., 2017).  Furthermore, certain Fe(II)- and 
2-oxoglutarate (2OG) dependent JmjC-domain-containing demethylases (KDM3A, KDM4E, KDM5C) 
also possess methylarginine demethylation activity for histone and non-histone substrates in vitro 
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(Blanc and Richard, 2017; Walport et al., 2016). Nevertheless, further research is needed to clarify 
whether these enzymes are actual arginine demethylases or whether there are other enzymes that 
carry out this function.  
 
1.7.2 Biological functions of arginine methylation 
PRMTs have various histone and non-histone substrates, including numerous RBPs, and thereby play 
a key role in transcription, mRNA translation, signal transduction, DNA repair signaling, pre-mRNA 
splicing and nuclear import (Blanc and Richard, 2017; Yang and Bedford, 2013).  
Among the multiple biological roles of arginine methylation, regulation of nucleocytoplasmic shuttling 
was the first uncovered function (Shen et al., 1998). RBPs are usually enriched in RGG, GAR, and PGM 
motives and thus prime targets for ADMA modification by the main type I enzymes PRMT1 and CARM1 
(Bedford and Clarke, 2009; Tang et al., 2000). RBPs, like hnRNPs, shuttle between the nucleus and the 
cytoplasm. Initial yeast studies uncovered that deletion of the primary yeast type I PRMT, Hmt1/Rmt1, 
causes a nuclear accumulation of RBPs and Hmt1 overexpression enhances cytoplasmic localization of 
RBPs (Shen et al., 1998). The cold-inducible RNA binding protein CIRP2 identified in Xenopus laevis 
becomes hypermethylated by overexpression of xPRMT1, resulting in a cytoplasmic accumulation of 
CIRP2 (Aoki et al., 2002). In mammalian cells, hypomethylated Sam68 is cytosolically mislocalized 
(Cote et al., 2003). Interestingly, hypomethylation causes an accumulation of some RBPs in the 
nucleus, while others become enriched in the cytoplasm upon hypomethylation, and the mechanisms 
how arginine methylation regulates nucleocytoplasmic transport remain mostly elusive (Bedford and 
Clarke, 2009).  
Nuclear import of FUS is also regulated by arginine methylation and this regulatory mechanism has 
been investigated in quite some detail: Chemical inhibition of methylation using adenosine dialdehyde 
(Adox) restores nuclear localization of FUS carrying an ALS-associated FUS-NLS mutation (Dormann et 
al., 2012; Tradewell et al., 2012) and of mutant EWS and TAF15 (Dormann et al., 2012). Similarly, 
PRMT1 knockdown revealed rescue of cytosolic mislocalization of NLS-mutated FUS and a restoration 
of nuclear localization (Dormann et al., 2012; Tradewell et al., 2012; Yamaguchi and Kitajo, 2012). 
Inhibition of arginine methylation causes enhanced TNPO1 binding to the unmethylated RGG3 domain 
of FUS compared to the methylated RGG3 domain and thereby results in improved TNPO1-dependent 
nuclear import of mutant FUS (Dormann et al., 2012).  
As previously mentioned, another physiological function of arginine methylation is regulation of RNA 
binding. Studies on synthetic peptides corresponding to a RGG-rich region of nucleolin, which unwinds 
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dsDNA, showed that binding strength to RNA is not altered by arginine dimethylation, but 
unmethylated RGGs perturb the helical structure of RNA (Raman et al., 2001). Furthermore, poly(U) 
RNA binding activity of Sam68 and Sam68-like mammalian proteins (SLM-1/-2) was shown to be 
disrupted by arginine methylation (Rho et al., 2007). Hung et al. showed that arginine methylation of 
the REF/ALY mRNA export adaptor does not affect interaction with the actual export receptor 
TAP/NXF1 via its RG-rich motif, but reduces RNA-binding of REF/ALY and therefore also disrupts the 
transfer of RNA from REF/ALY to TAP/NXF1 (Hung et al., 2010). Recently, in vitro methylation of FUS 
was shown to interfere with its ability to bind to lncRNAs (Cui et al., 2018). Despite of these findings, 
the physiological roles of arginine methylation, particularly for FUS, remain ambiguous.  
 
1.8 Stress granules: protective messenger ribonucleoprotein (mRNP) granules 
As mentioned in a previous section, a vast number of ALS and FTD cases are characterized by a loss of 
TDP-43 or FUS from the nucleus and their cytosolic aggregation (Fig. 1 and 2). Interestingly, 
pathological aggregates of FUS and TDP-43 identified in ALS and FTD patients are often also positive 
for other RBPs, such as TIA1 and PABP-1, which are key components of stress granules (SGs) (Dormann 
et al., 2010; Liu-Yesucevitz et al., 2010). RBPs interact with mRNAs and thereby form messenger 
ribonucleoprotein particles (mRNPs). Translationally inactive mRNPs were reported to have the 
capability to assemble into higher order membrane-less mRNP granules, such as processing bodies 
(PB), neuronal transport granules, and stress granules (SGs) (Erickson and Lykke-Andersen, 2011). 
Importantly, SGs are cytosolic compartments that temporally sequester mRNA and associated RBPs in 
response to cellular stress or external stimuli and thereby keep the mRNA silenced and protected from 
degradation. Furthermore, mRNP granules are dynamic compartments that interact with each other 
and exchange components (Buchan et al., 2008; Kedersha et al., 2005). SGs form in response to various 
stress conditions, such as heat or cold shock, hypoxia, osmotic and oxidative stress, mitochondrial 
dysfunction, viral infection, or UV irradiation. Under these conditions, most mRNAs are silenced while 
mRNAs encoding molecular chaperones and repair enzymes, which are essential to deal with the 
stress, can escape SGs and get preferentially translated (Anderson and Kedersha, 2006). This makes 
SGs protective cell compartments and inhibition of SG formation under stress conditions was 
demonstrated to cause cell death (Hofmann et al., 2012). SGs are usually reversible cytoplasmic 
compartments that can dissemble upon stress recovery or can be cleared by autophagic degradation 
(Buchan et al., 2013). SGs typically contain various components, such as polyA-mRNA, 40S ribosomal 
subunits, polyA-binding protein (PABP), and various translational initiation factors of the eIF family 
(Buchan and Parker, 2009). Furthermore, SGs contain SG-nucleating RBPs, e.g. TIA1 and G3BPs, that 
24 
 
promote the formation of SGs by LC domain-driven self-assembly  (Alberti et al., 2017; Cushman et 
al., 2010; Gilks et al., 2004), but also contain “passive client RBPs” that are simply recruited to SGs 
through their bound mRNAs (e.g. FUS, TDP-43, hnRNP-A1). Additionally, some SG-associated RBPs, 
such as Pumillio 2 and Staufen, play a role in translational silencing, while others are in involved in 
mRNA localization or degradation (Anderson and Kedersha, 2008; Bowden and Dormann, 2016).  
 
1.8.1 Stress granules as progenitors of pathological aggregates? 
In addition to pathological FUS and TDP-43 inclusions in ALS and FTD being positive for several SG 
markers (e.g. TIA1, G3BP, PABP-1) (Baumer et al., 2010; Bentmann et al., 2012; Dormann et al., 2010; 
Fujita et al., 2008; McGurk et al., 2014), other protein aggregation diseases were also demonstrated 
to have SG pathology. Several SG markers have been identified in tau aggregates in FTD-tau and 
Alzheimer´s disease (Apicco et al., 2018; Vanderweyde et al., 2016; Vanderweyde et al., 2012) as well 
as in ALS cases linked to SOD1 aggregates (Lu et al., 2009). Thus, the presence of SG marker proteins 
in pathological aggregates in various neurodegenerative diseases suggests that SGs may be 
progenitors of such pathological inclusions. This view is further supported by recent studies linking 
altered SG dynamics caused by mutations in ALS/FTD-associated RBPs (e.g. hnRNP-A1/A2 and TIA1) to 
the formation of pathological aggregates in ALS/FTD (Kim et al., 2013; Mackenzie et al., 2017; Martinez 
et al., 2016). 
Several studies demonstrated that ALS-causing point mutations in the NLS of FUS, which cause 
cytosolic mislocalization, drastically increase recruitment of FUS into SGs (Bentmann et al., 2012; 
Bosco et al., 2010; Dormann et al., 2010). These mutations cause altered TIA1 and G3BP1 binding as 
well as an increased number and size of SGs (Baron et al., 2013; Vance et al., 2013). These studies 
indicate that mutant FUS alters SG dynamics, possibly by recruiting and trapping additional SG 
components, and thereby contributes to ALS pathology (Bowden and Dormann, 2016; Dormann et al., 
2010; Kwiatkowski et al., 2009; Vance et al., 2009; Vance et al., 2013). 
In order to explain how nuclear FUS and TDP-43 accumulate in pathological inclusions, Dormann & 
Haass proposed a “two hit model” (Dormann et al., 2010) that has been modified to  the “multiple hit 
theory” (Fig. 5). Accordingly, a first pathological hit is evoked by defective nuclear import causing 
nuclear depletion and a diffuse, cytosolic mislocalization of FUS (or other disease-associated RBPs) 
(step 1). Nuclear import defects of FUS can arise from mutations in the NLS that impair the binding of 
the import receptor TNPO1 (as observed in ALS-FUS) or from aggregation of TNPO1 (as observed in 
FTD-FUS). A second pathological hit, e.g. cellular stress, then evokes the recruitment of cytosolically 
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mislocalized FUS  into SGs (Bentmann et al., 2012; Colombrita et al., 2009; Yang et al., 2015) (step 2). 
Persistent stress or other defects, e.g. genetic mutations, altered PTMs or defective protein quality 
control (PQC), as well as high local concentrations of FUS in SGs may induce aberrant SG dynamics and 
induce liquid-to-solid phase transition resulting in solidification of SGs (Note that the topic of phase 
separation and aberrant phase transitions will be discussed in more detail in section 1.9). This may 
lead to the formation of pathological aggregates as seen in ALS and FTD patients (step 3).  
Figure 5: Multiple hit theory for pathological aggregation of FUS and other disease-linked RNA-binding 
proteins. The model postulates that a nuclear import defect is the first pathological hit causing cytosolic 
mislocalization of the normally nuclear FUS protein.  Nuclear import defects may involve mutations in the NLS 
of FUS or mislocalization and aggregation of its nuclear import receptor TNPO1 (step 1). Cellular stress conditions 
act as a second hit and induce the formation of transient stress granules (SGs) driven by liquid-liquid phase 
separation (LLPS) of LC domain-containing RBPs and recruitment of mislocalized FUS into these SGs (step 2). 
Persistent stress, aggregation-promoting mutations, aberrant post-translational modifications (PTMs) or protein 
quality control (PQC) defects are believed to impair/reduce the dissolution of SGs and to cause liquid-to solid 
phase transition, leading to a solidification of FUS in SGs and ultimately to a conversion into pathological 
aggregates (step 3). Figure adapted from (Dormann and Haass, 2011) with permission from Elsevier. 
 
Cytosolic mislocalization of FUS and TDP-43 and consequent depletion from the nucleus with 
subsequent accumulation of insoluble FUS in cytosolic aggregates may evoke neurodegeneration by 
either loss-of-function, toxic gain-of-function, or a combination of both (Sharma 2006, Harrison & 
Shorter 2017). 
There are multiple mechanisms proposed how altered SG dynamics may contribute to 
neurodegeneration in RBP proteinopathies (extensively reviewed by (Bowden and Dormann, 2016)): 
First, solidification of SGs may cause persistent translational arrest of sequestered mRNAs. This 
mechanism is supported by studies showing that translational arrest mediated by phospho-eIF2α 
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causes synaptic loss and neurotoxicity (Moreno et al., 2012) as well as death of hippocampal neurons 
upon brain ischemia (Jamison et al., 2008; Kayali et al., 2005). 
Second, it may be possible that prolonged sequestration of regulatory RBPs, such as FUS, TDP-43, EWS, 
TAF15, in solidified SGs are toxic due to loss-of-function. Persistent trapping of FUS or TDP-43 in SGs 
may cause fatal impairment of the proteins functions in regulation of transcription and splicing, 
transcriptional regulation, DNA damage repair and mRNA localization and thus contribute to 
neurodegeneration (Bowden and Dormann, 2016; Lagier-Tourenne et al., 2012).  
Third, Polymenidou and Cleveland proposed that mutant RBPs with prion-like domains may act as 
“seeds of neurodegeneration”, by inducing misfolding and trapping of their native counterparts into 
SGs (Polymenidou and Cleveland, 2011). Consistently, Vance and colleagues reported mutant FUS to 
bind to and recruit wild-type FUS to SGs (Vance et al., 2013). Prion-like domains are supposed to switch 
between two conformational states, namely an intrinsically unfolded and an aggregated state that 
forces its native counterpart by direct interaction into the same misfolded conformation. This process 
is supposed to be reinforced by high local protein concentrations in SGs. Furthermore, it seems likely 
that aggregated proteins may also induce misfolding and aggregation of dissimilar proteins, referred 
to as cross-seeding phenomenon. Strikingly, these seeding aggregates may be transferred from cell to 
cell and initiate misfolding and aggregation of native FUS and TDP-43 in neighboring cells 
(Polymenidou and Cleveland, 2011). 
 
1.9 Phase separation of RBPs as driving force for protein aggregation 
Intracellular compartmentalization is achieved by membrane-bound organelles such as the 
endoplasmic reticulum (ER), mitochondria and the Golgi apparatus. Divided by membrane boundaries, 
these compartments are functionally distinct from the rest of the cell by providing certain molecules 
at the proper time in the proper place. Nevertheless, another type of intracellular compartments has 
recently received a lot of attention, namely compartments that are not separated from the 
surrounding area by membranes and therefore are referred to as membrane-less organelles or 
biomolecular condensates (Banani et al., 2017; Weber and Brangwynne, 2012). Membrane-less 
organelles often contain RBPs and RNA and consequently are also referred to as RNP granules, e.g. 
processing bodies (PB), SGs, neuronal transport granules, germ granules and nucleoli. As previously 
described, RNP granules are involved in RNA metabolism, including splicing, mRNA storage and 
degradation. Both membrane-bound and membrane-less organelles play pivotal roles in 
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spatiotemporal control of biological processes by compartmentalizing biomolecules in the cell 
(Brangwynne et al., 2015). 
 
1.9.1 Driving forces of phase separation and formation of membrane-less organelles 
RNP granules are formed when certain biomolecules (RBPs, RNAs) separate from a cytosolic or nuclear 
pool of soluble molecules, forming condensed liquid phases in a less concentrated surrounding milieu 
(Fig. 6). Different from irreversible protein aggregates seen in neurodegenerative diseases, these 
physiological compartments have been demonstrated to be highly dynamic and exhibit liquid-droplet-
like behavior including wetting surfaces, dripping in response to shearing and fusion into larger 
droplets/compartments upon contact (Brangwynne et al., 2009). 
In 2009, a study in C. elegans demonstrated that germ (P) granules form by a mechanism called liquid-
liquid phase separation (LLPS). Asymmetric localization of P granules to the posterior pole in the early 
embryo has been demonstrated to be based on spatiotemporally regulated LLPS structuring the 
cytoplasm (Brangwynne et al., 2009).  Subsequently, phase separation was also shown to drive the 
assembly of nucleoli in Xenopus (Brangwynne et al., 2011) and SGs in yeast and mammalian cells 
(Kroschwald et al., 2015; Patel et al., 2015), indicating a general biophysical mechanism underlying the 
formation of membrane-less RNP granules in cells.  
Phase separation not only drives the formation of membrane-less organelles, but is a ubiquitous 
phenomenon in nature. The most common examples are the different physical states that water can 
adopt, namely water vapor that condenses to liquid water that can further solidify into ice. In contrast 
to the molecules in vapor, transient hydrogen bonds formed in liquid water are permanently 
reorganized by thermal fluctuations allowing dynamic interactions between individual water 
molecules. In the frozen state, water molecules crystalize and stable hydrogen bonds hold the single 
molecules in place. Although phase transitions in this non-biological example are temperature-
dependent processes, the propensity to undergo phase separation is primarily determined by the 
molecular properties (Weber and Brangwynne, 2012). 
Although membrane-less compartments in cells have complex compositions containing multiple 
different proteins and RNAs, liquid-like compartments can be reconstituted in vitro using only one or 
two purified proteins that undergo LLPS (Fig. 6). These findings have provided evidence that in some 
cases a single protein may be necessary and sufficient to mediate the formation of membrane-less 
compartments by phase separation (Brangwynne et al., 2015). Major drivers of phase separation are 
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proteins harboring long stretches of intrinsically disordered regions of low amino acid complexity (so 
called LC domains), so called intrinsically disordered proteins (IDPs). The LC domains of IDPs show a 
preference for conformational disorder as well as inability to fold into defined three-dimensional 
structures (Brangwynne et al., 2015). Due to their high similarity to proteins in budding yeast forming 
prions , LC domains are termed prion-like domains (Alberti et al., 2009; King et al., 2012; Malinovska 
et al., 2013). IDPs can be subdivided into two groups. On the one hand IDPs that harbor mostly 
repetitive motifs of amino acids with polar sidechains (Q, S, G, N) as well as interspersed aromatic 
residues (F, Y), and on the other hand IDPs containing amino acids with positively charged side chains 
(mostly R), prominently found in repetitive RGG-rich domains. Most RBPs that are involved in 
formation of membrane-less, cytoplasmic RNP compartments are IDPs. Well-studied examples for this 
type of IDPs are FUS and hnRNP-A1. There is strong evidence that intracellular phase separation is 
driven by multivalent, low affinity interactions between LC domains that have a certain amino acid 
compositions (March et al., 2016; Shin and Brangwynne, 2017; Weber and Brangwynne, 2012). LLPS 
of hnRNP-A1 has been demonstrated to be promoted by lowering NaCl concentrations, indicating that 
LLPS of hnRNP-A1 is driven by electrostatic interactions between charged motifs (Molliex et al., 2015). 
Moreover, arginine-aromatic (cation-π) interactions between arginine residues in RG/GR motifs and 
aromatic FG/GF motifs were shown to contribute to phase separation of Ddx4 molecules (Nott et al., 
2015). As hnRNP-A1 is also enriched in aromatic residues containing F and Y as well as arginine 
residues, it is likely that cation-π interactions may be another driving force of LLPS of hnRNP-A1 
(Molliex et al., 2015). Additionally, interactions of dipoles (G, Q, N, S) and between aromatic residues 
(π-π stacking) are also considered to drive phase separation (Brangwynne et al., 2015; Lee et al., 2016). 
In summary, electrostatic interactions mediating long-range interactions complemented by short-
range, directional interactions (including cation-π, π-π stacking, and interactions between dipoles) 
appear to give a hierarchical interplay between the different types of weak multivalent interactions 
driving LLPS of IDPs (Brangwynne et al., 2015).  Besides weak multivalent interactions between 
disordered LC regions, modular binding domains and their multivalent ligands have been reported to 
drive phase separation (Li et al., 2012). Phase separation is a concentration-dependent process, in 
which a protein solution reaches a state of supersaturation, e.g. protein concentration beyond the 
phase transition boundary, and then forms liquid-like compartments with a much higher local 
concentration than the surrounding area. The level of molecular supersaturation can be modulated 
by changes in temperature, salt/proton concentration, changes in charge due to PTMs or mutations, 
pH or osmotic shocks as well as changes in the protein/RNA composition due to altered gene 
expression (Brangwynne et al., 2015). In addition to RBPs,  even certain types of RNA have been 
demonstrated to undergo phase separation on their own (Jain and Vale, 2017; Saha and Hyman, 2017). 
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1.9.2 Phase separation and protein aggregation 
A number of recent studies well demonstrated that FUS as well as other disease-linked RBPs, such as 
hnRNP-A1 and TDP-43, undergo reversible LLPS in vitro (Burke et al., 2015; Kato et al., 2012; Molliex 
et al., 2015; Monahan et al., 2017; Murakami et al., 2015; Patel et al., 2015). A number of studies 
suggested that LLPS and aggregation of FUS are mainly driven by its highly polar N-terminal SYGQ-rich 
domain (Burke et al., 2015; Kato et al., 2012; Murakami et al., 2015; Patel et al., 2015; Sun et al., 2011). 
Notably, full-length FUS undergoes LLPS at physiological concentrations which are considered to range 
between 1-10 µM in HeLa cells (Patel et al., 2015). The FUS droplets formed in vitro initially have 
dynamic, liquid-like properties similar to cellular RNP granules such as SGs and recover quickly after 
photobleaching. However, droplet properties can change over time and liquid droplets can undergo 
an aberrant liquid-to-solid phase transition and form solid, fibrous aggregates in vitro (Molliex et al., 
2015; Monahan et al., 2017; Patel et al., 2015) (Fig. 6). This liquid-to-solid phase transition is 
characterized by a conversion of liquid droplets to short cross-β fibrils (Burke et al., 2015; Kato and 
McKnight, 2017; Patel et al., 2015; Shorter, 2017) that are considered to be initially labile and 
reversible (Kato and McKnight, 2017) but eventually shift to solid, irreversible fibrils (Murakami et al., 
2015; Patel et al., 2015; Shorter, 2017). As demonstrated by the work of Patel and Murakami and 
colleagues, LLPS and liquid-to-solid phase transition of FUS is driven in a concentration-dependent 
manner (Murakami et al., 2015; Patel et al., 2015) (Fig. 6), suggesting that high local FUS 
concentrations, as found in SGs, may promote aberrant phase transition of FUS to solid cytoplasmic 
aggregates and pathological protein inclusions (Bentmann et al., 2013; Bowden and Dormann, 2016; 
Li et al., 2013) (Fig. 5).  
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Figure 6: Phase separation drives the adoption of different material states of proteins with multivalent 
interaction domains or low complexity domains. When reaching a state of supersaturation, soluble proteins in 
the mixed phase (top panel left), such as purified FUS, undergo liquid-liquid phase separation (LLPS) forming 
protein droplets with liquid-like properties in vitro. LLPS causes a high local protein concentration in the droplets 
(top panel center) and a less-concentrated, surrounding solution. This process is driven by weak multivalent 
interactions between low-complexity domains or multivalent motifs as well as protein concentration. 
Importantly, each phase-separating protein has a specific saturation concentration where it crosses the phase 
boundary. LLPS is initially reversible and the protein can return to the mixed phase. If the molecular interactions 
get stronger or the local protein concentration further increases, the dynamic properties of the droplets change 
causing droplet solidification and formation of insoluble aggregates (top panel right). The conversion of liquid 
droplets to solid aggregates is referred to as liquid-to-solid phase transition. In cells, LLPS is considered to drive 
the formation of physiological RNP granules, including SGs and PBs (bottom panel center). Liquid-to-solid phase 
transition may further cause the formation of irreversible, pathological protein aggregates (bottom panel right). 
Figure adapted from (Alberti et al., 2017). 
 
Multiple studies have demonstrated that disease-linked mutations in the LC domains of FUS, TDP-43 
and hnRNP-A1 as well as hnRNP-A2 induce a faster transition from dynamic liquid droplets to solid 
aggregates, possibly by enhancing multivalent interactions and changed binding affinities of IDPs 
(Conicella et al., 2016; Kim et al., 2013; Lee et al., 2016; Molliex et al., 2015; Patel et al., 2015; Ryan et 
al., 2018). The phenomenon of liquid-to-solid phase transition may also occur in mRNP granules in 
cells, where IDPs are locally highly concentrated and disease-associated mutations further increase 
their aggregation propensity (Kim et al., 2013; Vance et al., 2013). Thereby, physiological mRNP 
dynamics may become dysregulated and form solidified mRNP granules and pathological aggregates 
as found in ALS, FTD and other proteinopathies (Bowden and Dormann, 2016; Elbaum-Garfinkle et al., 
2015; Ramaswami et al., 2013) (Fig. 6). Furthermore, persistent SGs due to failure of the autophagy 
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machinery (e.g. caused by VCP or p62 mutations) or the UPS may also promote aberrant phase 
transition and be a key pathomechanism in ALS/FTD (Alberti and Hyman, 2016; Bowden and Dormann, 
2016; Dormann and Haass, 2013). 
 
1.9.3 Cellular determinants controlling RNP granule formation, aberrant phase separation 
and aggregation 
As FUS is among the most abundant cellular proteins (Wisniewski et al., 2014) and was demonstrated 
to undergo LLPS and liquid-to-solid phase transition in vitro at physiological concentrations, certain 
protein quality control (PQC) mechanisms have to be in place to efficiently prevent or reverse aberrant 
phase transition in cells. There are different mechanisms present in the cell that regulate RNP granule 
dynamics and prevent the formation of pathological aggregates and fibrils (Alberti et al., 2017). 
  
1.9.3.1 Adenosine triphosphate (ATP) 
First, it may be possible that cells use energy sources to suppress aberrant phase transitions and 
formation of pathological aggregates (Brangwynne et al., 2015). Adenosine triphosphate (ATP) serves 
as energy source for biological reactions in the cell and has been shown to maintain the fluidity of 
intracellular compartments (Jain et al., 2016b). Recently, ATP as molecule has been reported to 
suppress LLPS of RBPs and to dissolve preformed droplets of FUS, hnRNP-A3, and TAF15. Therefore, 
ATP is able to function as a biological hydrotrope independently of its role as an energy source driving 
chemical reactions (Patel et al., 2017) around its physiological concentration between 5 and 10 mM 
(Traut, 1994). As ATP-dependent biological processes require only micromolar concentrations of ATP, 
its function as hydrotrope may explain millimolar concentrations of ATP present in cells. Curiously, 
ATP is even able to inhibit aggregation of boiled egg in a dose-dependent manner, possibly by 
stabilizing the native globular state (Patel et al., 2017). 
 
1.9.3.2 Chaperones 
Another aspect that appears to be involved in protein quality control in cells is active regulation by 
protein chaperones and RNA helicases that either clear preformed RNP granules or prevent formation 
or solidification of such. The first identified chaperone is the chromatin assembly factor nucleoplasmin 
from Xenopus oocytes (Dingwall and Laskey, 1990) which is able to suppress undesired aggregation of 
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core histones upon DNA-binding (Jakel et al., 2002). The term chaperone was originally introduced in 
order to classify proteins with such nucleoplasmin-like disaggregation activity. Currently, the term 
chaperone is commonly used for factors executing disaggregation activity like HSPs and importins 
(Jakel et al., 2002).  
Studies on RNP granules in yeast under heat shock conditions revealed that deficiency in heat shock 
proteins (HSPs) such as HSP104 causes mislocalization of the P-body proteins Edc3 and Lsm4 resulting 
in their co-aggregation with misfolded proteins in SGs. Increased expression of HSP104 reduced the 
amounts of SG-localized Edc3, indicating that HSP104 can act as chaperone preventing protein 
aggregation (Kroschwald et al., 2015). Similarly, loss of the RNA helicase CGH-1/DDX6 in C. elegans 
induces polymerization of RNP granules to a solid state, indicating that this RNA helicase is able to 
modulate fluidity of RNP granules (Hubstenberger et al., 2013) 
Recently, the chaperone function of several HSPs to encounter aberrant phase transition of SGs has 
been extensively studied. Mutant proteins, such as SOD1, have been shown to strongly decrease SG 
dynamics (Ganassi et al., 2016; Mateju et al., 2017). Furthermore, SGs positive for mutant RBPs have 
been shown to be enriched for ubiquitin and chaperones, such as HSP27 and HSP70, indicating that 
HSPs are specifically recruited into aberrant SGs containing mutant proteins (Ganassi et al., 2016; 
Mateju et al., 2017). Additionally, HSP27 recruitment to SGs upon heat shock is slightly delayed 
compared to poly-ubiquitin, indicating that HSP27 recruitment to SGs occurs in response to 
aggregation of misfolded proteins (Mateju et al., 2017). Remarkably, wild-type RBPs like FUS, TDP-43 
and G3BP2 are depleted from SGs upon prolonged stress (Mateju et al., 2017). Since misfolded 
proteins are gradually recruited to SGs alongside with recruitment of chaperones while certain RBPs 
are depleted, SG composition changes over time. Moreover, inhibition of HSP70 was accompanied by 
a significant increase of SGs positive for misfolded SOD1, Ubc9TS, or poly-ubiquitinated proteins, 
denoting that HSP70 prevents both, formation and recruitment of misfolded proteins into SGs (Mateju 
et al., 2017). Aggregation of misfolded proteins significantly impairs SG disassembly alongside with 
HSP70 inhibition indicating that HSP70 mediates rapid SG disassembly (Ganassi et al., 2016; Mateju et 
al., 2017). Ganassi et al. (2016) uncovered that the chaperone holdase HSPB8 is recruited to SGs and 
in turn recruits the BAG3-HSP70 subcomplex that mediates disassembly of SG containing mutant 
proteins (Ganassi et al., 2016). On a molecular basis, HSPs suppress aggregation by binding exposed 
hydrophobic regions of folding and assembly intermediates and thereby ensure proper folding 
(Agashe and Hartl, 2000). Impaired PQC, possibly by defects in HSP chaperone activity, may cause the 
conversion of aberrant SGs into aggregates. To clear persisting aberrant SGs, cells have developed an 
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alternative clearance pathway that involves degradation by autophagy (Alberti et al., 2017; Ganassi et 
al., 2016; Mateju et al., 2017) (see section 1.9.3.3). 
Notably, Jackrel and colleagues demonstrated that mutations of single residues of Hsp104 can cause 
a gain-of-function by potentiating its ability to dissolve TDP-43, FUS, and α-synuclein aggregates and 
thereby suppress proteotoxicity and even restore proper localization of the RBPs (Jackrel et al., 2014; 
Jackrel and Shorter, 2015, 2017; Yasuda et al., 2017). These potentiating missense mutations are 
restricted to the coiled-coil middle domain of Hsp104 (Jackrel et al., 2014) that possesses ATPase 
activity and disaggregase activity (Desantis and Shorter, 2012), and elevate its ATPase activity by ~2-
to 4-fold indicating faster ATP binding and hydrolysis (Jackrel et al., 2014; Jackrel and Shorter, 2015). 
Engineering such enhanced protein disaggregases offers new therapeutic potential to encounter toxic 
protein aggregates (Jackrel and Shorter, 2015, 2017). 
 
1.9.3.3 SG clearance by the autophagy machinery 
In addition to molecular chaperones, also components of the UPS (ubiquitin proteasome system) and 
of the autophagy machinery are recruited to SGs.  Among these are ubiquitin, HDAC6 (histone 
deacteylase 6) and VCP/p97 which is involved in the degradation of ubiquitinated proteins (Buchan et 
al., 2013; Kawaguchi et al., 2003; Kwon et al., 2007). Besides HSP-mediated disassembly of SGs, there 
is evidence for clearance of persisting SGs by autophagy mediated by VCP/p97. Inhibition of VCP 
activity by siRNA or by chemical inhibition causes decreased rates of SG clearance (Buchan et al., 
2013). Autophagy is crucial for the removal of aggregated proteins that may have deleterious 
potential. Impaired autophagy is associated with numerous disorders including cancer and 
neurodegeneration (Yang and Klionsky, 2010). Furthermore, accumulation of p62 in SGs (Matus et al., 
2014) further points to an essential role of autophagy in SG degradation (Alberti et al., 2017). Stress 
granules can be divided into physiological SGs and aberrant SGs containing misfolded proteins which 
recruit PQC factors and the autophagy machinery (Ganassi et al., 2016; Mateju et al., 2017). 
Furthermore, recent studies  provide evidence for SG clearance by transport to the aggresome and 
degradation by the autophagy machinery (Ganassi et al., 2016; Mateju et al., 2017). Aggresome 
formation is dependent on SG-localized VCP and the VCP/p97-binding protein HDAC6 (Ju et al., 2008) 
that is furthermore involved in the recognition of misfolded proteins and their packaging into 
aggresomes (Kawaguchi et al., 2003). This tight link of SGs and aggresome formation indicates an 
important mechanism of cells to cope with an excess of aberrant SGs (Alberti et al., 2017) even though 
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the favored pathway of SG clearance is the chaperone-mediated disassembly of SGs and recycling of 
components upon stress release (see section 1.9.3.2) (Ganassi et al., 2016; Mateju et al., 2017). 
In summary, SGs can be cleared by two pathways: first, by fast disassembly of dynamic SGs by 
molecular chaperones like HSP70 or second, by transport of aberrant SGs containing misfolded 
proteins to the aggresome that are eventually degraded by the autophagy machinery (Mateju et al., 
2017). Many cases of age-related neurodegenerative diseases, such as ALS and FTD, arise from 
impaired SG dynamics leading to aggregate formation driven by aberrant phase transition of SG 
components. Additionally, mutations in genes encoding factors involved in SG clearance, such as 
HSPB8, BAG3, VCP/p97, or p62 cause functional impairment and promote conversion of aberrant SGs 
into aggregates (Alberti et al., 2017). Strikingly, mutations in VCP are causative for ALS and FTD cases 
with characteristic TDP-43 inclusions (Johnson et al., 2010; Neumann et al., 2007). 
 
1.9.3.4 Posttranslational modifications (PTMs) 
IDPs are characterized by their low amino acid complexity in the IDRs that allows the formation of 
weak multivalent interactions driving phase separation. The enriched amino acids in the IDRs are 
highly post-translationally modified, e.g. by phosphorylation, methylation, ubiquitination, 
glycosylation and SUMOylation. There is quickly growing evidence that PTMs are a key control 
mechanism in cells to regulate proper dynamics and composition of RNP granules (Wang et al., 2014) 
and control phase separation processes. 
The best-characterized example for fine-tuning RNP granule dynamics and LLPS of RBPs is 
phosphorylation. Phase separation of tau protein is promoted by phosphorylation as seen under 
physiological and pathological conditions (Wegmann et al., 2018). Furthermore, single point-
mutations, introduction of a phospho-mimicking, negatively charged residue, as seen for the ALS-
linked G156E mutation in FUS, can severely alter dynamic properties of FUS droplets (Patel et al., 2015) 
and significantly increase its aggregation propensity in vitro and in vivo (Nomura et al., 2014). Beside 
these promoting effects of phosphorylation on phase separation, there is also an increasing number 
of studies demonstrating suppression of phase separation and aggregation by phosphorylation. P-
granule disassembly in C. elegans embryo is regulated by phosphorylation of MEG-3 and MEG-4 
proteins by MBK-2/DYRK kinase and granule formation is promoted and stabilized by MEG-3/4 
dephosphorylation by PP2APPTR-1/PPTR2 phosphatase (Wang et al., 2014). Hyperphosphorylation of TDP-
43 at five C-terminal serine residues (379, 403, 404, 409 and 410)  was confirmed in ALS and FTD-U 
inclusions and initially proposed to be a driving force towards the formation of aggregates (Hasegawa 
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et al., 2008). More recently, this assumption changed as Li et al. demonstrated with phosphorylation-
mimetic mutations at these serine residues (S5D or S5E) that hyperphosphorylation of TDP-43 reduces 
its propensity to form aggregates as well as cytotoxic effects of C-terminal TDP fragments in neurites. 
In contrast to that, phosphorylation-deficient mutations to alanine (S5A) promote aggregation of TDP-
43. In the same study, phosphorylation of TDP-43, and also ubiquitination, were furthermore shown 
to occur after aggregate formation (Li et al., 2011).  Moreover, phospho-mimetic substitution at serine 
48 (S48E) in the NTD of TDP-43 severely disrupts its ability to phase separate, but also impairs splicing 
activity (Wang et al., 2018a). Recently, phosphorylation of specific serine and threonine residues in 
the N-terminal LC-domain (SYGQ-rich) of FUS has been reported to suppress its phase separation and 
aggregation in vitro. Similarly, McKnight and colleagues earlier showed that in vitro phosphorylation 
at certain serine residues (S26, S42, S61, and S84) of the LC domain by DNA-PK reduces hydrogel 
retention (Han et al., 2012). The study by Fawzi and colleagues revealed that an even higher number 
of consensus serine/tyrosine sites in the LC domain of FUS (T7, T11, T19, S26, S30, S42, S61, T68, S84, 
S87, S117, and S131) can be phosphorylated by DNA-PK in vitro and in cells. As phosphorylation of 
serines and tyrosines causes a change from uncharged, polar residues in the LC domain to a net 
negative charge, this high number of possible phosphorylation sites interferes with FUS LC domain 
self-interaction and phase separation (Monahan et al., 2017) by electrostatic repulsion which disrupts 
tyrosine-mediated π-π stacking (Wang et al., 2018b). In contrast, the full-length FUS protein is 
practically unaffected in its phase separation behavior by the phospho-mimetic 12E substitution 
suggesting that LLPS behavior of full-length FUS is more complex involving the N-terminal RGG 
domains (Monahan et al., 2017). Phosphorylation of full-length FUS may change the cation-π 
interactions to electrostatic interactions (phosphorylated S/Y with positive R in RGG) and maintain 
LLPS. This is supported by the finding that phase separation of full-length FUS carrying the 12E 
substitution is disrupted by high salt while wild-type FUS is less affected (Monahan et al., 2017).  
In addition to phosphorylation, there is currently increasing evidence emerging that also methylation, 
especially at arginine residues, has an important contribution to the regulation of phase separation. 
In contrast to phosphorylation where negative charge is added to an initially uncharged, polar amino 
acid, methylation does not alter the positive charge of arginines, but hydrogen bonding and local 
hydrophobicity is altered (Fuhrmann et al., 2015). Yamaguchi and Katajo demonstrated that SG 
formation related to truncated FUS lacking the PY-NLS (FUS-dC) is significantly reduced by conditional 
overexpression of PRMT1 in HEK293 cells. Furthermore, PRMT1-overexpression reduces the amount 
of detergent-insoluble FUS-dC aggregates (Yamaguchi and Kitajo, 2012). Comparison of unmethylated 
LC domain of Ddx4 (Ddx4N1) with Ddx4N1 asymmetrically dimethylated at 5 to 6 arginines by PRMT1 
revealed a significant suppression of Ddx4N1 droplet formation. The degree of droplet destabilization 
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corresponds to a lower phase separation temperature of 25 °C or a doubling in salt concentration 
(Nott et al., 2015). In vitro methylation of the hnRNP-A2 LC domain using recombinant PRMT1 reveals 
ADMA marks at four arginine residues (R191, R201, R216, R254), causing decreased phase separation 
of methylated hnRNP-A2 LC. Furthermore, Fawzi and colleagues also show that methylation of RGG 
disrupts the intermolecular contacts of R191, R201, and R216 with aromatic residues suggesting that 
arginine methylation reduces hnRNP-A2 LC phase separation by interfering with cation-π interactions 
(Ryan et al., 2018). 
Arginine residues are not only post-translationally modified by methylation, but can be also converted 
into citrulline residues. Citrullination by peptidylarginine deiminases (PADs) causes a loss of positive 
charge and a conformational change (Anzilotti et al., 2010; Vossenaar et al., 2003). PAD4-mediated 
citrullination significantly reduced aggregation of TAF15, FUS, EWSR1, and hnRNP-A1 in cells. 
Furthermore, sodium arsenite treatment caused a significantly higher recruitment of FUS and TAF15 
to SGs in MEF cells derived from Padi4-deficient mice (Tanikawa et al., 2018). Although the 
physiological role of citrullination remains mostly unclear, the observations by Matsuda and 
colleagues suggest that citrullination may suppress phase separation and aggregation by disrupting 
cation-π or electrostatic interactions formed by arginines as the positive charge is eliminated. 
Poly(ADP-ribosyl)ation is a PTM catalyzed by poly(ADP-ribose) polymerase (PARP) enzymes in 
response to DNA damage. Poly (ADP-ribose) (PAR) rapidly recruits FUS to sites of DNA DSBs by direct 
interaction with FUS-RGG2 (Mastrocola et al., 2013). Lukas and colleagues demonstrated that PAR 
induces intracellular accumulation of FUS, EWS, and TAF15 at sites of DNA damage in vitro and in vivo 
(Altmeyer et al., 2015). At the same time, Alberti and colleagues reported that PARP1/2 inhibition 
prevents FUS recruitment to DNA lesions and inhibition of a PAR-degrading enzyme (PARG) causes 
longer persistence of FUS at sites of DNA damage (Patel et al., 2015). This indicates that negatively 
charged PAR forms electrostatic interactions with the RGG2 domain driving liquid demixing at sites of 
DNA damage and thereby may allow immediate response to DNA breakage (Altmeyer et al., 2015) as 
FUS is recruited within seconds after PARP1 arrival (Patel et al., 2015). 
 
1.10 Aims of the Ph.D. project 
It has been shown that the interaction of FUS with TNPO1 is fine-tuned by methylation of arginines in 
the RGG3-PY of FUS (Dormann et al., 2012).  Apart from this, only little is known about the 
physiological function of arginine methylation of FUS. So, it is unknown whether it affects other 
protein-protein interactions, RNA-binding or the phase separation properties of FUS. Furthermore, it 
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is still unclear whether the loss of FUS arginine methylation and the pathological deposition of TNPO1, 
as seen in FTD-FUS patients (Dormann et al., 2012; Suarez-Calvet et al., 2016), contributes to 
pathogenesis.   
In order to shed light in these ambiguities, the following questions were addressed in my Ph.D. project: 
 
1) Contribution of arginines to LLPS of FUS 
Based on previous studies, it has been suggested that phase separation of FUS is mainly driven by the 
N-terminal SYGQ-rich domains  (Burke et al., 2015; Kato et al., 2012; Murakami et al., 2015; Patel et 
al., 2015; Sun et al., 2011). A closer look at the sequence of FUS reveals that also the three RGG 
domains, which are the sites of arginine methylation, and the C-terminal NLS (RGG3-PY) are also highly 
disordered LC sequences, making them good candidates to contribute to phase separation of FUS. 
Therefore, the contribution of arginines in the RGG domains and of the RGG3-PY domain of FUS to 
LLPS of FUS were addressed in this thesis. 
 
2) Effect of TNPO1 on LLPS and aggregation of FUS 
A number of nuclear import receptors have been reported to suppress aggregation of highly basic 
ribosomal proteins and histones in the cytoplasm (Jakel et al., 2002). We speculated that the nuclear 
import receptor TNPO1 may exert a similar chaperone function towards its cargo FUS and suppress 
LLPS and aggregation of FUS. This may be of particular relevance, as TNPO1 is aggregated in FTD-FUS 
cases (Brelstaff et al., 2011; Davidson et al., 2013; Neumann et al., 2012; Troakes et al., 2013) and its 
binding to FUS is impaired in ALS-FUS patients due to FUS-NLS mutations (Dormann et al., 2012; 
Dormann et al., 2010). Thus, impaired TNPO1 function or binding may have a critical contribution to 
pathological aggregation of FUS in ALS and FTD. Therefore, one aim of this thesis was to address the 
impact of TNPO1 on LLPS and aggregation of FUS. 
 
3) Effect of arginine methylation on LLPS and RNA-binding of FUS 
RGG-rich motifs are a highly abundant sequence pattern in RBPs, including FUS, which has been shown 
to undergo extensive asymmetric dimethylation in its RGG domains in vitro and in vivo (Araya et al., 
2005; Belyanskaya et al., 2001; Du et al., 2011; Hung et al., 2009; Jobert et al., 2009; Ong et al., 2004; 
Pahlich et al., 2005; Rappsilber et al., 2003). Beyond its involvement in regulating nucleocytoplasmic 
shuttling of FUS, little is known about the physiological and pathological functions of FUS arginine 
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methylation, e.g. whether it regulates phase separation or RNA/protein-interactions of FUS. As 
arginine methylation of FUS is lost in FTD-FUS patients (Dormann et al., 2012; Suarez-Calvet et al., 
2016) and arginines may have a critical contribution to LLPS of FUS (see Aim 1), we speculated that 
arginine methylation may affect phase separation of FUS. Thus, another aim of this thesis was to study 
the role of arginine methylation in LLPS and RNA-binding of FUS. 
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2 RESULTS 
DECLARATION OF COPYRIGHT AND CONTRIBUTIONS BY OTHER RESEARCHERS 
This section of my Ph.D. thesis was prepared in parallel to the paper ‘Phase separation of FUS is 
suppressed by its nuclear import receptor and arginine methylation’ published in Cell (Hofweber et 
al., 2018). Thus, the data, structure and text of this Ph.D. thesis and the paper will partially overlap. 
Elsevier holds the copyright (2018) for this article published in Cell and permits the usage of text and 
figures in this dissertation. 
Table 1: Summary of contributions to the result section by other researchers. Please note that Saskia Hutten 
contributed equally to Hofweber et al. 2018. These data are included in this Ph.D. thesis and comprise the 
pulldown assays, sedimentation assays and semi-permeabilized cell assays. 
Figure 11D, E 
Figure 13B,C 
Figure 18B, C 
Sedimentation assays conducted and quantified by Saskia Hutten 
Figure 13D Pulldown assays performed and quantified by Saskia Hutten 
Figure 14B TEM imaging conducted by Martina Schifferer 
Figure 15A, B 
Figure 22C, D 
Cytosolic anchoring of FUS performed and quantified by Saskia 
Hutten 
Figure 15D, E 
Figure 19C, D 
Figure 22A, B 
Semi-permeabilized cell assays conducted and analyzed by Saskia 
Hutten  
Figure 16A, B 
NMR experiments performed by Benjamin Bourgeois and Emil 
Spreitzer 
Table 2 
ITC experiments performed by Benjamin Bourgeois and Emil 
Spreitzer 
Figure 16C, D, E 
Figure 20C, D 
Table 3 
Radioactive filter-binding assays conducted and analyzed by Annika 
Niedner-Boblenz 
Figure 20B 
Electrophoretic Mobility Shift Assays (EMSA) performed by Annika 
Niedner 
 
 
2.1 The C-terminal RGG3-PY domain of FUS can undergo phase separation 
As previously mentioned, FUS contains multiple low-complexity (LC) domains characterized by low 
amino acid complexity. These LC domains include the very N-terminal SYGQ-rich domain as well as 
three C-terminal RGG domains that are highly enriched in repetitive RGG/RG motifs. Applying the 
amino acid sequence of FUS to the PONDR (Predictor of Natural Disordered Regions) algorithm yields 
a plot showing the degree of order/disorder of the protein (Fig. 7A). This demonstrates that the LC 
domains of FUS are highly disordered (Fig. 7A). Based on previous studies addressing phase separation 
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behavior of FUS, the prion-like SYGQ-rich domain was considered to be the main driver of phase 
separation of FUS (Burke et al., 2015; Kato et al., 2012; Murakami et al., 2015; Patel et al., 2015; Sun 
et al., 2011), but there is also evidence that the disordered C-terminal domains of FUS may also 
contribute to phase separation and aggregation (Boeynaems et al., 2017; Burke et al., 2015; Schwartz 
et al., 2013; Sun et al., 2011).  
 
Figure 7: The RGG-rich motifs and PY-NLS of FUS are highly disordered. A) Schematic representation of the FUS 
domain structure and order/disorder plot predicted by the PONDR algorithm. A high degree of disorder is 
predicted for the SYGQ-rich domain, RGG1, RGG2 and RGG3-PY domain. B) Amino acid sequence of the isolated 
RGG3-PY domain (residues 454-526) (RGG3 in green, PY in red) demonstrating high enrichment of RGG/RG 
motifs (bold). In the KGG3-PY mutant, all arginines in RGG motifs are mutated to lysines (blue). 
 
To test this hypothesis, I purified the C-terminal RGG3-PY domain of FUS (for sequence see Fig. 7B) 
from E. coli and examined its propensity to undergo phase separation in vitro. For affinity purification, 
the RGG3-PY domain was N-terminally His6-Z-tagged, separated by a TEV protease cleavage site that 
allows proteolytic removal of the tag (Dormann et al., 2012) (Fig. 8A). Its disordered nature renders 
the RGG3-PY domain resistant to denaturation, allowing its purification from E. coli by boiling the 
bacterial pellet. This results in precipitation and removal of all folded proteins (Livernois et al., 2009), 
41 
 
while the RGG3-PY domain remains soluble.  Noteworthy, the proteins were purified in a nucleic-acid 
free form, by incubation of the immobilized protein with Benzonase Nuclease (Sigma) and subsequent 
high salt washes (2M NaCl) (see Fig. 8B and 8C), as confirmed by 260/280 nm ratios of 0.6 - 0.8.  
 
Figure 8: Purification of the C-terminal RGG3-PY domain. A) Schematic diagram of the purified protein (C-
terminal RGG3-PY domain fused to an N-terminal His6-Z-tag separated by a TEV protease cleavage site). B) 
Schematic representation of the workflow for purification of RGG3-PY domain of FUS. The resuspended bacterial 
pellet is subjected to boiling lysis allowing fast removal of most contaminating proteins while the disordered 
His6-Z-RGG3-PY stays soluble during boiling. Immobilized on NiNTA agarose, the protein is subjected to 
Benzonase nuclease treatment and high salt washes (2M NaCl) in order to remove bound nucleic acids. Following 
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elution, His6-TEV protease is added to the protein to remove the His6-Z-tag. The liberated tag and His6-TEV 
protease bind to NiNTA agarose and the untagged RGG3-PY remains in the supernatant. C) Exemplary SDS-PAGE 
gels visualizing the purification of RGG3-PY. Protein bands are visualized by Coomassie stain. Note, that the lanes 
are not loaded equally. Due to low amount used, His6-TEV protease is not visible on the gel. Furthermore, 
untagged RGG3-PY and the liberated tag are of similar molecular weight (8-10 kDa) and therefore run on similar 
heights on the SDS-PAGE gel. Elution fractions have been pooled. Molecular weight markers (in kDa) are 
indicated on the left and right, respectively. 
 
Initial experiments on phase separation of the RGG3-PY domain were performed with the His6-Z-
tagged RGG3-PY protein in presence of 150 mg/ml Ficoll. His6-Z-RGG3-PY undergoes liquid-liquid 
phase separation in a concentration- and salt dependent manner (Fig. 9A and 9B). The fact that the 
His6-Z-tag exhibits also some degree of disorder raised concerns about possible artifacts on phase 
separation. In order to eliminate this risk factor, the His6-Z-tag was removed after elution from NiNTA 
by incubating the protein with His6-TEV protease. By an additional Ni2+-affinity purification step, His6-
TEV and the liberated His6-Z-tag as well as uncleaved His6-Z-RGG3-PY were removed from the solution 
and untagged RGG3-PY remained in the supernatant (see Fig. 8B and 8C). In presence of 
substoichiometric amounts of RNA, RGG3-PY undergoes phase separation and forms liquid droplets 
in a concentration-dependent manner (Fig. 9C). Titrating different types of RNA, namely in vitro 
transcribed MAPT RNA (a known FUS target (Orozco et al., 2012)) and total RNA isolated from HeLa 
cells (data not shown), revealed that there is an optimal RNA-to-protein ratio resulting in a maximal 
degree of phase separation of RGG3-PY (Fig. 9D). In the case of MAPT RNA, the optimum ratio 
RNA:RGG3-PY was 1:50, which was used for subsequent experiments addressing the phase separation 
behavior of RGG3-PY (including Fig. 9C). Similar to the N-terminal SYGQ-rich domain of FUS (Burke et 
al., 2015; Murakami et al., 2015), RGG3-PY forms droplets in a temperature-dependent manner (Fig. 
9E). At defined protein concentrations, phase separation of RGG3-PY can be enhanced by lowering 
the temperature and decreased with increasing temperature. Furthermore, droplet formation of 
RGG3-PY is promoted by lower salt concentrations and suppressed at higher salt concentrations (Fig. 
9F), indicating that phase separation of this domain is driven by electrostatic interactions, most likely 
involving positively charged RGG/RG motifs. 
In the end, the results obtained from untagged and tagged RGG3-PY showed similar trends (Fig. 9).  
Furthermore, removal of the tag has another advantage for subsequent protein analysis by Western 
blotting, namely that the Z-tagged protein is recognized by the constant region of IgGs causing 
unspecific signal for any antibody and therefore makes selective blotting of His6-Z-RGG3-PY 
impossible. Furthermore, for initial tests the crowding agents Ficoll (Fig. 9A and 9B) or polyethylene 
glycol (PEG) (data not shown) were used to promote phase separation of His6-Z-RGG3-PY, as described 
in a number of publications addressing phase separation of RBPs or DPR proteins (Boeynaems et al., 
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2017; Murakami et al., 2015; Patel et al., 2015). Addition of crowding agents was sufficient to induce 
droplet formation of His6-Z-RGG3-PY in absence of RNA, even though higher protein concentrations 
were required (Fig. 9A and 9B). Like in the case of the His6-Z-tag, crowding agents were subsequently 
excluded to avoid artifacts and thus all experiments were repeated with untagged RGG3-PY in the 
absence of crowding agents.  
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Figure 9: The C-terminal RGG3-PY domain of FUS undergoes LLPS. A) Droplet formation of His6-Z-RGG3-PY at 
indicated concentrations in the presence of 150 mg/ml Ficoll. Images acquired by phase contrast microscopy. 
Scale bar, 10 µm. B) Phase diagram of His6-Z-RGG3-PY in presence of 150 mg/ml Ficoll at different protein 
concentrations as a function of salt concentration. C) Addition of substoichiometric amounts of MAPT RNA 
(molar ratio 1:50) induces liquid droplet formation of RGG3-PY at indicated concentrations. The KGG3-PY mutant 
does not phase separate at 60 µM upon addition of MAPT RNA. Images acquired by phase contrast microscopy. 
Scale bar, 10 µm. D) Titration of substoichiometric amounts of in vitro transcribed MAPT RNA to RGG3-PY reveal 
maximal turbidity at a molar RNA-to-protein ratio of 1:50 which was used for all phase separation assays with 
untagged RGG3-PY. E) and F) phase diagrams of RGG3-PY as a function of temperature E) and salt concentration 
F) over protein concentration. Presence (green circles) or absence (red diamonds) of droplets were scored using 
phase contrast microscopy.  
 
 
2.2 The RGG3-PY domain and arginine residues are essential for phase separation of 
FUS 
In order to elucidate the influence of arginine residues on phase separation of RGG3-PY, we purified 
a mutant version, termed KGG3-PY, in which all eight arginines in RGG motifs of the RGG3 domain 
were mutated to lysines (K), thus maintaining the positive charge of the residues (for sequence see 
Fig. 7B). Remarkably, under conditions inducing large liquid droplets of RGG3-PY, mutant KGG3-PY 
does not phase separate at all and remains completely dispersed (Fig. 9C). Thus, arginines in the RGG3 
motif are essential for LLPS of the RGG3-PY domain.   
To address whether the C-terminal RGG3-PY as well as arginines in the RGG/RG motifs are also 
essential for phase separation of full-length FUS, human FUS was cloned into a vector encoding an N-
terminal MBP-tag and a C-terminal His6-tag (MBP-FUS-His6 WT). Both tags were separated from FUS 
by TEV protease cleavage sites, allowing proteolytic removal of the tags by TEV protease (for scheme 
see Fig. 10A). Purification of MBP-FUS-His6 proteins was demanding and required much effort for 
optimization. First, no bacterial expression constructs giving proper expression in E. coli were 
available. In particular, protein expression from some constructs could not be induced whereas others 
(both GST- or MBP-tagged at the N-terminus of FUS) could be induced, but the protein of interest did 
not bind to the respective affinity matrices. Eventually, an expression construct encoding MBP-FUS-
His6 WT, which could be successfully induced, was obtained from a collaborator and the protein of 
interest was binding to Amylose and NiNTA resins via the respective affinity tags.  Second, good yields 
of soluble protein could be only obtained by very mild induction of protein expression at 12°C for at 
least 22 h in E. coli. Third, it was crucial to use optimized bacterial strains, such as Rosetta, that have 
tRNAs for rare arginine codons (AGA, AGG, CGA) and glycine codons (GGA) to improve protein 
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expression, since the bacterial expression construct for full-length, human FUS is not codon optimized. 
The N-terminal MBP-tag keeps the proteins soluble and also serves as an affinity tag for purification. 
Following sonification, tandem affinity purification using NiNTA and Amylose resin was performed (see 
Fig. 10B and 10C). 
As a side note, the RGG3-PY domain in general and any full-length FUS proteins used in assays involving 
the addition of RNA were purified in a nuclei acid-free form. In contrast to RGG3-PY (see scheme in 
Fig. 8B), this was not straightforward for full-length FUS, as simple high-salt washes were not sufficient 
to remove nucleic acids and any nuclease treatments caused irreversible precipitation of the protein 
during purification. Furthermore, treatment of the bacterial lysates or purified proteins with 
polyethyleneimine (PEI) (0.1% w/v)) or protamine sulfate (1% (w/v)) did not facilitate precipitation 
and removal of nucleic acids, but caused precipitation of the protein (not shown). Initially, purification 
of the double-tagged MBP-FUS-His6 protein was performed via single-affinity purification yielding full-
length FUS free of contaminating protein bands, but bound to nucleic acids. Surprisingly, tandem-
affinity purification by itself yields soluble, nucleic acid-free FUS. 
 In addition to MBP-FUS-His6 WT (hereafter referred to as MBP-FUS), I also cloned two mutant 
versions, a C-terminal deletion mutant where the RGG3-PY domain was deleted (ΔRGG3-PY) and a 
variant in which all arginines in RGG/RG motifs were mutated to lysines (all-KGG) (Fig. 10D). All MBP-
FUS proteins were purified as described above. Besides plasmid sequencing, we performed Western 
Blot analysis of the WT and mutant MBP-FUS proteins using different FUS antibodies to confirm the 
protein identities. First, we used an anti-pan-FUS antibody (4H11) directed against a common epitope 
N-terminally of the RGG3 domain. It recognizes all three versions of FUS and confirmed a lower 
molecular weight of ΔRGG3-PY. Second, an anti-FUS-RGG3 antibody (14G1), which only detects MBP-
FUS WT, was used to confirm the mutations (Fig. 10E). 
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Figure 10: Purification of MBP-FUS-His6 proteins. A) Scheme of MBP-FUS construct. Full-length FUS was N-
terminally tagged with MBP to keep the protein soluble as well as C-terminally His6-tagged. Both tags are 
separated from FUS by TEV cleavage sites and can be utilized for tandem–affinity purification. B) Schematic of 
the workflow for purification of all MBP-FUS-His6 proteins. Induction of protein expression in E. coli was 
performed under very mild conditions at 12°C for 22h, in order to obtain soluble MBP-FUS. Following 
sonification, tandem-affinity purification using both affinity tags via NiNTA agarose and Amylose resin was 
performed. Pure MBP-FUS-His6 proteins were buffer exchanged to IVM buffer and concentrated. C) Exemplary 
SDS-PAGE gels visualizing the purification of MBP-FUS-His6 (WT). Protein bands are visualized by Coomassie 
stain. Note, that the lanes are not loaded equally. Elution fractions were pooled before buffer exchange. 
Molecular weight markers (in kDa) are indicated on the left. D) Schematic diagram of FUS full-length (WT), FUS 
with deletion of the RGG3-PY (ΔRGG3-PY), and a FUS mutant in which all RGGs in the RGG domains were mutated 
to KGGs (all-KGG). The three proteins are N-terminally tagged with MBP and C-terminally with His6, as shown in 
the scheme in A). E) Western blots for verification of protein identities. Antibody specific for FUS-RGG3 (14G1) 
does not recognize mutant MBP-FUS proteins (ΔRGG3-PY and all-KGG). Equal loading demonstrated using an 
anti-FUS antibody that binds N-terminally of the RGG3 domain (4H11). 
 
Upon liberation from the MBP-tag by proteolytic cleavage, full-length FUS (WT) starts to undergo 
liquid-liquid phase separation and forms liquid-like protein droplets (see scheme Fig. 11A) at 
physiological concentrations (1-10 µM in HeLa cells (Patel et al., 2015)). In order to exclude that phase 
separation of FUS is induced simply by the presence of TEV protease independent of its proteolytic 
cleavage activity, recombinant MBP-FUS harboring a PreScission cleavage site was used.   This protein 
only phase separates upon addition of PreScission protease, while addition of TEV protease does not 
induce its phase separation. Complementary, addition of PreScission protease is unable to induce 
phase separation of MBP-FUS containing a TEV cleavage site (Fig. 11B).  
When a protein phase separates, the solution rapidly turns turbid and its optical density (OD) 
increases. The optical density can be measured at 600 nm and used as a quantitative readout for phase 
separation. When analyzed in such a turbidity assay, FUS WT shows a strong increase in turbidity, 
whereas turbidity of FUSΔRGG3-PY reaches significantly lower turbidity values. The all-KGG mutant 
completely fails to phase separate and the solution remains clear (Fig. 11C). Furthermore, a 
sedimentation assay was performed, where protein samples are centrifuged and the partitioning of 
the protein into the pellet fraction is used as a measure for phase separation. Concordant with the 
turbidity measurements, FUSΔRGG3-PY partitions significantly less into the pellet fraction in 
comparison to WT, and the all-KGG mutant remains almost completely in the supernatant (Fig. 11D, 
see Fig. 11E for quantification). Together, these results demonstrate that phase separation of FUS is 
not exclusively driven by the N-terminal SYGQ-rich domain (Burke et al., 2015; Kato et al., 2012; 
Murakami et al., 2015; Patel et al., 2015; Sun et al., 2011), as arginines in the C-terminal RGG/RG 
motifs and the RGG3-PY domain also have a crucial contribution to phase separation of FUS. 
48 
 
 
Figure 11: Arginines residues in the RGG/RG motifs crucially contribute to LLPS of full-length FUS. A) Schematic 
representation of TEV protease cleavage-induced phase separation of FUS. Addition of TEV protease to soluble 
MBP-tagged FUS causes proteolytic liberation of the MBP-tag (and His6-tag, not shown in this scheme) and 
induces formation of liquid-like FUS droplets. B) TEV protease selectively induces phase separation of MBP-FUS 
harboring a TEV cleavage site by liberating the MBP-tag, but does not induce droplet formation of MBP-
PreScission-FUS. Images acquired by phase contrast microscopy. Scale bar, 10 µm. C) Turbidity assay for 
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quantitative comparison of TEV cleavage-induced phase separation of MBP-FUS-WT with the mutants MBP-FUS-
ΔRGG3-PY and MBP-FUS-all-KGG (all proteins at 7 µM). Phase separation of the C-terminal deletion mutant 
(ΔRGG3-PY) and the all-KGG mutant are strongly impaired in comparison to FUS WT. Values represent means ± 
SEM (n=3). ***p < 0.001 by one-way ANOVA with Dunnett´s multiple comparison test. D) Sedimentation assay 
for quantitative comparison of TEV cleavage induces phase separation of MBP-FUS-WT, MBP-FUS-ΔRGG3-PY and 
MBP-FUS-all-KGG (all proteins at 1 μM). The mutant proteins are significantly less partitioned to the pellet 
fraction, confirming decreased phase separation compared to FUS WT. Proteins were detected by SyproRuby 
staining, molecular weight markers (in kDa) are indicated on the left. E) Quantification of the FUS band intensities 
in supernatant (S) and pellet (P) fractions is depicted as S/P ratio. Values represent means ± SEM (n=3). ** p<0.01 
and ***p < 0.001 by one-way ANOVA with Bonferroni multiple comparison test. 
 
 
2.3 Phase transitions of FUS are suppressed by TNPO1 in vitro 
Several importin β-type nuclear import receptors have been shown to suppress aggregation of 
positively charged ribosomal proteins and histones in the cytoplasm (Jakel et al., 2002). As TNPO1 
mediates nuclear import of FUS by interacting with the RGG3-PY domain (Dormann et al., 2012; Lee 
et al., 2006), which we have shown to be required for phase separation, we assumed that TNPO1 may 
fulfill a similar chaperone function towards its import cargo FUS. In order to test the hypothesis 
whether TNPO1 affects liquid-liquid phase separation of FUS, we cloned a C-terminally EGFP-tagged 
version of the previously used MBP-FUS, referred to as MBP-FUS-EGFP, and purified the protein 
analogously from E. coli (for scheme see Fig. 10B). This EGFP-tagged protein allowed us to visualize 
liquid droplets by fluorescence microscopy. EGFP-His6 was fused to the C-terminus of FUS by a flexible 
13-amino-acid linker (GAPGSAGSAAGSG), which according to Patel et al. (2015) maintains 
functionality of the FUS C-terminus (Fig. 12A). Similar to non-fluorescently labelled MBP-FUS, MBP-
FUS-EGFP is soluble at physiological concentrations, but starts to phase separate upon proteolytic 
removal of the MBP-tag by TEV protease (Fig. 12B).   
In order to test whether TNPO1 influences LLPS of FUS, equimolar amounts of recombinant TNPO1 or 
buffer only were added to MBP-FUS-EGFP-His6 and formation of TEV cleavage-induced (+ TEV) FUS-
EGFP droplets was visualized using confocal microscopy. Remarkably, FUS droplet formation is 
completely suppressed in presence of equimolar amounts of TNPO1 (Fig. 12B, see quantification of 
droplet area in Fig. 12C). Notably, half-molar amounts of TNPO1 are not sufficient to suppress droplet 
formation of FUS completely, but only suppress LLPS partially (approximately to fifty percent) (Fig. 
12B), indicating that a 1:1 ratio of FUS:TNPO1 is needed for efficient suppression of LLPS. Furthermore, 
addition of TNPO1 to preformed FUS droplets causes an instantaneous dissolution of the droplets (Fig. 
12D). These results show that TNPO1 is not only able to prevent, but also to reverse phase separation 
of FUS. In order to examine, whether this effect is specific to TNPO1, we added two other known FUS 
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interactors, namely PRMT1 that binds to FUS-RGG domains (Scaramuzzino et al., 2013; Tradewell et 
al., 2012) and an anti-FUS-RGG3-specific antibody (Suarez-Calvet et al., 2016) (direct binding 
confirmed in an in vitro binding assay, Fig. 13D), does not suppress phase separation of FUS to the 
same degree as TNPO1 (Fig. 12B, see Fig. 12C for quantification). Furthermore, the presence of the 
nuclear import receptor Importin 5 (Imp5), which is not a cognate import receptor of FUS and does 
not interact with FUS in vitro (Fig. 13D), is also not able to suppress phase separation of FUS (Fig. 12B 
and 12C). 
 
 
Figure 12: Transportin (TNPO1) suppresses and reverses droplet formation of FUS-EGFP in vitro. A) Scheme of 
MBP-FUS-EGFP construct. The construct is analogous to the MBP-FUS constructs and was purified as depicted in 
Fig. 10B. Instead of the C-terminal His6-tag, it contains a C-terminal EGFP-His6 separated by a 13 amino acid 
linker, to maintain functionality of the PY-NLS of FUS. B) Phase separation of MBP-FUS-EGFP induced by TEV 
protease cleavage is efficiently suppressed by equimolar amounts of TNPO1, but not by PRMT1, an antibody 
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specific for FUS-RGG3 (14G1) or by Importin 5 (Imp5). Note that the FUS-RGG3-specific antibody appears to 
increase the size of liquid FUS droplets, possibly by crosslinking two FUS molecules. Images were acquired by 
confocal fluorescence microscopy. Scale bar, 10 µm. C) Quantification of image area covered by FUS-EGFP 
droplets in percent. Values represent means ± SEM (n=3). ***p < 0.001 by one-way ANOVA with Dunnett´s 
multiple comparison test. D) Preformed droplets of FUS-EGFP (6 µM) dissolve instantaneously upon mixing with 
equimolar amounts of TNPO1. Changes in FUS-EGFP concentration and buffer conditions were obviated by using 
a highly concentrated stock of TNPO1 (140 µM) in droplet buffer. Scale bar, 5 µm. 
 
Besides microscopic observation of droplet formation with subsequent quantification of droplet area, 
there are also other assays to monitor phase separation in a more quantitative way, namely the above 
described turbidity and sedimentation assays (Fig. 11C and 11D), for which non-EGFP-tagged FUS was 
utilized. To confirm our findings with EGFP-tagged FUS, we analyzed the effect of TNPO1 or control 
proteins on phase separation of MBP-FUS in a turbidity assay or sedimentation assay, respectively. In 
the presence of buffer, PRMT1, anti-FUS-RGG3 antibody or Imp5, respectively, the protein solution 
becomes turbid upon TEV protease-induced removal of the MBP-tag from FUS, whereas in the 
presence of TNPO1 the optical density of the solution remains low, comparable to the uncleaved and 
therefore dispersed MBP-FUS (Fig. 13A). Similarly, in a sedimentation assay, TEV cleavage causes 
quantitative partitioning of FUS into the pellet fraction after centrifugation, whereas FUS remains 
soluble in the presence of TNPO1. In contrast to TNPO1, PRMT1, the FUS-RGG3-specific antibody, and 
Imp5 are not able to keep FUS in the supernatant (Fig. 13B, see Fig. 13C for quantification).  
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Figure 13: TNPO1 suppresses phase separation of FUS in vitro. A) Turbidity measurement for quantitative 
analysis of MBP-FUS phase separation in presence or absence of TNPO1 or various control proteins (PRMT1, 
Imp5 and anti-FUS-RGG3 antibody (14G1)). The MBP-tag of recombinant MBP-FUS (7 µM) was cleaved by TEV 
protease in presence or absence of equimolar amounts of TNPO1 or various control proteins, respectively. 
Values represent means ± SEM (n=3). ***p < 0.001 by one-way ANOVA with Dunnett´s multiple comparison test. 
B) Sedimentation assay to quantify TEV cleavage-induced phase separation of MBP-FUS (1µM) in the presence 
or absence of equimolar amounts of TNPO1 or the control proteins PRMT1, Imp5 or anti-FUS-RGG3 antibody, 
respectively. C) Quantification of the FUS band intensities in supernatant (S) and pellet (P) fractions is depicted 
as S/P ratio. Values represent means ± SEM (n=3). ***p < 0.001 by one-way ANOVA with Tukey´s multiple 
comparison test. D) Pulldown (PD) assay to test direct interactions of MBP-FUS-EGFP with TNPO1 or indicated 
control proteins. Input and PD represent 5 % or 30 % of the sample, respectively. Protein bands are visualized 
by SyproRuby. Molecular weight markers (in kDa) are indicated on the left. 
 
As recently reported in multiple studies, recombinant FUS can form solid aggregates and fibril-like 
structures in vitro through a liquid-to-solid state transition (Monahan et al., 2017; Patel et al., 2015). 
In order to study whether TNPO1 is not only able to prevent FUS droplet formation, but also to 
suppress the formation of FUS aggregates, in vitro “aging” assays were performed according to Patel 
53 
 
et al. (2015). Here, droplet formation of FUS-EGFP is induced by TEV protease cleavage and is followed 
by incubation for eight hours under mild agitation, leading to solidification and formation of large 
amorphous structures (Fig. 14A). The presence of equimolar amounts of TNPO1 suppresses droplet 
formation of FUS and consequently prevents the formation of large aggregates. In contrast, PRMT1 or 
Imp5, are not able to suppress the formation of amorphous aggregates (Fig. 14A). Notably, large 
amorphous aggregates form only when sample agitation is combined with pipetting up and down 
every hour. Otherwise, droplets only attach to each other and form chain-like structures.  90 min after 
TEV protease cleavage of MBP-FUS, we observed rod-like FUS fibrils by transmission electron 
microscopy (TEM). In line with the previously described assays, formation of FUS fibrils is completely 
suppressed in the presence of TNPO1 (Fig. 14B).  
In sum, these results provide strong evidence that TNPO1 fulfills a dual function towards FUS: It not 
only mediates its nuclear import, but also keeps FUS soluble, by suppressing LLPS and subsequent 
solidification and aggregation of FUS in vitro. 
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Figure 14: TNPO1 prevents solidification and fibrilization of FUS in vitro. A) In vitro liquid-to-solid phase 
transition of FUS-EGFP droplets (7 µM) is suppressed by equimolar amounts TNPO1, but not by the control 
proteins PRMT1 and Imp5, respectively. Images were acquired by confocal fluorescence microscopy. Scale bar, 
50 µm. B) Fibril formation of FUS is suppressed in presence of equimolar amounts of TNPO1. MBP-FUS (7 µM) 
was incubated with TEV protease for 90 min in presence or absence of equimolar amounts of TNPO1 and images 
acquired by TEM. Arrows denote fibrillary FUS aggregates. Scale bar, 200 nm. 
 
 
2.4 TNPO1 exerts its chaperone function in cells independent of its nuclear import 
activity 
As high RanGTP levels mediate dissociation of import complexes in the nucleus (Gorlich et al., 1996; 
Lee et al., 2006; Rexach and Blobel, 1995), it can be assumed that TNPO1 fulfills its chaperone activity 
towards FUS mainly in the cytoplasm, where RanGTP levels are low and therefore allow for the binding 
of TNPO1 to its cargoes. In order to test this hypothesis and to separate the chaperone activity of 
TNPO1 from its nuclear import activity, FUS was anchored in the cytoplasm by fusing it to a hormone-
responsive domain of the glucocorticoid receptor (GCR) (GCR2-tagRFP2-FUS) (Love et al., 1998). 
Trapping of the GCR domain in the cytoplasm is maintained as long as no steroid hormones are present 
in the growth medium. In order to interfere with FUS-TNPO1 binding, a high affinity peptide inhibitor 
of TNPO1 (EGFP-M9M), that competes with regular TNPO1 cargoes (Cansizoglu et al., 2007), was co-
expressed. Expression of the importin alpha (Imp α)-specific peptide inhibitor EGFP-bimax was used 
as a control. Bimax impairs Imp α-cargo interaction and consequently Imp α/β-dependent nuclear 
import (Bentmann et al., 2012; Dormann et al., 2010; Kosugi et al., 2008). Notably, expression levels 
of GCR2-tagRFP2-FUS in M9M-expressing cells were comparable or lower compared to cells co-
expressing Bimax (data not shown). While Bimax-expressing cells show a diffuse cytosolic distribution 
of GCR2-tagRFP2-FUS, almost 50% of cells expressing the TNPO1-specific inhibitor M9M exhibit 
cytosolically anchored FUS localized to TIA1 positive SGs (Fig. 15A, see Fig. 15B for quantification), 
which were induced by transfection stress under both conditions. These results demonstrate that 
interference with FUS-TNPO1 binding promotes SG association of cytosolic FUS, suggesting that 
TNPO1 may chaperone cytoplasmic FUS and suppress its recruitment into SGs. 
In order to directly assess the capability of TNPO1 to suppress SG partitioning of FUS, a variation of 
the semi-permeabilized cell assay was applied. Here, HeLa cells were treated with the proteasome 
inhibitor MG132 to evoke the formation of SGs (Ganassi et al., 2016), followed by selective 
permeabilization of the plasma membrane using digitonin. Subsequently, soluble proteins, including 
importins and other chaperones, were washed out from the cytoplasm (see scheme in Fig. 15C). Then, 
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in order to separate the nuclear import function of TNPO1 from its cytosolic chaperone activity, the 
nuclear pores were blocked using wheat germ agglutinin (WGA), thus preventing active nuclear 
transport through nuclear pore complexes (Yoneda et al., 1987). Afterwards, recombinant MBP-FUS-
EGFP was added to the semi-permeabilized cells in presence or absence of TNPO1 and cells were 
washed to remove unbound proteins. In absence of TNPO1, recombinant FUS is bound to SGs, as 
indicated by co-staining with the SG marker protein G3BP1 (Fig. 15D). Notably, a 10-fold excess of 
TNPO1 was necessary to obtain efficient shielding of FUS in this assay. Equimolar amounts of TNPO1 
are not sufficient, possibly due to a high abundance of other TNPO1 interactors in the preformed SGs 
that may capture most of TNPO1 added to the semi-permeabilized cells. Under these conditions, FUS 
shows significantly less association with SGs in presence of TNPO1 (Fig. 15D, see Fig. 15E for 
quantification). 
Remarkably, these results demonstrate that TNPO1 suppresses SG association of FUS independent of 
its function as nuclear import receptor. Thus, in addition of its capability to suppress phase separation 
of FUS in vitro, TNPO1 also fulfills chaperone activity towards FUS in the cytoplasm, and hence reduces 
the likelihood of FUS to accumulate in SGs and undergo concentration-dependent aggregation in these 
structures.  
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Figure 15: TNPO1 exerts chaperone activity in the cytoplasm and suppresses of SG association of FUS. A) 
Overexpression of the specific TNPO1 inhibitor EGFP-M9M causes a partial localization of cytosolically anchored 
FUS (GCR2-tagRFP2-FUS) with SGs, whereas overexpression of the importin α/β-specific inhibitor EGFP-bimax 
does not cause SG partitioning of GCR2-tagRFP2-FUS. For better visibility, the EGFP signal is depicted in magenta 
and the tRFP fluorescence is depicted in green in the overlay to the right. SGs were visualized by co-
immunostaining with a TIA1-specific antibody (red) and nuclei were counterstained with DAPI (turquois).  Images 
were acquired by confocal fluorescence microscopy. Scale bar, 20 µm. B) Quantification of cells exhibiting GCR2-
tagRFP2-FUS localized to SGs. Values represent means ± SEM (n=3; ≥100 cells each). ***p < 0.001 by Fisher´s 
exact test. C) Schematic representation of the modified semi-permeabilized cell assay allowing detection of SG 
partitioning of recombinant FUS. Following SG induction using MG132, the plasma membrane is selectively 
permeabilized by digitonine and all soluble proteins are washed out of the cytoplasm. In order to eliminate active 
nuclear import, nuclear pores are blocked by WGA prior to addition of recombinant MBP-FUS-EGFP in presence 
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or absence of TNPO1. D) SG recruitment of MBP-FUS-EGFP in semi-permeabilized cells is prevented by TNPO1. 
SGs visualized by G3BP1-immunostaining (red). Nuclei were counterstained with DAPI (turquois).  Images were 
acquired by confocal fluorescence microscopy. Scale bar, 10 µm. E) Quantification of log-transformed mean 
fluorescence intensity MBP-FUS-EGFP in SGs from three replicates ± SEM (≥ 10 cells, ≥ 32 SGs each). ***p < 
0.001 by Mann-Whitney test.  
 
 
2.5 Mechanisms contributing to the chaperone activity of TNPO1 
Based on our finding that the nuclear import receptor TNPO1 is able to suppress phase separation of 
FUS, we postulated two putative mechanisms how TNPO1 may interfere with phase separation of FUS. 
As FUS harbors multiple domains involved in RNA binding and specifically RGG/RG-rich motifs were 
recently reported to be essential for RNA-binding of FUS (Ozdilek et al., 2017), our first hypothesis was 
that TNPO1 may interfere with RNA-driven phase separation of FUS by competing with RNA-binding 
to RGG/RG motifs. Second, as arginines are crucial for phase separation of FUS (see section 2.2 and 
Fig. 11), we considered the possibility that TNPO1 suppresses arginine-driven phase separation of FUS 
by directly interacting with arginines. 
In order to test the first hypothesis, the effect of TNPO1 on RNA-driven LLPS of the RGG3-PY domain 
was addressed by NMR spectroscopy. To this end, unlabeled (UG)12 RNA was titrated to 15N-labeled 
RGG3-PY, causing an increase in turbidity and leading to progressive disappearance of 1H-15N cross 
peaks (Fig. 16A). At the same time, the signal intensity in the corresponding 1D NMR spectrum 
decreases (Fig. 16B), indicating the formation of high-molecular weight RGG3-PY/RNA droplets, 
resulting in a broadening of NMR signals as a result of reduction in rotational tumbling time of the 
RGG3 region within droplets. Since NMR signals of unlabeled RNA were absent in the 1D NMR spectra 
(Fig. 16B), RNA is quantitatively bound in RGG3-PY droplets. Upon addition of equimolar amounts of 
TNPO1 to the RGG3-PY/RNA droplet sample, turbidity is lost and 1H NMR signals of the RNA 
reappeared, indicating that RNA is displaced from RGG3-PY by TNPO1 binding and consequently 
droplets dissolved (Fig. 16B). Next, radioactive filter-binding experiments were conducted using RGG3-
PY (Fig. 16C) or MBP-FUS (Fig. 16D) preincubated with radiolabeled ASH1 E3-51 RNA, TNPO1 was 
subsequently titrated into the RGG3-PY- or MBP-FUS-RNA complexes in order to test whether TNPO1 
displaces RNA from FUS. In a radioactive filter-binding assay, RNA-protein complexes are visualized on 
a nitrocellulose (NC) membrane, whereas free RNA is detected on a nylon membrane. Consistent with 
the NMR experiments, radioactive signal intensity on the nitrocellulose membrane (NC), decreases 
with increasing amounts of TNPO1, demonstrating that TNPO1 displaces RNA from RGG3-PY (Fig. 16C) 
and MBP-FUS (Fig. 16D and 16E). Thus, TNPO1 competes with RNA for the same binding sites and 
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competes away RNA that is bound to the C-terminal RGG3-PY domain or full-length FUS. However, 
although phase separation of RGG3-PY is clearly promoted upon addition of RNA (Fig. 9D), we did not 
detect a significant alteration in phase separation of full-length FUS upon titration of ASH1 E3-51 RNA 
(Fig. 16F). Concordantly, similar results were obtained for titration of MAPT RNA (Fig. 16G) and total 
RNA (data not shown). Together, these results indicate that, under our experimental conditions, phase 
separation of full-length FUS is not strongly affected by RNA. Consequently, the displacement of RNA 
from FUS by TNPO1, does not seem to be the major mechanism by which TNPO1 suppresses phase 
separation of FUS. 
Previously published data have demonstrated that TNPO1 directly binds to a synthetic FUS-RGG3 
peptide (Dormann et al., 2012) as well as to several arginine residues in the RGG3 motif of FUS (R472, 
R473, R476) (Gobl et al., 2016). This supports the second hypothesis that TNPO1 suppresses arginine-
driven phase separation of FUS by direct interaction with arginines in the RGG3-PY domain. Our ITC 
data show a strong decrease in binding of TNPO1 to RGG3-PY at higher salt concentrations (Table 2), 
indicating that the interaction of TNPO1 with FUS-RGG3 is primarily charge-driven. This furthermore 
supports the idea that TNPO1 undergoes electrostatic interactions with positively charged arginines 
and thus may interfere with arginine-driven phase separation of FUS. 
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Figure 16: Different mechanisms may be involved in the chaperoning by TNPO1. A) NMR data visualizing RNA-
driven phase separation of FUS RGG3-PY. 1H-15N SOFAST HMQC spectrum of 15N-labeled RGG3-PY in presence 
(orange) or absence (black) of 0.2 stochiometric equivalents of (UG)10 RNA. Spectra were recorded with an 
interscan delay of 1.0 s, spectral widths of 16/32 ppm, centered at 4.7/115.0 ppm in 1H/15N, with 512 and 128 
complex data points, respectively, and 8 scans per increment. B) NMR data confirming RNA displacement from 
FUS RGG3-PY by TNPO1. 1H NMR spectra of 15N-labeled RGG3-PY (black), supplemented with 0.2 stochiometric 
equivalents of (UG)10 RNA (orange), and with equimolar amounts of TNPO1 (light blue), respectively. The 
reference 1H NMR spectrum of free RNA at the same concentration is depicted in grey (dotted line). Protein 
concentrations were 100 μM. Spectra were recorded with an interscan delay of 1.0 s, spectral widths of 20 ppm, 
centered at 4.7 ppm in 1H, with 512 complex data points and 256 scans. C) Representative images of a filter-
binding assay with FUS RGG3-PY, TNPO1, and radiolabeled ASH1 E3-51 RNA. RNA-protein binding (nitrocellulose 
membrane: NC) and free RNA (nylon membrane) are visualized by phosphorimaging. Increasing amounts of 
TNPO1 displace bound RNA from FUS RGG3-PY (NC) and cause an increasing signal of liberated RNA (nylon). D) 
Representative images of a radioactive filter-binding experiment with MBP-FUS, TNPO1 and, radioactively 
labeled ASH1 E3-51 RNA. Titration of TNPO1 results in reduction of RNA bound to MBP-FUS (NC) and 
concomitant increase in free RNA (nylon). E) Representative plot of relative signal intensities from radioactive 
filter-binding assay shown in D). The relative signal intensity was plotted over the titrated TNPO1 concentration. 
For curve fitting the exponential decay fitting algorithm (in Origin software) was applied. Summary of the decay 
factor and amplitude of three independent experiments are depicted in the table. F) and G) Turbidity assay to 
determine the influence of in vitro transcribed ASH1 E3-51 RNA (F) and MAPT RNA (G) on TEV cleavage-induced 
phase separation of MBP-FUS (5µM), demonstrating no promoting effect of RNA on LLPS of full-length FUS at 
the indicated RNA:FUS ratios. Values represent means ± SEM (n=3). 
 
 
Table 2: Thermodynamic parameters of ITC titrations to TNPO1 
Protein Kd (nM) ΔH (kcal*mol-1) ΔS (kcal*mol-1) 
unmeRGG3-PY 3 ± 1 -26.5 ± 0.1 - 49.7 
meRGG3-PY 126 ± 20 -25.3 ± 0.1 - 48.6 
unmeRGG3-PY (1 M NaCl) 398 ± 31 -18.9 ± 0.4 -34.3 
unmeRGG3-PY P525L 27 ± 2 -17.6 ± 0.1 -24.5 
meRGG3-PY P525L 356 ± 27 -17.4 ± 0.2 -28.6 
unmeRGG3-PY P525L (1M NaCl) not detectable 
 
Errors represent the SD of the fit. 
Stoichiometry associated with complex formation was set to 1. 
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2.6 Loss of arginine methylation promotes phase separation of FUS 
Arginines in RGG/RG-rich motifs are common targets for PRMTs and therefore are frequently 
methylated (Guo et al., 2014; Thandapani et al., 2013; Wooderchak et al., 2008). As arginines in the 
RGG domains of FUS are usually asymmetrically dimethylated (Dormann et al., 2012; Guo et al., 2014; 
Ong et al., 2004; Rappsilber et al., 2003; Suarez-Calvet et al., 2016; Uhlmann et al., 2012) and we found 
that arginines and RGG/RG motifs have an essential contribution to phase separation of FUS (see 
section 2.2 and Fig. 11), we next addressed whether arginine methylation of RGG/RG motifs may alter 
phase separation of FUS. This question is of particular importance, since asymmetric dimethylation of 
arginines of FUS-RGG3 domain is lost in pathological inclusions of FTD-FUS patients and instead FUS is 
unmethylated and monomethylated (Dormann et al., 2012; Suarez-Calvet et al., 2016). In spite of that, 
it remains elusive whether and how loss of methylation of FUS contributes to pathology of FTD-FUS. 
In order to address this question, we aimed to compare unmethylated and methylated MBP-FUS-
EGFP, MBP-FUS or RGG3-PY in phase separation assays. As proteins are not post-translationally 
modified in bacteria, the purified proteins are originally unmethylated. In order to specifically obtain 
asymmetric dimethylated FUS, in vitro methylation of FUS proteins with PRMT1 as methylating 
enzyme was performed. To do so, recombinant His6-PRMT1 was expressed in E. coli and purified via a 
HisTrap column. In order to remove bound nucleic acids, the bound protein was subjected to high salt 
washes (1M NaCl). Applying an imidazole gradient allowed to gradually elute contaminating proteins 
in a first peak followed by almost pure His6-PRMT1 (second peak). Notably, fast buffer exchange of 
PRMT1 by a HiPrep Desalting column had to be performed (see scheme in Fig. 17A and 17B), as prompt 
use of PRMT1 in in vitro methylation reactions emerged to be crucial for efficient methyltransferase 
activity. Particularly, freezing or short term storage of recombinant PRMT1 was not possible, since 
PRMT1 precipitated and lost its enzymatic activity upon freeze-thawing or storage at 4°C. Similarly, 
buffer exchanges using overnight dialysis or spin concentrator tubes provoked precipitation and loss 
of activity (not shown). For in vitro methylation, FUS proteins were incubated with purified PRMT1 
and SAM (+ SAM) as a methyl group donor. As a control, unmethylated FUS proteins were incubated 
with PRMT1 in absence of SAM (- SAM) (see scheme in Fig. 17C). Successful in vitro methylation was 
verified by Western blotting using antibodies specific for FUS-RGG3 carrying unmethylated arginines 
(UMA), monomethyl arginines (MMA), and asymmetric dimethylarginines (ADMA) (Dormann et al., 
2012; Suarez-Calvet et al., 2016) (Fig. 17D). Incubation with PRMT1 and SAM caused a strong signal 
reduction for UMA-FUS and an appearance of an ADMA-FUS signal (Fig. 17D), confirming that 
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unmethylated proteins were efficiently converted to a primarily asymmetrically dimethylated form. In 
contrast, proteins remained unmethylated when incubated with PRMT1 only (- SAM) (Fig. 17D). 
 
Figure 17: Purification of His6-PRMT1 for in vitro methylation of FUS. A) Schematic of the workflow with 
representative ÄKTA chromatograms for purification of His6-tagged protein arginine methyltransferase 1 (His6-
PRMT1). Following sonification, the cleared bacterial lysate was applied to a HisTrap column using a peristaltic 
pump and subjected to high salt washes (1M NaCl). Subsequently, imidazole gradient elution was performed via 
an ÄKTA system and the pooled elution fractions were desalted via a HiPrep Desalting column. The 
chromatogram of HiPrep Desalting provides a first peak containing the buffer exchanged protein (blue) followed 
by a salt peak.  B) Exemplary SDS-PAGE gels visualizing the purification of His6-PRMT1. Protein bands are 
visualized by Coomassie stain. Note that the lanes are not loaded equally. Indicated fractions yielded from 
gradient elution were pooled and further processed with a HiPrep Desalting column. All fractions of the protein 
peak were pooled and used for subsequent in vitro methylation. Molecular weight markers (in kDa) are indicated 
on the left. C) Schematic representation of in vitro methylation of FUS proteins. Purified proteins were incubated 
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with purified His6-PRMT1 and the methyl group donor S-adenosylmethionine (+SAM overnight at room 
temperature). To obtain an unmethylated control, recombinant FUS was incubated with PRMT1 in absence of 
SAM (-SAM). D) Representative immunoblots for MBP-FUS-EGFP confirming successful in vitro methylation. 
Immunoblotting performed with monoclonal antibodies specific for FUS-RGG3 containing unmethylated 
arginines (UMA-FUS, 14G1), monomethylated arginines (MMA-FUS, 15E11) and asymmetrically dimethylated 
arginines (ADMA-FUS, 9G6), respectively, demonstrates a strong reduction of the UMA-FUS signal and a 
conversion to ADMA-FUS. Equal loading was confirmed by immunoblotting with an EGFP-specific antibody. 
Similar results were obtained for MBP-FUS and RGG3-PY in vitro methylation (data not shown). 
 
First, we compared the propensity to undergo LLPS of unmethylated and methylated MBP-FUS-EGFP 
in a droplet assay. This revealed that unmethylated FUS forms liquid droplets at lower protein 
concentration than dimethylated FUS (Fig. 18A). In order to exclude that reduced phase separation of 
FUS is caused by the presence of SAM, addition of SAM alone did not alter LLPS of unmethylated FUS 
(data not shown). Similarly, in a sedimentation assay, unmethylated FUS shows a significantly higher 
degree of partitioning into the pellet fraction than methylated FUS (Fig. 18B, see Fig. 18C for 
quantification). Concordantly, in a turbidity assay where TEV-induced phase separation of 
unmethylated and methylated FUS was monitored over time, unmethylated FUS reaches higher 
turbidity compared to unmethylated FUS (Fig. 18D). In order to exclude that phase separation of 
methylated FUS is compromised by bound nucleic acids, since the protein samples used in Fig. 18 A-D 
were not completely nucleic acid-free, the droplet assay was repeated with a nucleic acid-free 
preparation of unmethylated and methylated FUS-EGFP (Fig. 18E). In line with the previously 
performed assays, RNA-free methylated FUS-EGFP also shows reduced droplet formation compared 
to unmethylated FUS-EGFP (Fig. 18E). Thus, irrespective of RNA-binding, loss of arginine methylation 
promotes LLPS of FUS. 
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Figure 18: Arginine methylation reduces phase separation of FUS. A) Droplet formation of unmethylated 
(unme) FUS-EGFP is enhanced compared to methylated (me) FUS-EGFP after TEV protease-induced removal of 
the MBP-tag. Images were acquired by widefield fluorescence microscopy. Scale bar, 5 µm. B) Phase separation 
of methylated (me) FUS is strongly reduced in comparison to unmethylated (unme) FUS. Sedimentation assay 
to compare precipitation of unmethylated (unme) and methylated (me) MBP-FUS upon TEV protease-cleavage. 
Equal volumes of supernatant (S) and pellet (P) fractions were visualized by SyproRuby stain. Molecular weight 
markers (in kDa) are indicated on the left. Note that PRMT1 (but not SAM) was present in both samples to assure 
comparability, as indicated in Fig. 17C. C) Quantification of FUS levels in supernatant (S) and pellet (P) fractions 
are depicted as P/S ratio. Values represent means ± SEM (n=3). *p < 0.05 by paired t-test. D) Turbidity 
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measurements to monitor TEV protease-induced phase separation of unmethylated (unme) and methylated 
(me) MBP-FUS (7µM) in presence of 75 mM NaCl over time demonstrating reduced phase separation of 
methylated (me) FUS in comparison to unmethylated (unme) FUS. Values represent means ± SEM (n=3). E) 
Droplet formation of unmethylated (unme) and methylated (me) FUS-EGFP from a nucleic-acid free preparation 
upon TEV protease cleavage. Arrows denote small droplets observed for unmethylated FUS-EGFP at a 
concentration of 1 µM. Images were acquired by widefield fluorescence microscopy. Scale bar, 5 µm. 
 
 
2.7 Loss of arginine methylation alters droplet dynamics and promotes SG association 
of FUS 
To address the effect of arginine methylation on phase separation of FUS in more detail, we examined 
the droplet dynamics of unmethylated FUS-EGFP compared to methylated FUS-EGFP and monitored 
fluorescence recovery after photobleaching (FRAP) in the bleached area. For these assays, in contrast 
to other droplet assays, the droplet buffer was supplemented with 150 mg/ml Ficoll 400 in order to 
obtain droplets of similar size and shape for unmethylated and methylated FUS. For droplet half-
bleach, only droplets with a size of approximately 2 µm were selected. In contrast to methylated FUS, 
unmethylated FUS displays incomplete and decelerated recovery of the bleached area (Fig. 19A and 
19B). These results demonstrate reduced internal mobility within the dense droplet phase of 
unmethylated FUS. In accordance with the findings from the in vitro aging assays, droplets of both 
unmethylated and methylated FUS-EGFP show reduced mobility over time, indicating a progressive 
conversion from a liquid to a more solid state. To overcome this issue, no more than three droplets 
were analyzed per sample preparation and samples were prepared freshly. 
In order to evaluate whether unmethylated and methylated FUS also show different dynamics in cells, 
we examined whether SG association in the semi-permeabilized cell assay is affected by arginine 
methylation of FUS. Therefore, unmethylated or methylated MBP-FUS-EGFP was added to stressed, 
WGA-blocked, semi-permeabilized HeLa cells (Fig. 19C, for schematic diagram see Fig. 15C). 
Significantly more unmethylated FUS binds to G3BP1-positive SGs (Fig. 19C, see quantification of log 
transformed fluorescent intensities in Fig. 19D), confirming a higher association of unmethylated FUS 
with SGs. These observations indicate that unmethylated FUS is more stably associated with SGs than 
methylated FUS. In conclusion, loss of arginine methylation of FUS, as detected in pathological 
inclusions of FTD-FUS patients (Dormann et al., 2012; Suarez-Calvet et al., 2016), promotes LLPS and 
SG association of FUS and reduces FUS droplet dynamics. This may contribute to altered SG dynamics 
and consequent solidification and aggregation of FUS in FTD-FUS patients. 
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Figure 19: Arginine methylation alters droplet dynamics and reduces SG association of FUS. A) Droplets of 
unmethylated (unme) FUS-EGFP exhibit reduced droplet dynamics compared to methylated (me) FUS-EGFP. 
FRAP recovery curves following half-bleach of unmethylated (unme) and methylated (me) FUS-EGFP droplets (9 
µM). To obtain droplets of similar size and shape, droplet buffer (75 mM NaCl) was supplemented with 150 
mg/ml Ficoll 400 in FRAP experiments. B) Representative heat map images of bleached droplets to visualize 
recovery over time. Boxes indicate bleached area. Scale bar, 2 µm. Fluorescence in the bleached area recovers 
more quickly for meFUS-EGFP droplets, indicating higher droplet dynamics than for unmeFUS-EGFP. C) Semi-
permeabilized cell assay demonstrating enhanced SG partitioning of unmethylated (unme) MBP-FUS-EGFP 
compared to methylated (me) MBP-FUS-EGFP. SGs were visualized by anti-G3BP1 immunostaining and nuclei 
were counterstained with DAPI (turquois). Images were acquired by confocal fluorescence microscopy. Scale 
bar, 10 µm. D) Quantification of the log-transformed mean fluorescence intensity of MBP-FUS-EGFP in SGs. (n = 
3; ≥10 cells, ≥ 28 SGs each). ***p < 0.001 by Mann-Whitney test. 
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2.8 Arginine methylation stabilizes RNA binding of FUS-RGG3-PY 
Titrating substoichiometric amounts of in vitro transcribed MAPT RNA to unmethylated and 
methylated RGG3-PY revealed that both proteins reach maximal turbidity at a molar RNA-to-protein 
ratio of 1:50. At this molar ratio, unmethylated RGG3-PY shows a significantly higher turbidity 
compared to methylated RGG3-PY (Fig. 20A). The different degrees of phase separation raise the 
question whether methylation of RGG3-PY alters RNA binding, consequently affecting phase 
separation. To address this question, we performed electrophoretic mobility shift assays (EMSAs) by 
titrating unmethylated or methylated RGG3-PY to radiolabeled ASH1 E3-51 RNA (Fig. 20B). While a 
band shift is detectable upon titrating in methylated RGG3-PY, confirming RNA binding, no band shift 
is detectable by titrating in unmethylated RGG3-PY, indicating that RNA binding is altered by arginine 
methylation. As EMSA experiments indicate differences in RNA binding, we further investigated 
whether RNA binding affinities are altered by arginine methylation in RGG/RG motifs. Thus, we 
compared unmethylated and methylated RGG3-PY in filter-binding assays showing similar signal 
intensities for bound RNA (Fig. 20C). Determination of dissociation constants (Kd) using Hill fitting 
algorithm yields similar affinities and Hill coefficients (Fig. 20D, Table 3). Note, the obtained Hill 
coefficients indicate cooperative binding of RNA. At first glance, the result from the EMSAs and filter-
binding assays appear contradictory, but in combination indicate higher complex stability for 
methylated RGG3-PY compared to unmethylated RGG3-PY. The contradictory results most likely arise 
from a different nature of the assays. Namely, the filter-binding assay has a relatively short incubation 
time and existing interactions between RNA and protein are promptly blotted on the membranes. In 
contrast, EMSAs have a longer incubation time and additional gel running time during which less stable 
complexes may dissociate again and may create a false appearance of a lack of RNA binding.  In 
conclusion, our filter-binding assays demonstrate that the observed difference in LLPS of 
unmethylated and methylated RGG3-PY was not due to altered binding affinities. Importantly, the 
EMSA experiments indicate improved complex stability for methylated RGG3-PY which may have an 
effect on LLPS. Nevertheless, methylation-dependent differences in FUS-RNA complex stability may 
not be of particular importance for the phase separation behavior of full-length FUS proteins, as the 
presence of RNA has not a significant effect on the promotion of phase separation of full-length FUS 
(Fig. 16F and 16G). 
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Figure 20: Arginine methylation stabilizes RNA binding of FUS RGG3-PY. A) Methylated (me) RGG3-PY exhibits 
strongly reduced phase separation compared to unmethylated (unme) RGG3-PY. Turbidity assay for quantitative 
analysis of phase separation of unmethylated (unme) or methylated (me) RGG3-PY (30 µM) in presence of 
increasing amounts of in vitro transcribed MAPT RNA. Values represent means ± SEM (n=3). *P < 0.05 and **p 
< 0.01 by paired t-test.  B) Representative EMSAs with radiolabeled ASH1 E3-51 RNA and increasing 
concentrations of unmethylated (unme) or methylated (me) RGG3-PY demonstrating a band shift only for 
meRGG3-PY, but not for unmeRGG3-PY. C) Unmethylated (unme) and methylated (me) RGG3-PY show similar 
binding affinities to RNA, indicating that RNA binding of RGG3-PY is not affected by arginine methylation. 
Representative images of nitrocellulose membranes from filter-binding assay with unmethylated (unme) and 
methylated (me) RGG3-PY and radiolabeled ASH1 E3-51 RNA. D) Equilibrium dissociation constants (Kd) were 
determined using Hill fitting algorithm (n=6). 
 
 
Table 3: Kinetic parameters of filter-binding assays (RGG3-PY with RNA) 
 unmeRGG3-PY meRGG3-PY 
Kd (µM) 1.01 ± 0.05 1.04 ± 0.14 
Hill coefficient 3.55 ± 0.78 3.62 ± 0.6 
N 6 6 
 
Values represent the mean ± SD. 
 
 
2.9 ALS-associated FUS-P525L mutant impairs chaperone activity of TNPO1 
In contrast to FTD patients with FUS pathology, most ALS-FUS patients harbor a mutation in the C-
terminal PY-NLS (Dormann and Haass, 2013; Mackenzie et al., 2010) that impair interaction with 
TNPO1 and thus severely impair nuclear import of FUS (Dormann et al., 2010; Niu et al., 2012; Zhang 
and Chook, 2012). There are more than 30 point-mutations identified in the PY-NLS of FUS that are 
associated with cases of ALS (Dormann and Haass, 2013). These mutations vary in the degree of 
cytosolic mislocalization that correlates with disease severity (Dormann et al., 2010). The P525L 
mutation severely impairs TNPO1 binding (Niu et al., 2012; Zhang and Chook, 2012) and in turn causes 
early disease onset and rapid progression of ALS (Chio et al., 2009; Kwiatkowski et al., 2009). Based 
on the results described above demonstrating that TNPO1 suppresses LLPS and SG partitioning of FUS 
(sections 2.3 and 2.4 and Figs. 12-15), we speculated that aberrant phase transition and SG association 
of mutant FUS may be promoted due to impaired binding and chaperoning of FUS by TNPO1. 
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To address this question, we purified recombinant RGG3-PY and MBP-FUS-EGFP with intact PY-NLS 
(WT) or carrying the P525L mutation. As arginines in the RGG3 domain of FUS are asymmetrically 
dimethylated both, under normal conditions as well as in ALS-FUS patients, and this additionally 
reduces binding affinity to TNPO1 (Dormann et al., 2012; Suarez-Calvet et al., 2016), WT and mutant 
FUS proteins were in vitro methylated to resemble the situation in healthy individuals and ALS-FUS 
patients (see Fig. 21A for protein purity). Immunoblotting using antibodies for UMA-FUS (14G1), 
MMA-FUS (15E11), and ADMA-FUS (9G6) confirms reduction of UMA-FUS and quantitative conversion 
to ADMA-FUS to a similar degree for both WT and mutant FUS (Fig. 21B).  ITC measurements revealed 
that unmethylated RGG3-PY WT and P525L mutant show only slightly different binding affinities to 
TNPO1, but the dissociation constant (KD) for TNPO1 interaction is drastically increased for the 
methylated RGG3-PY P525L mutant compared to the methylated RGG3-PY WT (Table 2). As the major 
binding epitopes for TNPO1 interaction are located in the RGG3-PY (Dormann et al., 2012; Zhang and 
Chook, 2012), similar affinities are expected for full-length FUS proteins. Subsequently, the phase 
separation behavior of WT and mutant in absence and presence of TNPO1 was explored. In the 
absence of TNPO1, both WT and mutant proteins undergo phase separation to a similar degree (Fig. 
21C), indicating that LLPS of FUS is not directly affected by the P525L mutation. While LLPS of the WT 
protein is efficiently suppressed in the presence of TNPO1, the P525L mutant protein is completely 
insensitive to the chaperone activity of TNPO1 and still forms liquid droplets (Fig. 21C, see Fig. 21D for 
quantification), supporting of our hypothesis. In order to test whether chaperoning of the P525L 
mutant by TNPO1 can occur over time upon prolonged incubation of both proteins, WT and mutant 
FUS were subjected to prolonged incubation (8h) with TNPO1, revealing no difference to the early 
time point (microscopic examination immediately after mixing, 0h) (Fig. 21C and 21D). 
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Figure 21: ALS-associated P525L mutation causes reduced chaperoning of FUS by TNPO1 in vitro. A) Coomassie-
stained SDS-PAGE gels of purified, in vitro methylated WT and P525L mutant version of MBP-FUS-EGFP (~ 150 
kDa), both samples contain recombinant PRMT1 (~ 40 kDa), as indicated in the scheme in Fig. 17C. Molecular 
weight markers (in kDa) are indicated on the left. B) Representative blot for MBP-FUS-EGFP WT and MBP-FUS-
EGFP-P525L confirm similar degrees of methylation. Successful methylation was verified by immunoblotting 
with antibodies specific for FUS-RGG3 containing unmethylated arginines (UMA-FUS, 14G1), monomethylated 
arginines (MMA-FUS, 15E11) and asymmetrically dimethylated arginines (ADMA-FUS, 9G6), respectively. The 
Blot demonstrates reduction of UMA-FUS signal and conversion to ADMA-FUS upon overnight incubation with 
PRMT1. Experiments depicted in Figures 21C-D and 22A-B were performed with samples from overnight (o.n.) 
in vitro methylation reaction. C) Droplets of the FUS-P525L mutant are less sensitive to the chaperone activity 
by TNPO1 compared to FUS WT droplets. TEV cleavage-induced droplet formation of methylated MBP-FUS-EGFP 
WT versus P525L (both at 11 µM) in presence or absence of equimolar amounts of TNPO1. After 0 h and 8 h, 
images were acquired by confocal fluorescence microscopy. Scale bar, 15 µm. D) Quantification of image area 
covered by FUS-EGFP droplets in percent. Values represent means ± SEM (n=3). **p < 0.01 by paired t test. 
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In order to test whether chaperoning of the FUS-P525L mutant by TNPO1 is also impaired in cells, the 
ability of TNPO1 to reduce SG partitioning of WT and P525L mutant FUS was addressed in a semi-
permeabilized cell assay (see scheme in Fig. 15C). In the absence of TNPO1, both WT and mutant FUS 
exhibit a similar degree of SG association (Fig. 22A). While SG association of the WT protein is 
significantly reduced in the presence of TNPO1, the P525L mutant protein show still a higher degree 
of SG association (Fig. 22A, see Fig. 22B for quantification), demonstrating that TNPO1 is unable to 
efficiently chaperone the mutant protein and prevent its accumulation in SGs. As nuclear import is 
abrogated in this assay due to blocked nuclear pores using WGA, better chaperoning of the WT protein 
is not a result of enhanced nuclear import. 
To further examine the effect of the P525L mutation in the cellular context, cytosolically trapped GCR2-
tagRFP2-FUS-WT or P525L were transiently expressed in HeLa cells, in order to assess whether 
chaperoning of the FUS-P525L mutant is also impaired in intact cells. The GCR-mediated cytosolic 
anchoring, which occurs in the absence of steroid hormones (Love et al., 1998), allows an investigation 
of the chaperoning activity of endogenous TNPO1 independent of its nuclear import activity. Notably, 
transient transfection of cytosolically anchored WT and mutant FUS yields comparable expression 
levels and both induced formation of TIA1-positive SGs (Fig. 22C). The WT protein exhibits diffuse 
cytosolic distribution with a low degree of SG partitioning. Contrary to that, the FUS-P525L mutant 
protein localizes to SGs in a significantly higher number of cells (Fig. 22C, see Fig. 22D for 
quantification). 
In summary, the cellular assays and in vitro data demonstrate that besides impairing nuclear import 
of FUS, ALS-causing mutations localized in the NLS of FUS additionally abrogate the chaperone activity 
of TNPO1. These findings prove that ALS-associated FUS mutations, by disrupting proper interaction 
with TNPO1, promote aberrant phase transition and SG association of cytosolically mislocalized FUS. 
Thus, elevated phase separation and aggregation of FUS in stress granules could be a second 
detrimental consequence of ALS-associated FUS-NLS mutations and may contribute to the 
pathogenesis of ALS. 
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Figure 22: The P525L mutation renders FUS less sensitive to chaperone activity of TNPO1 in cellular assays. A) 
SG association of the P525L mutant is not strongly reduced in presence of TNPO1. Semi-permeabilized cell assay 
depicting SG partitioning of MBP-FUS-EGFP WT versus P525L in presence or absence of recombinant TNPO1. 
Nuclei were counterstained with DAPI (turquois), SGs were stained with a G3BP1-specific antibody (red). Images 
were acquired by confocal fluorescence microscopy. Scale bar, 10 µm. B) Mean reduction of SG association of 
FUS-EGFP WT and P525L normalized to respective condition with absence of TNPO1 (n=3; ≥10 cells, ≥37 SGs 
each). *p < 0.05 by paired t test. C) SG localization of the P525L mutant is higher compared to WT. SG recruitment 
of cytosolically anchored (GCR2-tagRFP2-tagged) FUS WT or P525L was assessed by co-immunostaining for 
tagRFP (displayed in green in the merge on the right for better visibility) and TIA1 (displayed in red). Nuclei were 
counterstained with DAPI (turquois). Images were acquired by confocal fluorescence microscopy. Scale bar, 20 
µm. D) Quantification of the percentage of cells exhibiting GCR2-tagRFP2-FUS localized to SGs. Values represent 
means ± SEM (n=3; ≥100 cells each). **p < 0.01 by paired t test. 
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3 DISCUSSION 
DECLARATION OF COPYRIGHT AND CONTRIBUTIONS 
This section of my Ph.D. thesis was prepared in parallel to the paper ‘Phase separation of FUS is 
suppressed by its nuclear import receptor and arginine methylation’ published in Cell (Hofweber et 
al., 2018). Thus, the structure and text of this Ph.D. thesis and the paper will partially overlap. Elsevier 
holds the copyright (2018) for this article published in Cell and permits the usage of text and figures in 
this dissertation. 
 
3.1 Arginines in the RGG/RG motif are crucial for phase separation of FUS 
Previously published studies deemed the N-terminal SYGQ-rich domain to be the primary driver of 
phase separation and aggregation of FUS (Burke et al., 2015; Kato et al., 2012; Murakami et al., 2015; 
Patel et al., 2015; Sun et al., 2011). The data presented in this Ph.D. thesis and accompanying 
publications (Hofweber et al., 2018; Qamar et al., 2018; Wang et al., 2018b) reveal that, in addition to 
the SYGQ-rich domain, the C-terminal RGG3-PY domain and, in particular, arginine residues in the 
RGG/RG motifs of FUS have an essential contribution to phase separation of FUS (Fig. 9 and 11). The 
isolated RGG3-PY domain, similarly to SYGQ-rich alone (Burke et al., 2015; Murakami et al., 2015), 
requires much higher protein concentrations or presence of RNA to undergo phase separation 
compared to full-length FUS (Fig. 9C), which forms liquid droplets at physiological concentrations 
(Patel et al., 2015) upon proteolytic liberation from the solubility tag. Furthermore, deletion of the C-
terminal RGG3-PY domain or the all-KGG mutant showed significantly reduced or no phase separation 
compared to full-length FUS (Fig. 11C-E). These data indicate that the C-terminal arginines in the 
RGG/RG motifs drive phase separation of FUS in conjunction with the N-terminal SYGQ-rich domain. 
These findings are in line with previous studies showing that a 40 amino-acid long, synthetic FUS 
peptide from the RGG3 domain (FUS471-510) undergoes phase separation in presence of a molecular 
crowder (PEG) or polyU RNA (Boeynaems et al., 2017) and that the RGG2-ZnF-RGG3 fragment of FUS 
forms fibrils in an RNA-dependent manner in vitro (Schwartz et al., 2013). The observation that 
RGG/RG motifs can drive phase separation are not exclusive to FUS, but have been demonstrated for 
multiple RBPs. Synthetic RGG boxes of hnRNP-A1, FMRP and arginine-rich dipeptide repeat (DPR) 
proteins, i.e. glycine-arginine (GR)n and proline-arginine (PR)n, produced by unconventional translation 
of the C9orf72 repeat expansion, have also been reported to phase separate upon addition of a 
crowding agent (Boeynaems et al., 2017). Additionally, phase separation of human RNA helicase Ddx4 
as well as the Ddx3 helicase LAF-1 and PGL-3, both found in P granules of C. elegans, is driven by their 
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RGG repeats (Elbaum-Garfinkle et al., 2015; Nott et al., 2016; Nott et al., 2015). The disordered domain 
of Ddx4 is highly enriched in FG/GF and RG/GR pairs, which are required for LLPS, indicating that 
aromatic phenylalanines and positively charged arginines are engaged in cation-π interactions driving 
droplet formation of Ddx4 (Nott et al., 2015). Similarly, to Ddx4, the RGG3-PY of FUS is also highly 
enriched in RGG and GR/RG repeat interspersed by YG/GY and FG/GF dipeptides. As droplet formation 
of the RGG3-PY domain can be promoted by the addition of RNA and lowering of the salt 
concentration, RNA-driven phase separation of RGG3-PY may be primarily driven by electrostatic 
interactions. The contribution of cation-π interactions between RGG3-PY molecules formed by 
RG(G)/GR and aromatic (F,Y) residues, as reported for Ddx4 (Nott et al., 2015), needs to be clarified. 
If this is the case, RNA may act as a scaffold to bring RGG3-PY molecules in close proximity. 
Furthermore, it has been shown that the high density of tyrosine residues in the N-terminal SYGQ-rich 
domain of FUS is required to drive hydrogel formation of the SYGQ-rich domain (Kato et al., 2012). 
Furthermore, the SYGQ-rich domain requires higher concentrations to undergo phase separation 
compared to the full-length protein (Burke et al., 2015; Murakami et al., 2015). The full-length FUS 
protein is able to undergo phase separation at physiological conditions as soon as liberated from the 
MBP-tag. As full-length FUS does not require presence of RNA to phase separate and deletion of the 
RGG3-PY significantly reduces the phase separation propensity, it may be conjectured that the 
interplay between C-terminal arginines and N-terminal tyrosines in the SYGQ-rich domain have a 
crucial contribution to phase separation of FUS by forming tyrosine-arginine (cation-π) interactions 
that drive phase separation. Supporting this assumption, mixing of the N-terminal SYGQ-rich domain 
with the C-terminal arginine-containing RBDs was reported to cause enhanced co-phase separation. 
Moreover, substitutions of tyrosines (Y) in the SYGQ-rich domain with alanines (A) or serines (S) reduce 
the propensity of full-length FUS to undergo phase separation (Qamar et al., 2018; Wang et al., 2018b). 
Even though lysine substitutions in the all-KGG mutant maintain positive charge, this seems to be not 
sufficient to form cation-π interactions. In contrast to arginines, lysines form interactions involving the 
amine with reduced or negligible directionality towards aromatic residues (Wang et al., 2018b). In 
sum, the interplay between the prion-like SYGQ-rich domain and the C-terminal RGG-rich domains of 
FUS has an important contribution to LLPS of full-length by forming cation-π interactions between C-
terminal arginines and N-terminal tyrosines. 
 
3.2 Nuclear import receptors as chaperones 
Our data reveal an unknown dual function of TNPO1 towards FUS, namely that it i) mediates not only 
nuclear import of FUS, ii) but it also acts as a chaperone that suppresses LLPS and solidification as well 
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as SG association of FUS. FUS is a highly abundant RBP (Patel et al., 2015; Wisniewski et al., 2014) with 
a concentration in the nucleus between 2 and 8 µM, which is within the concentration range where 
recombinant FUS undergoes LLPS and liquid-to-solid phase separation (Patel et al., 2015) (Fig. 11C and 
12B). In order to regulate LLPS and prevent aberrant phase transitions in the cell, potent protein 
quality control (PQC) mechanisms have to be in place. Reported PQC mechanisms include ATP acting 
as a hydrotope (Patel et al., 2017), high nuclear RNA concentrations (Maharana et al., 2018) and heat 
shock proteins (Ganassi et al., 2016; Mateju et al., 2017). Our data reveal that TNPO1 also has the 
ability to suppress phase transition of FUS in vitro and thus fulfills such a protein quality control 
function. Additionally, we have demonstrated that TNPO1 also exerts its chaperone function towards 
FUS in the cytoplasm and thus reduces association of FUS with SGs (Fig. 15) that may become aberrant 
and develop detrimental potential (Bentmann et al., 2013; Maziuk et al., 2017; Wolozin, 2012). It has 
been proposed that aggregation-prone RBPs like FUS are sequestered to SGs and become highly 
concentrated at these sites, thus promoting aberrant phase transition and aggregation (Alberti and 
Hyman, 2016; Dormann and Haass, 2011; Li et al., 2013). SGs are considered to play a pivotal role in 
pathogenesis as progenitors of pathological aggregates, as various SG marker proteins, such as TIA1 
and G3BP1, have been identified in aggregates of ALS and FTD patients with FUS and TDP-43 pathology 
(Bentmann et al., 2013). Additionally, ALS-causing mutations in FUS and other RBPs, such as TIA1, 
hnRNP-A1/A2 and TDP-43, were recently reported to enhance SG association or impair SG dynamics 
(Dewey et al., 2011; Kim et al., 2013; Mackenzie et al., 2017; Martinez et al., 2016). These ALS-
associated mutations increase the cytoplasmic protein concentration and/or enhance intermolecular 
interactions and thereby increase the propensity to undergo aberrant phase separation. Notably, our 
data demonstrate that TNPO1 reduces SG localization of FUS (Fig. 15) and disruption of FUS-TNPO1 
interaction promotes SG partitioning in cells (Fig. 22A-D). Our cellular assays reveal that the chaperone 
activity of TNPO1 towards FUS is independent of its nuclear import activity, as nuclear import of FUS 
was disrupted in our assays either by cytosolic-anchoring of FUS or by blocking the nuclear pores with 
WGA. Taken together, our data indicate that the chaperone activity of importins towards phase 
separating RBPs may play an essential role in regulating SGs in the cytoplasm. This may not only be 
the case for SGs, but also apply for other FUS-containing cytoplasmic RNP granules, such as neuronal 
transport granules. 
Supporting our finding, there are a number of studies showing that several other importins have been 
demonstrated to fulfill chaperone function and thereby prevent protein aggregation. In 2002, Jakel 
and colleagues demonstrated that, in addition to TNPO1, several other importin β-type importins 
suppress the aggregation of basic ribosomal proteins and histones. This indicates that also other 
importins may exert chaperone activity towards aggregation-prone RBPs with basic stretches. 
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Notably, they also showed that importins fulfill this chaperone function specifically towards their 
cognate import cargoes (Jakel et al., 2002). In line with that, we have shown that TNPO1, but not Imp5, 
suppresses phase separation of FUS. Further evidence for the importin-cargo specificity required to 
prevent phase transitions of aggregation-prone RBPs is provided by the data published by the groups 
of Shorter and Chook (Guo et al., 2018; Yoshizawa et al., 2018).  Moreover, mere interaction with the 
RGG3 of FUS, is not sufficient to suppress phase separation of full-length FUS, as we show that other 
RGG3-binding proteins, i.e. PRMT1 and an α-RGG3 specific antibody, are unable to prevent droplet 
formation of FUS (Fig. 12B). As a side note, droplet size increases in presence of the α-RGG3 specific 
antibody whereas fluorescence intensity decreases. This may be caused by crosslinking of two FUS 
molecules by the antibody and incorporation of the antibody into the droplets. Overall, phase 
separation in general seems not to be promoted by the α-RGG3 specific antibody, as evidenced in the 
quantification of covered image area as well as turbidity and sedimentation assays (Fig. 12B-C and 
13A-C). Similarly, Shorter and colleagues recently reported that importin α/β is able to inhibit and 
reverse fibril formation of TDP-43 and that TNPO1 prevents and reverses fibilization of FUS and other 
PY-NLS-containing import cargoes such as TAF15, EWS, and hnRNPA-A1/A2 (Guo et al., 2018). In line 
with these findings, the Imp β/7 heterodimer was shown to prevent aggregation of the nucleolar RNA 
methyltransferase EMG1 by binding to its basic regions (Warda et al., 2016). Similar to heat shock 
proteins that act as chaperones for exposed hydrophobic patches, importins may have a general 
chaperone function preventing ionic aggregation of highly basic nucleic acid binding proteins, by 
shielding their basic nucleic acid-binding stretches (Jakel et al., 2002). As importins reach cellular 
concentrations of ~ 1-2 µM each, they are similarly abundant as HSPs (Jakel et al., 2002), they seem 
suitable to encounter the high abundance of RBPs associated with ALS cases, such as FUS, TDP-43, and 
hnRNP-A1/A2, by shielding their basic stretches. It has been proposed that although efficient nuclear 
import should be achievable by a common NLS in combination with a cognate import receptor, 
mammalian cells have ~ 15 different importins to encounter the polymorphism of basic nucleic-acid-
binding stretches of cargoes and thereby execute their chaperone function. Notably, nuclear import 
of rpS7 can be mediated by Imp α/β and Imp 9, but its aggregation is chaperoned only by Imp9 (Jakel 
et al., 2002), indicating a complex network of importins mediate import and chaperone activity in 
response to particular cellular conditions. Interestingly, Lemke and co-workers showed that Importin 
β inhibits aggregation of FG-rich nucleoporins (Nups) (Milles et al., 2013). Furthermore,  TNPO1 
enables specific and fast nuclear import of its cargoes by disrupting weak transient interactions 
between FG-rich Nups when crossing the nuclear pore (Frey et al., 2006; Milles et al., 2015). Taken 
together, importins may furthermore have a chaperone function towards hydophobic FG-Nups to 
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mediate passaging of the nuclear pore complex, even though the chaperoning mechanism has to be 
determined. 
 
3.3 Possible mechanisms underlying the chaperone activity of TNPO1 
The findings presented in this thesis showing that TNPO1 is able to suppress and reverse phase 
separation of FUS raise the question of the underlying mechanism. According to the solved crystal 
structure of the FUS PY-NLS - TNPO1 complex, TNPO1 binds to three epitopes in the PY-NLS of FUS, 
namely the very C-terminal PY motif, a polarized arginine-rich α-helix and a hydrophobic motif (Zhang 
and Chook, 2012). Furthermore, there is also a fourth binding epitope of TNPO1 in the preceding RGG3 
domain (Dormann et al., 2012) with direct binding to specific arginine residues (R472, R473, R476) 
(Gobl et al., 2016). As we show that arginines in the RGG/RG motifs drive phase separation of FUS (Fig. 
9C and 11C-E), direct interaction of TNPO1 with arginine residues may mediate the chaperone activity 
of TNPO1 towards FUS by interfering with weak multivalent interactions of arginines, most likely 
cation-π interactions with tyrosines in the SYGQ-rich domain, and thereby suppress phase separation 
of FUS driven by arginines residues. Supporting the hypothesis of TNPO1 interfering with cation-π 
interactions, the study by Yoshizawa et al. demonstrated that TNPO1 additionally interacts with 
tyrosine motifs in the N-terminal SYGQ-rich domain (Yoshizawa et al., 2018) that are known to 
contribute to phase separation of FUS (Kato et al., 2012; Qamar et al., 2018; Wang et al., 2018b). 
Furthermore, recent NMR studies revealed that TNPO1 also forms weak interaction with the folded 
RRM and ZnF domains (Yoshizawa et al., 2018), suggesting that interactions of TNPO1 with these RNA 
binding domains may also be involved in the chaperoning mechanism. 
TNPO1 interaction with multiple RNA-binding domains (RBDs) of FUS (RRM, ZnF and RGG/RG repeat 
motifs) may be the basis for the RNA displacement observed upon addition of TNPO1 to RNA-bound 
MBP-FUS and RGG3-PY, respectively (Fig. 16B-E). Since previous studies demonstrated a promoting 
effect of phase separation upon addition of RNA (Burke et al., 2015; Maharana et al., 2018; Schwartz 
et al., 2013), displacement of RNA from FUS by TNPO1 may also contribute to the chaperone activity 
of TNPO1. For the isolated RGG3-PY this seems to apply, as phase separation of RGG3-PY can be 
promoted by addition of RNA (Fig. 9C,D and 20A). Possible explanation for this may be that, first, 
electrostatic interactions with the negatively charged RNA-backbone drive phase separation, and/or 
second, RNA binding of isolated RGG3-PY brings more RGG3-PY molecules in close proximity and 
thereby RNA may act as a scaffold that allows the formation of more multivalent interactions between 
arginines in RGG/RG-rich motifs and aromatic residues driving phase separation (cation-π).  As TNPO1 
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competes with RNA for FUS binding, RNA displacement eliminates RNA-driven phase separation of 
RGG3-PY. 
In contrast to previously published data (Burke et al., 2015; Maharana et al., 2018; Schwartz et al., 
2013), and to our results for the RGG3-PY domain, we did not observe a promotion of phase separation 
of full-length FUS by RNA in our turbidity assays. The absence of a promoting effect was most likely 
not due to the nature of the used RNAs, as we used different types of RNA (51 bp ASH1 E3-51 RNA, 
330 bp MAPT RNA or total RNA from HeLa cells) (Fig. 16F and 16G, data not shown), and of which 
MAPT RNA has been previously reported to interact with FUS (Orozco et al., 2012). High 
concentrations of RNA rather have a suppressive effect on phase separation of both full-length FUS 
and RGG3-PY (Fig. 16F, 16G and 20A), suggesting that high amounts of RNA may interfere with 
multivalent interactions within and between full-length FUS or RGG3-PY molecules, in particular 
cation-π interactions, driving phase separation. In regard of FUS being an RBP involved in many 
processes of RNA metabolism and the high concentrations of RNA in the nucleus, the observed 
suppressive effect of high RNA concentrations on phase separation of FUS in vitro may be a feasible 
strategy to prevent aberrant phase separation of FUS in addition to the chaperoning activity by TNPO1. 
This view is supported by a recent study demonstrating that high RNA/protein ratios prevent droplet 
formation of FUS in vitro. Furthermore, a reduction of nuclear RNA concentrations by microinjection 
of RNase A was shown to cause droplet formation and solidification of FUS in HeLa cells (Maharana et 
al., 2018). This may be of particular relevance in the nucleus where high RanGTP levels mediate 
dissociation of the TNPO-FUS import complex.  
Even though RNA displacement from FUS by TNPO1 seems to be not involved in the chaperoning 
function of TNPO1 under our experimental conditions, it may nevertheless fulfill important functions 
in the cell. First, RNA displacement by TNPO1 may assure that FUS as well as other RBPs are imported 
in the nucleus in an RNA-free form and thus prevent mRNA reimport in the nucleus in order to fulfill 
their nuclear functions in RNA metabolism. Second, RNA displacement may permit the release of 
bound mRNAs from RBPs to allow local translation in the cytoplasm, as reported for Kap104p, the 
yeast homologue of TNPO1 (van den Bogaart et al., 2009). Such an RNA displacement mechanism 
mediated by TNPO1 may play a role in neuronal transport granules and thereby regulate local 
translation in axons and/or dendrites. Thus, further research is needed to follow up these potential 
functions of RNA displacement by TNPO1. In this regard, in vitro translation assays could be carried 
out to evaluate whether recombinant TNPO1 has a suppressive effect on translation. Furthermore, 
the presence of TNPO1 in neuronal RNP granules has to be validated and whether TNPO1 is responsive 
to neuronal stimulation. 
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3.4 Arginine methylations suppresses phase separation and SG association of FUS 
We showed that RG/RGG motifs of FUS are essential for LLPS of FUS (Fig. 11). RGG motifs are the 
second most prevalent RNA-binding motif of RBPs and arginines in these domains have been shown 
to be extensively methylated (Araya et al., 2005; Belyanskaya et al., 2001; Du et al., 2011; Hung et al., 
2009; Jobert et al., 2009; Ong et al., 2004; Pahlich et al., 2005; Rappsilber et al., 2003). As FUS is known 
to be asymmetrically dimethylated in RGG domains, but was shown to be hypomethylated in 
pathological inclusions of FTD-FUS patients (Dormann et al., 2012; Suarez-Calvet et al., 2016), we 
hypothesized that arginine methylation may be involved in phase separation of FUS. Indeed, we 
discovered that asymmetric dimethylation of RGG/RG motifs of FUS suppresses its propensity to 
undergo LLPS (Fig. 18) and methylated FUS exhibits higher droplet dynamics than unmethylated FUS 
(Fig. 19). Supporting these observations, Nott and colleagues reported that LLPS of the RGG domain 
of Ddx4 is significantly suppressed by asymmetric dimethylation of arginines and lowers phase 
transition temperature by 25 °C (Nott et al., 2015). Similarly, Fazwi and co-workers showed that 
arginine methylation of the hnRNP-A2 LC domain reduces its phase separation (Ryan et al., 2018). 
Concordantly, Qamar et al. reported in the same issue of Cell that asymmetrically dimethylated FUS 
purified from HeLa cells exhibits lower LLPS and a higher propensity for droplet fusion (Qamar et al., 
2018). In contrast to phosphorylation, another common PTM in IDPs, methylation of arginines, does 
not alter the positive net charge, but alters hydrogen bonding and local hydrophobicity (Fuhrmann et 
al., 2015). Consequently, cation-π interactions between arginines and tyrosines driving the phase 
separation of FUS are mitigated. As RGG/RG motifs are highly prevalent in the human proteome and 
are frequently methylated further there is evidence by a number of recent studies that RGG/RG-rich 
motifs crucially contribute to phase separation (Boeynaems et al., 2017; Elbaum-Garfinkle et al., 2015; 
Hofweber et al., 2018; Nott et al., 2015; Saha et al., 2016), it is likely that arginine methylation also 
regulates phase separation of many other proteins. 
Loss of arginine methylation is a pathological hallmark of aggregated FUS in FTD-FUS patients 
(Dormann et al., 2012; Suarez-Calvet et al., 2016), which may be also a major pathomechanism in 
other neurodegenerative diseases. Since we and others have demonstrated that LLPS of FUS is 
affected by arginine methylation (Hofweber et al., 2018; Qamar et al., 2018) (Fig. 18), it seems likely 
that the other members of the FET protein family, EWS and TAF15, that are co-aggregating with FUS 
in inclusions of FTD-FUS cases (Neumann et al., 2011), are also regulated by arginine methylation. 
Additionally, hnRNP-A1 and hnRNP-A2, that have been found in pathological aggregates of 
multisystem proteinopathy (MSP) and rare ALS cases (Kim et al., 2013; Mori et al., 2013b), undergo 
arginine methylation in RGG/RG motifs in their prion-like domain (Liu and Dreyfuss, 1995; Nichols et 
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al., 2000; Ong et al., 2004) that may affect LLPS. The first evidence for this assumption has been 
provided by Fawzi and colleagues by showing that arginine methylation within RGGs of hnRNP-A2 LC 
disrupts cation-π interactions with aromatic residues and consequently interferes with its phase 
separation (Ryan et al., 2018). Nevertheless, studies on the full-length hnRNP-A2, and other full-length 
RBPs in general, are required to unravel the actual role of methylation on its phase separation 
behavior. Notably, genetic screens in Drospohila have uncovered PRMT1 as a major modifier of DPR-
toxicity (Boeynaems et al., 2016; Lee et al., 2016). This suggests that arginine-rich DPRs (i.e. PR, GR) 
may be also methylated in vivo and therefore arginine methylation may also play an important role in 
DPR toxicity.  
Besides in vitro studies, arginine methylation has also been shown to be an essential determinant of 
phase separation in cells, by regulating RNP granule formation. PRMT1-overpression causes 
hypermethylation of the SG-nucleating protein G3BP1 and suppresses SG nucleation (Tsai et al., 2016). 
Conversely, oxidative stress causes active demethylation of G3BP1 by JMJD6 and thereby promotes 
SG formation (Tsai et al., 2017). Therefore, arginine methylation may directly affect LLPS and RNP 
granule dynamics by interfering with cation-π interactions formed between arginines and aromatic 
residues. Furthermore, LLPS and RNP granule dynamics may be indirectly affected by methylation-
dependent protein-protein as well as protein-RNA interactions. This may be of particular relevance 
for the recruitment or exclusion to/from preformed structures. Phase separation of FUS, and most 
likely other RBPs with similar domain structure, is driven by weak multivalent interactions between 
arginines within the RBDs and residues in the prion-like domains (Qamar et al., 2018; Wang et al., 
2018b), which are enriched for amino acids that are potential targets for phosphorylation (Monahan 
et al., 2017). Thus, it seems likely that arginine methylation most likely acts together with other PTMs, 
such as phosphorylation. Eventually, combinations of different PTMs and binding partners control 
phase separation and RNP granule dynamics.  
 
3.5 Distinct mechanisms driving phase separation and SG association of FUS in ALS-FUS and 
FTD-FUS 
3.5.1 Pathomechanisms of FTD-FUS 
Previous studies revealed that FUS in pathological aggregates of FTD-FUS cases is hypomethylated, i.e. 
unmethylated and monomethylated, whereas FUS in healthy individuals and ALS-FUS patients 
characteristically contains asymmetrically dimethylated arginines (Dormann et al., 2012; Suarez-
Calvet et al., 2016). Since we show that loss of arginine methylation, as seen in FTD-FUS, enhances 
82 
 
phase separation and SG association of FUS, it can be speculated that this may favor aberrant phase 
separation and pathological aggregation of FUS and thus contribute to pathogenesis. Since 
unmethylated FUS is efficiently chaperoned by its nuclear import receptor TNPO1, it remains elusive 
why TNPO1 is not able to prevent aberrant phase transition and aggregation formation FUS in FTD-
FUS patients. The pattern of arginine methylation does not impair chaperoning activity of TNPO1. 
Unmethylated and monomethylated FUS exhibit a higher binding affinity to TNPO1 (Dormann et al., 
2012; Suarez-Calvet et al., 2016) (Table 2) and phase separation of both unmethylated (Guo et al., 
2018; Yoshizawa et al., 2018) (Fig. 12 and 13) as well as asymmetrically dimethylated FUS (WT) (Fig. 
21C and 21D) is efficiently suppressed by the chaperone function of TNPO1. Since TNPO1 is co-
aggregating with FET proteins in FTD-FUS post mortem brains (Brelstaff et al., 2011; Davidson et al., 
2013; Neumann et al., 2012; Troakes et al., 2013), irrespective of what may cause this, it is likely that 
TNPO1 may become functionally impaired and is not capable of exerting its cytosolic chaperone 
function towards its cargoes. Assuming TNPO1 is compromised in its functionality, nuclear import of 
TNPO1 cargoes (e.g. FUS, EWS, TAF15, hnRNPs) may also be disturbed, causing elevated levels of 
mislocalized RBPs and eventually a higher tendency to aggregate. So, there are two not mutually 
exclusive scenarios that could explain how aggregated TNPO1 is sequestered into detergent-insoluble 
aggregates. 
A first hypothesis could be that, cellular stress causes the recruitment of TNPO1 to stress granules, as 
shown in several studies (Chang and Tarn, 2009; Jain et al., 2016b; Mahboubi et al., 2013). Then, 
altered SG dynamics or defective PQC mechanisms may cause a solidification and aggregation of 
TNPO1 (discussed in more detail below), resulting in functionally impaired TNPO1. 
A possible hint towards a second hypothesis is provided by the study of Deng et al. (2014) that links 
the co-aggregation of TNPO1 and the FET proteins to DNA damage. Induction of DNA damage was 
shown to induce DNA-PK-dependent phosphorylation of FUS, causing cytosolic translocation and 
accumulation of FUS, EWS, TAF15, and TNPO1 (Deng et al., 2014). A possible explanation for the 
cytosolic translocation of TNPO1 may be that it also becomes phosphorylated upon DNA damage, but 
this has to be further investigated. Alternatively, phosphorylated FUS (or FET proteins) could show a 
higher affinity to TNPO1, thus sequestering TNPO1 into phosphorylated FET aggregates. 
Phosphorylated FUS may be also more prone to aggregation. Supporting this view, phospho-mimetic 
amino acid substitution (G/S/T-to-D) of the FUS LC domain was reported to enhance co-phase 
separation with the RBDs of FUS by the formation of electrostatic interactions with positively charged 
arginines, indicating that the introduction of negative charges by phosphorylation in the FUS LC 
domain enhances phase separation of full-length FUS (Wang et al., 2018b). As a side note, phase 
separation of the FUS LC domain alone is suppressed by phospho-mimetic substitution due to 
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electrostatic repulsion (Monahan et al., 2017; Wang et al., 2018b). Although phosphorylation of the 
FET proteins upon DNA damage may trigger a first accumulation in the cytoplasm (Deng et al., 2014), 
it is not clear whether this could affect the chaperone activity of TNPO1 and cause its aggregation. 
Furthermore, Deng et al. also showed that sections of post mortem brains from FTD-FUS patients have 
increased levels of the DNA DSBs marker p-H2AX. Even though phosphorylation seems to be transient, 
this may suggest that DNA-PK dependent phosphorylation of FUS triggered by DNA damage may 
contribute to the characteristic accumulations seen in FTD-FUS (Deng et al., 2014), although its validity 
has to be verified in regard of a recent publication reporting FUS phosphorylation upon a specific kind 
of DNA damage without altering nuclear FUS localization (Rhoads et al., 2018). 
In order to assess which of the above mentioned hypotheses for the aggregation of TNPO1 in 
pathological FTD-FUS aggregates is more likely, the question whether TNPO1 or the FET proteins 
aggregate first has also to be addressed. Future research is needed to clarify whether TNPO1 gets 
aggregated and dysfunctional first (e.g. due to SG recruitment upon stress) and subsequently the FET 
protein become pathologically altered, or whether alternatively, the FET proteins aggregate first, e.g. 
due to loss of methylation, and subsequently trap TNPO1 into the granules/aggregates. 
Since general methylation defects haven not been identified so far in FTD-FUS patients (Ravenscroft 
et al., 2013) and are expected to also affect other RGG-containing RBPs (e.g. EWS, TAF15, hnRNP-A1, 
hnRNP-A2, G3BP1), presumably causing even more detrimental effects, primary aggregation of the 
FET proteins due to general arginine methylation defects seems disputable, but may be specific for 
FET proteins.  
In line with the “multiple hit theory” (see section 1.8.1), the SG hypothesis (or at least in combination 
with DNA damage) for TNPO1 aggregation appears more suitable to explain the pathogenesis in FTD-
FUS. Recruitment of TNPO1 to SGs has been reported in multiple studies (Chang and Tarn, 2009; Jain 
et al., 2016b; Mahboubi et al., 2013). Abrogated nuclear import of the FET proteins due to impaired 
TNPO1 function could then lead to increasing cytosolic concentrations. Downregulation of arginine 
methylation of FUS, possibly by active demethylation or regulation of PRMT activity, could be a 
compensatory response to encounter reduced activity of TNPO1 by increasing the binding affinity and 
thus reestablish some degree of nuclear import. Fatally, this even worsens FUS aggregation in FTD-
FUS patients, as it enhances phase separation and SG partitioning of FUS (Fig. 18, 19 and Fig. 23). Since 
p62 and ubiquitin are also present in pathological aggregates of FTD-FUS (and ALS-FUS) (Baumer et 
al., 2010; Neumann et al., 2009; Seelaar et al., 2010), PQC mechanisms may also be compromised 
(Pankiv et al., 2007) and further contribute to pathological aggregation. Nevertheless, it cannot be 
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excluded that DNA-damaged induced phosphorylation of FUS in combination with cellular stress may 
trigger initial SG formation followed by the above described cascade. 
Still, the above postulated hits need to be validated in detail. Therefore, further components of FTD-
FUS inclusions will have to be identified and TNPO1/FET protein ratios in the pathological aggregates 
have to be determined. Especially the relevance of DNA damage-induced FUS phosphorylation due to 
DNA damage or other stresses has to be examined. Furthermore, it is essential to address whether 
TNPO1 levels are altered in these patients or whether there are cell type-specific differences in TNPO1 
levels. Moreover, it remains unclear how arginine methylation of FUS is regulated in cells and how the 
normal methylation pattern is lost in FTD-FUS patients. So far, no mutations or expression changes for 
PRMTs (PRMT1, PRMT3, PRMT8) have been identified in FTD-FUS cases (Ravenscroft et al., 2013), but 
the responsible PRMTs for arginine methylation of FUS (i.e. PRMT1 and PRMT8) have to be studied in 
further depth. Moreover, putative arginine demethylases, such as JMJD6 or JmJC enzymes (Tsai et al., 
2016; Tsai et al., 2017; Walport et al., 2016) may be candidates for demethylation of FUS which need 
further testing.  
 
3.5.2 Pathomechanisms of ALS-FUS 
Patients suffering from ALS-FUS, in contrast to FTD-FUS, have a normal pattern of arginine methylation 
(Dormann et al., 2012; Suarez-Calvet et al., 2016), but typically carry a mutation in the PY-NLS of FUS 
that impair binding to TNPO1 (Niu et al., 2012; Zhang and Chook, 2012) and consequently interferes 
with nuclear import of FUS (Dormann et al., 2010; Niu et al., 2012; Vance et al., 2013; Zhang and 
Chook, 2012). Notably, there are also N-terminal FUS mutations associated with ALS cases not 
affecting the binding to TNPO1 (e.g. G156E and R244C), but promote LLPS (Patel et al., 2015) as well 
as aggregation (Nomura et al., 2014) by a different mechanism. Our data and an accompanying study 
(Guo et al., 2018) (Fig. 21 and 22) demonstrate that ALS-associated mutations affecting the PY-NLS of 
FUS, like P525L and 495X, render FUS less sensitive to the chaperone activity of TNPO1. Notably, ALS-
linked FUS mutations causing mild cytosolic mislocalization of FUS (e.g. R521G) (Dormann et al., 2012) 
do not impair TNPO1 binding as much as P525L (Zhang and Chook, 2012) and are still efficiently 
chaperoned by TNPO1 (Guo et al., 2018). This indicates that the chaperone activity is only disrupted 
by mutations causing frame-shifts, truncations (495X) or severe point-mutations such as P525L. Even 
though our findings indicate that the ALS-linked P525L mutation does not promote phase separation 
per se (Fig. 21C), it provides multiple hits towards pathogenesis of ALS-FUS, by impairing nuclear 
import causing cytosolic mislocalization and accumulation under stress as well as abolished 
chaperoning by TNPO1 (Fig. 21-23). Notably, hypomethylation of FUS, which promotes detrimental 
85 
 
aggregation in FTD-FUS, may be a potential treatment approach for ALS-FUS as it restores binding of 
ALS-associated FUS mutations to TNPO1 and thus reestablishes the chaperone activity and rescues 
cytosolic mislocalization (Dormann et al., 2012; Tradewell et al., 2012). 
 
 
Figure 23: Distinct pathomechanisms drive phase separation of FUS in FTD and ALS. In healthy individuals, FUS 
is kept soluble by the cytoplasmic chaperone activity of TNPO1 (top panel). Loss of arginine methylation, as seen 
in FTD-FUS patients, enhances the phase separation of FUS. Furthermore, TNPO1 is aggregating in FTD-FUS 
patients and its chaperone function towards FUS is disturbed (middle panel). ALS-associated mutations in the 
FUS-NLS impair the interaction with TNPO1 causing reduced chaperoning by TNPO1 (bottom panel). 
 
 
3.6 Conclusion and Outlook 
In sum, we report two novel mechanisms to regulate liquid-liquid phase separation of aggregation–
prone RBPs, namely suppression of LLPS by specific binding proteins and post-translational 
modifications (PTMs), in the case of FUS by the import receptor TNPO1 and arginine methylation (Fig. 
23). Both are not only involved in nuclear import of FUS, but furthermore suppress phase separation 
and SG association of FUS. When these control mechanisms are disrupted, they may lead to 
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neurodegeneration. Therefore, such LLPS-regulating binding partners and PTMs of aggregation-prone 
RBPs need to be identified and subsequently verified whether these are affected in ALS/FTD cases and 
whether they have potential for therapeutic targeting. 
Aberrant phase separation is not exclusive to FUS, but seems to be a common mechanism in 
neurodegeneration. Notably, for the hexanucleotide repeat expansion in the C9orf72 gene as most 
common genetic cause of ALS-FTD (DeJesus-Hernandez et al., 2011; Renton et al., 2011), a similar 
pathomechanism has been suggested recently. One of the three proposed mechanism how the 
GGGGCC repeat expansions contributes to pathology is the synthesis of dipeptide repeat (DPR) 
proteins that arise from unconventional RAN translation (Ash et al., 2013; Gendron et al., 2013; Mori 
et al., 2013a; Mori et al., 2013b; Zu et al., 2013). The most toxic forms of these DPR proteins, arginine-
containing poly-GR and poly-PR, have been demonstrated to not only undergo liquid-liquid phase 
separation in the presence of RNA or crowding agent but also to interact with LC-containing RBPs that 
are components of membrane-less organelles, such as SGs and nucleoli (Boeynaems et al., 2017; Lee 
et al., 2016; Lin et al., 2016). Poly-GR and poly-PR promote droplet formation of LC-containing proteins 
in vitro and furthermore reduce dynamics of stress granule and nuclear speckles in living cells (Lee et 
al., 2016). Furthermore, the microtubule-associated protein Tau is aggregating in Alzheimer´s disease 
(AD) and other neurodegenerative diseases (Goedert and Spillantini, 2011; Maziuk et al., 2017). Tau 
has been shown to accelerate SG formation (Vanderweyde et al., 2016), to undergo phase separate in 
vitro and form droplet like condensates in neurons (Ambadipudi et al., 2017; Hernandez-Vega et al., 
2017; Wegmann et al., 2018). Hyperphosphorylation of Tau, as found in AD and FTD patients (Braak 
and Braak, 1995; Gong et al., 2005; Kopke et al., 1993), enhances phase separation and aggregation 
of FUS (Ambadipudi et al., 2017; Wegmann et al., 2018). Further studies demonstrated that a number 
of ALS/FTD-associated mutations in the LC domains of hnRNP-A1/A2, TIA1 and FUS impair SG 
dynamics (Kim et al., 2013; Mackenzie et al., 2017; Martinez et al., 2016; Patel et al., 2015). 
Besides disturbed phase transition, defective nuclear import seems to be another common theme in 
the pathogenesis of ALS and FTD, as nuclear import defects were not only shown for cases with FUS 
pathology, but also linked to DPR toxicity (Boeynaems et al., 2016; Freibaum et al., 2015; Jovicic et al., 
2015; Zhang et al., 2015) and TDP-43 pathology (Chou et al., 2018; Nishimura et al., 2010). 
Furthermore, polyglutamine repeats (polyQ) in the huntingtin (Htt) protein were shown to cause co-
aggregation of Ran GTPase-activating protein 1 (RanGAP1) and to impair nuclear export of mRNAs 
(Gasset-Rosa et al., 2017). Similarly, aggregation of RanGAP1 and NUP62 in post mortem brains from 
patients with Huntington’s disease (HD) and defective nucleocytoplasmic transport in human HD iPSC-
derived neurons have been shown (Grima et al., 2017). In general, defects in nucleocytoplasmic 
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transport seem to be characteristic for aged neurons (Mertens et al., 2015). Defective nuclear 
transport factors found in neurodegenerative diseases or the aging brain may have several 
detrimental downstream consequences: First, nuclear export of factors required in the cytoplasm, 
such as mRNA, may be disturbed. Second, disturbed nuclear import of aggregation-prone RBPs may 
elevate their cytosolic concentrations. Third, the cytosolic chaperone function of nuclear import 
receptor to suppress detrimental aggregation may be also disturbed. 
To put it in a nutshell, both aberrant phase transition and defective nuclear import seem to play key 
roles in the pathology of ALS/FTD. 
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4 EXPERIMENTAL PROCEDURES 
DECLARATION OF COPYRIGHT AND CONTRIBUTIONS 
This section of my Ph.D. thesis was prepared in parallel to the paper ‘Phase separation of FUS is 
suppressed by its nuclear import receptor and arginine methylation’ published in Cell (Hofweber et 
al., 2018). Thus, the structure and text of this Ph.D. thesis and the paper will partially overlap. Elsevier 
holds the copyright (2018) for this article published in Cell and permits the usage of text and figures in 
this dissertation. 
 
4.1 Cloning of cDNA constructs 
pMal-Tev-Flag-FUS-Tev-His6 was created by cloning PCR amplified N-terminal Flag-tagged and C-
terminal Tev-His6 tagged FUS cDNA into the SalI-HindIII sites of pMal-Tev using primers SalI_flag_F and 
HindIII_His6-Tev-FUS_R. pMal-Tev was created by cloning annealed double stranded oligonucleotides 
Tev_F and Tev_R (coding for the Tev cleavage site) into the EcoRI-SalI sites of pMal-c. 
To generate pMal-Tev-FUS-EGFP-Tev-His6, FUS cDNA was PCR amplified from pMal-Tev-Flag-FUS-Tev-
His6 using primers SalI_FUS_F and BamHI_FUS_R, thus introducing a C-terminal BamHI restriction site. 
EGFP-His6 with low-complexity linker was cut from synthetic pEX-A2-linker-EGFP-His6 (IDT) using 
BamHI and HindIII sites. In a triple ligation, FUS and EGFP-His6 fragments were cloned into the pMal-
Tev backbone derived from pMal-Tev-flag-FUS-Tev-His6. 
pMal-Tev-FUS (P525L)-EGFP-Tev-His6 was generated by site directed mutagenesis of pMal-Tev-FUS-
EGFP-Tev-His6 using primers FUS wt-EGFP mut P525L_F and FUS wt-EGFP mut P525L_R. 
To generate pMal-C2-Tev, the C-terminus of MBP including parts of the MCS was PCR-amplified 
(MBP_NcoI_F; MBPLinker_Tev_EcoRI) introducing a Tev-cleavage site in the reverse primer and 
replacing the factor Xa cleavage site in the original pMal-C2 (NEB) vector. 
pMal-C2-Tev-Flag-FUS ΔRGG3-PY-Tev-His6 was generated by cloning PCR amplified N-terminal Flag-
tagged and C-terminal Tev-His6 tagged FUS cDNA encoding amino acids 1-453 into the SalI-HindIII sites 
of pMal-C2-Tev using primers SalI_flag_F and HindIII_FUS453X-Tev-His6_R. 
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To generate pMal-C2-Tev-Flag-FUS-all-KGG-Tev-His6, FUS cDNA was PCR amplified from a synthetic 
plasmid with all RGGs mutated to KGGs using primers XhoI_FUS_F and HindIII_Tev-His6- -FUS_R and 
cloned into the pMal-C2-TEV backbone derived from pMal-C2-Tev-Flag-FUS ΔRGG3-PY-Tev-His6. 
petM11-His6-ZZ-Tev-FUS-KGG3-PY was generated by cloning FUS cDNA encoding amino acids 454-526 
from a synthetic plasmid with all RGGs mutated to KGGs using primers FUS 454_NcoI_F and 
BamHI_FUS_R and cloned into the petM11-His6-ZZ backbone derived from petM11-His6-ZZ-Tev-FUS-
RGG3-PY. 
To generate pETM11-His6-ZZ-Tev-TNPO1, the human TNPO1 cDNA sequence was codon optimized for 
protein production in bacterial cells and flanked by NcoI and BamHI restriction sites (Genscript). The 
coding region was cloned into a modified pETM11 bacterial expression vector, which includes an N-
terminal His6, protein A (ZZ) tag and a TEV protease cleavage site. 
To generate GCR2-tagRFP2-FUS, the EGFP2-sequence in a modified EGFP-C1 vector containing a GCR2-
EGFP2-cassette (Hutten et al., 2008) was replaced sequentially with two cDNAs coding for tagRFP 
(primer: TagRFP_AgeI/TagRFP_EcoRV and TagRFP_Spe/ TagRFP_AgeI_R). FUS wt or P525L was 
inserted via EcoRV/BamHI sites replacing the NLS sequence (primer: FUS_EcoRV_f with either 
FUS_BamHI_R or FusP525L_BamHIr). 
The pRSV-EGFP-M9M construct was generated by replacing the CMV-promoter in pEGFP-M9M 
(Dormann et al., 2010) by a RSV promoter sequence (gift from M. Kiebler) via AseI/NheI. 
For detailed list of bacterial expression constructs as well as primer sequences see appendix. 
 
4.2 Recombinant protein expression and purification 
All bacterial cultures were grown at 37°C under constant shaking (140-160 rpm) in standard lysogeny 
broth (LB) medium. Before induction of protein expression, cultures were cooled down to the 
temperature indicated for the respective protein. 
For expression of recombinant MBP-FUS-His6 (WT, ΔRGG3-PY, and all-KGG) and MBP-FUS-EGFP-His6 
(WT and P525L), the respective bacterial expression vectors were transformed into E. coli BL21-DE3-
RIPL and BL21-DE3-Rosetta-LysS, respectively, and grown in standard lysogeny broth (LB) medium. At 
an OD (600 nm) of ~ 0.8, cells were induced with 0.1 mM IPTG for 22 h at 12°C. Cells were lysed in 
resuspension buffer (50 mM Na2HPO4/NaH2PO4, pH 8.0, 300 mM NaCl, 10 µM ZnCl2, 40 mM imidazole, 
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4 mM βME) + 10 % glycerol and tandem-affinity purification using HisTrap FF columns (GE Healthcare) 
and amylose resin (NEB) was performed. The protein was washed with resuspension buffer and eluted 
in resuspension buffer including 250 mM imidazole and 20 mM maltose, respectively.  
For expression of recombinant His6-TEV, E. coli BL21-Ros-LysS were transformed with the expression 
plasmid and grown in standard LB medium. Induction of expression was induced at OD (600 nm) of 
~0.6 with 1 mM IPTG overnight at 20°C. Cells were lysed in lysis buffer (50 mM Tris pH 8.0, 200 mM 
NaCl, 20 mM imidazole, 10% glycerol, 4 mM β-mercaptoethanol, 1 µg/ml each of aprotinin, leupeptin 
and pepstatin) by addition of lysozyme and sonification. The lysate was incubated in the presence of 
RNase A (0.1mg/ml final concentration) for 30 min at RT. His6-TEV was purified using Ni-NTA beads 
and washed using lysis buffer containing 1 M NaCl. His6-TEV was eluted in lysis buffer (pH 8.5) 
containing 800 mM imidazole and dialyzed against storage buffer (20 mM Tris-HCl pH 7.4; 150 mM 
NaCl; 20% glycerol, 2 mM DTT). 
For expression of the RGG3-PY domain, pETM11-His6-ZZ-FUS-RGG3-PY (WT and KGG3-PY) were 
transformed into E. coli BL21-DE3 Rosetta and were expressed at 37 °C for 4 h. Cells in resuspension 
buffer were lysed by boiling for 20 min at 90 °C, as boiling lysis allows removal of folded proteins from 
cell lysates, while intrinsically disordered proteins stay soluble (Livernois et al., 2009). His6-Z-tagged 
proteins were bound to nickel-nitrilotiacetic (Ni-NTA) resin (Qiagen), incubated with Benzonase® 
Nuclease (Sigma) overnight at 4°C in Benzonase buffer (50 mM Na2HPO4/NaH2PO4, pH 8.0, 50 mM 
NaCl, 2 mM MgCl2) and subjected to high salt washes with resuspension buffer containing 2 M NaCl 
and then eluted in resuspension buffer + 250 mM imidazole. In order to proteolytically remove the 
His6-Z-tag, His6-TEV protease (2.5 mg) was added to eluted His6-Z-RGG3-PY proteins and dialyzed 
against TEV cleavage buffer (20 mM Na2HPO4/NaH2PO4, pH 8.1, 150 mM NaCl, 5% glycerol, 4 mM βME) 
overnight at 4 °C. His6-TEV and His6-Z-tag were removed by incubation with Ni-NTA resin (Qiagen), 
while untagged RGG3-PY remains in the supernatant. 
For ITC or NMR experiments, pETM11-His6-Z-FUS-RGG3-PY (WT or P525L) were transformed into E. 
coli BL21-DE3 Star strain. For the unlabeled protein, cells were grown for 1 day at 37°C in standard 
lysogeny broth (LB) medium. At an OD (600 nm) of ~ 0.8, cells were induced with 0.1 mM IPTG for 22 
h at 12°C. To obtain 15N labeled protein, cells were grown for 1 day at 37°C in minimal medium (100 
mM KH2PO4, 50 mM K2HPO4, 60 mM Na2HPO4, 14 mM K2SO4, 5 mM MgCl2; pH 7.2 adjusted with HCl 
and NaOH with 0.1 dilution of trace element solution (41 mM CaCl2, 22 mM FeSO4, 6 mM MnCl2, 3 
mM CoCl2, 1 mM ZnSO4, 0.1 mM CuCl2, 0.2 mM (NH4)6Mo7O24, 17 mM EDTA) supplemented with 6 g 
of 12C6H12O6 and 1 g of 15NH4Cl (Sigma). At an OD (600 nm) of ~ 0.8, cells were induced with 0.5 mM 
IPTG for 16 h at 20°C. Cell pellets were harvested and sonicated in denaturing buffer containing 50 
91 
 
mM Tris-HCl pH 7.5, 150 mM NaCl, 20 mM imidazole, 2 mM Tris(2-carboxyethyl)phosphine (TCEP), 
20% glycerol and 6 M urea. His6-ZZ proteins were purified using Ni-NTA agarose (Qiagen) and eluted 
in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 200 mM imidazole, 2 mM TCEP and subjected to TEV 
treatment. Untagged proteins were then isolated performing a second affinity purification using 
NiNTA beads. A final exclusion chromatography purification step was performed in the buffer of 
interest on a gel filtration column (Superdex peptide, GE Healthcare). 
For expression of recombinant His6-TNPO1, the bacterial expression vector pETM11-His6-ZZ-Tev-
TNPO1 was transformed into E. coli BL21-DE3 Star cells. Expression cultures of 1 l volume were grown 
for 2 days in minimal medium (100 mM KH2PO4, 50 mM K2HPO4, 60 mM Na2HPO4, 14 mM K2SO4, 5 
mM MgCl2; pH 7.2 adjusted with HCl and NaOH with 0.1 dilution of trace element solution (41 mM 
CaCl2, 22 mM FeSO4, 6 mM MnCl2, 3 mM CoCl2, 1 mM ZnSO4, 0.1 mM CuCl2, 0.2 mM (NH4)6Mo7O24, 17 
mM EDTA) supplemented with 6 g of glucose and 3 g of NH4Cl. Cells were diluted to an OD (600 nm) 
of 0.8 and induced with 0.5 mM IPTG followed by protein expression for 4 h at room temperature. 
His6-TNPO1 was purified using Ni-NTA agarose (Qiagen) and eluted in 50 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 200 mM imidazole, 2 mM TCEP. A final size exclusion chromatography step was performed in 50 
mM Tris-HCl pH 7.5, 150 mM NaCl, 20 mM imidazole, 2 mM TCEP, 20% glycerol on a gel filtration 
column (Hiload 16/600 Superdex 200 pg, GE Healthcare). Note, that for ITC/NMR experiments, the 
His-tag was removed by TEV cleavage.  
For expression of recombinant His6-PRMT1, the pET28b-PRMT1 vector was transformed into E. coli 
BL21-DE3 Star and 1 l expression culture was grown in LB medium. Cells were induced at an OD (600 
nm) of 0.8 with 0.5 mM IPTG followed by protein expression for 16 h at 20°C. Cell pellets were 
harvested and sonicated in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 20 mM imidazole, 2 mM TCEP, 20% 
glycerol. His6-PRMT1 was purified using 5 mL HisTrap HP column (GE Healthcare), washed with lysis 
buffer supplemented with 1 M NaCl, and eluted with a gradient of 20-500 mM imidazole in 50 mM 
Tris-HCl pH 7.5, 1 M NaCl, 2 mM TCEP.  Subsequently, elution fractions were pool and concentrated 
to ≤ 15 ml and applied to a HiPrep Desalting Column 26 (GE healthcare) to in vitro methylation (IVM) 
buffer. Alternatively, elution fractions of HisTrap column were further purified by size exclusion 
chromatography as described for TNPO1 above. 
Protein concentrations were determined from their absorbance at 280 nm using ε predicted by the 
ProtParam tool. For all assay that involved addition of RNA, 260/280 nm ratios of purified proteins 
were between 0.6 and 0.8. 
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4.3 In vitro methylation 
FUS proteins and PRMT1 were dialyzed against in vitro methylation (IVM) buffer containing 20 mM 
Na2HPO4/NaH2PO4, pH 8.1, 150 mM NaCl, 5% glycerol, 1 mM EDTA, 1 mM DTT or 50 mM 
Na2HPO4/NaH2PO4, pH 8.0, 150 mM NaCl, 2 mM TCEP for ITC and NMR experiments. FUS proteins 
were in vitro methylated by incubating with PRMT1 and 1 mM S-adenosyl-L-methionine (SAM) 
overnight at room temperature. PRMT1 was used at a molar ratio of 2:1 for MBP-FUS, 1.5:1 for RGG3-
PY or KGG3-PY (used in droplet and turbidity assays) and 0.2:1 for RGG-PY proteins used in ITC or NMR 
experiments. For RGG3-PY proteins, PRMT1 was removed by boiling the samples for 10 min at 90°C. 
 
4.4 In vitro transcription 
MAPT RNA and ASH1 E3-51 RNA were produced by in vitro transcription (MEGAshortscript Kit; 
Ambion) using linearized pGM3 mTauI9-28560 or primers P45 and P132, respectively. 
For electrophoretic mobility shift assays (EMSAs) and filter-binding assays the ASH1 E3-51 RNA was 
radioactively labeled using [γ32P]ATP and T4 polynucleotide kinase (NEB). The RNA was separated 
from free nucleotides using NucAway spin columns (Ambion). 
 
4.5 In vitro phase separation assays 
4.5.1 Droplet assay for microscopy 
Purified RGG3-PY or KGG3-PY and His6-TNPO1 were buffer exchanged to droplet buffer (20 mM 
Na2HPO4/NaH2PO4, pH 7.5, 75 mM NaCl, 2.5% glycerol, 1 mM DTT) and concentrated in Amicon® Ultra 
Centrifugal Filter Devices (Millipore). For droplet formation of C-terminal RGG3-PY proteins, proteins 
were diluted to indicated concentrations and supplemented with in vitro transcribed MAPT RNA (a 
known FUS target RNA, Orozco et al., 2012) at a molar ratio of 1:50, as this ratio was found to 
maximally promote phase separation. His6-TNPO1, His6-Importin 5, α-FUS-RGG3, or His6-PRMT1, 
respectively, were used at equimolar concentrations to FUS. 
Purified full-length MBP-FUS-EGFP (WT or P525L) or MBP-FUS were diluted in droplet buffer including 
150 mM NaCl, if not otherwise stated in the figure legend. Full-length FUS was only supplemented 
with RNA when explicitly mentioned in the figure legend (Fig. 16F and 16G). Phase separation was 
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induced by addition of acTEV protease (Invitrogen) at 25°C. With the exception of Figure 18A and 18E, 
where widefield fluorescence microscopy was applied, imaging of EGFP-tagged FUS was performed by 
confocal microscopy. Non-fluorescent FUS-droplets were imaged by phase contrast microscopy.  
Note that phase separation properties, i.e. critical concentration for droplet formation, differ slightly 
between different protein preparations. 
 
4.5.2 In vitro aging assay 
To induce aging of FUS-EGFP droplets, TEV-cleaved samples were subjected to 700 rpm on an orbital 
shaker at RT for 8h and additionally mixed by pipetting up and down every hour. Samples were imaged 
in 384-well plates by confocal microscopy. 
 
4.5.3 Turbidity assay 
Phase separation of RGG3-PY and MBP-FUS in the absence or presence of equimolar amounts of His6-
TNPO1, His6-Importin 5, α-FUS-RGG3, or His6-PRMT1, respectively, was induced as described above 
for the droplet assay. Turbidity measurements were conducted at 600 nm in 384-well plates with 20 
µl samples using a BioTek Power Wave HT plate reader. All experiments were performed in triplicate. 
 
4.5.4 Sedimentation assay 
For sedimentation analysis of full-length FUS, the MBP-tag of 1 µM purified MBP-FUS protein in the 
absence or presence of equimolar amounts of His6-TNPO1, His6-Importin 5, α-FUS-RGG3, or His6-
PRMT1, respectively, was cleaved using 0.1 mg/ml His6-TEV in 50 µl reaction buffer (50 mM Tris pH 8, 
0.5 mM EDTA, 1 mM DTT) for 60 min at 30 °C, followed by centrifugation at room temperature for 15 
min at 16,000-20,000 g. Equal volumes of supernatant and pellet fraction were analyzed by SDS-PAGE 
and either SyproRuby stain (Fig. 11D, 18B) or Western Blot with a FUS-specific antibody (4H11) (Fig. 
13B).  
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4.6 Cell culture and transfection 
HeLa Kyoto cells for transient transfection experiments and HeLa-P4 cells (Charneau et al., 1994) for 
semi-permeabilized cell assays were grown in DMEM high glucose GlutaMAX (Invitrogen) 
supplemented with 10% dialyzed FBS, or 10% standard FBS and 10 µg/ml gentamicin, respectively. 
Cells were maintained in a humidified incubator at 37°C with 5% CO2. Transient transfections were 
performed using Turbofect following manual instructions. Note, that for transfection of GCR2-tagRFP2-
FUS constructs low DNA amounts (20% GCR2-tagRFP2-FUS, 80% plasmid coding for EGFP/EGFP-
bimax/EGFP-M9M) to minimize aggregation of FUS due to overexpression.  
 
4.7 Semi-permeabilized cell assay 
HeLa P4 cells were grown on poly-L-lysine coated 12 mm coverslips, permeabilized with 0.003-0.005% 
digitonin in KPB (20 mM potassium phosphate pH 7.4, 250 mM sucrose, 5 mM Mg(OAc)2, 200 mM 
KOAc, 1 mM EGTA, 2 mM DTT and 1 µg/ml each aprotinin, pepstatin and leupeptin). After several 
washes to remove soluble proteins (4 x 4 min in KPB on ice), nuclear pores were blocked by 15 min 
incubation with 200 µg/ml wheat germ agglutinin (WGA) on ice. Cells were then incubated for 30 min 
at room temperature with 125 nM MBP-FUS-EGFP in the absence or presence of 1.25 µM His6-TNPO1 
in KPB. Note that a 10-fold excess of TNPO1 was required for efficient shielding of FUS, possibly due 
to other RBPs present in SGs that bind to TNPO1. Subsequently, cells were washed (3 x 5 min in KPB 
on ice) to remove unbound MBP-FUS-EGFP. SGs were visualized by immunostaining of G3BP1. Note 
that G3BP1 immunostaining also served as a control for proper permeabilization, as non/poorly-
permeabilized cells still show diffuse cytoplasmic G3BP1 staining. Cells were imaged by confocal 
microscopy using identical settings for reactions within the same experiment. 
 
4.8 Filter-binding assay 
The indicated protein concentrations were incubated with 0.5 nM of in vitro transcribed, radiolabeled 
ASH1 E3-51 RNA in a total volume of 80 µL in filter-binding buffer (20 mM Na phosphate, 50 mM NaCl, 
2 mM DTT, pH 7.5). Samples were applied to nitrocellulose and nylon membranes, using a Dot Blot 
Aparatus (BioRad), and washed twice with 80 µl filter-binding buffer. Membranes were air-dried and 
analyzed by phosphorimaging using a Fujifilm FLA-3000 scanner.  
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4.9 Electrophoretic mobility shift assay (EMSA) 
Experiments were conducted according to (Niedner et al., 2013). Increasing protein concentrations 
(0.35 - 9 µM) were mixed with 5 nM of radiolabeled ASH1 E3-51 RNA in droplet buffer (20 mM 
Na2HPO4/NaH2PO4, pH 7.5, 75 mM NaCl, 1 mM DTT) with 4% glycerol in a final volume of 20 µl. The 
samples were incubated for 25 min at room temperature and afterwards resolved on a 6% native TBE-
PAGE gel in 1x TBE running buffer. Gels were incubated in fixation solution [10% (v/v) acetic acid, 30% 
(v/v) methanol] for 15 min and vacuum dried and subsequently analyzed with radiograph films. 
 
4.10 Immunostaining or Immunocytochemistry 
Cells grown on coverslips were either fixed ~20 h after transfection or after the semi-permeabilized 
cell assay in 3.7% formaldehyde/PBS buffer for 7-10 min at RT and permeabilized in 0.5% TX-100/ PBS 
for 5 min at room temperature. Cells were blocked for 10 min in blocking buffer (1% donkey serum in 
PBS/ 0.1% Tween-20) and incubated with primary antibodies in blocking buffer for 1-2h at RT or 
overnight at 4°C. Secondary antibodies were diluted in blocking buffer and incubated for 1h at room 
temperature. Washing steps after antibody incubation were performed with PBS/0.1% Tween-20. 
DNA was stained with DAPI at 0.5 µg/ml in PBS and cells mounted in ProLong™ Diamond Antifade. 
Imaging was performed by confocal microscopy. 
For detailed list of used antibodies see appendix. 
 
4.11 Microscopy 
4.11.1 Phase contrast and wide-field fluorescence microscopy 
For imaging of FUS droplets, samples were placed in sealed sample chambers formed by a hole 
punched into a double-sided sticky tape, taped onto a glass slide and sealed with a coverslip.  
For imaging of RGG3-PY and FUS droplets by phase contrast microscopy, a 63x/1.40 Oil/Ph3 objective 
was used; FUS-EGFP droplets in Fig. 18A and Fig. 18E were imaged by fluorescence microscopy using 
a 63x/1.40 Oil objective, both on an Axio Oberver.Z1 wide-field fluorescence microscope and an 
AxioCam 506 (Zeiss, Oberkochen, Germany).  
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4.11.2 Confocal microscopy 
Confocal microscopy was performed at the Bioimaging core facility of the Biomedical Center with an 
inverted Leica SP8 microscope, equipped with lasers for 405, 488, 552 and 638 nm excitation. Images 
were acquired using two-fold frame averaging with a 63x1.4 oil objective, and an image pixel size of 
71 nm or 59 nm for droplets and cells, respectively. The following fluorescence settings were used for 
detection: DAPI: 419-442 nm, GFP: 498-533 nm, RFP/Alexa 555: 562-598 nm, Alexa 647: 650-700 nm. 
If applicable, recording was performed sequentially to avoid bleed-through using a conventional 
photomultiplier tube.  
 
4.11.3 Fluorescence Recovery after Photobleaching (FRAP)  
In contrast to all other experiments in this study, droplet buffer including 75 mM NaCl was 
supplemented with 150 mg/ml Ficoll 400 in order to obtain droplets of similar size and shape for FRAP 
experiments. Experiments were performed on an inverted microscope (Axio Observer.Z1; Carl Zeiss, 
Oberkochen, Germany) equipped with a confocal spinning disk unit (CSU-X1; Yokogawa, Tokyo, Japan) 
and a Zeiss 100x/1.46 Oil Ph3 oil immersion lens. Images were acquired in the streaming mode using 
the 488 nm SD laser line and fixed exposure times of 50 ms and an EM-CCD camera (EvolveDelta; 
Photomoetrics) at bin 1x1. For localized photobleaching (“half-bleach”), a laser scanning device (UGA-
42 Geo; Rapp OptoElectronic, Hamburg, Germany) was used. The “Geo” module allowed for 
simultaneous laser illumination within hardware-defined shapes of different sizes. Here, a square-like 
shape with an illumination size of ~4 µm in the sample was selected. For each experiment, half of the 
observed structure was bleached to approximately 50% of the initial intensity using a 473 nm diode 
laser (DL-473/75; Rapp OptoElectronic, Hamburg, Germany). 
 
4.11.4 Transmission electron microscopy (TEM) 
Carbon coated copper grids (carbon film coated 400 mesh copper grids, Science Services) were glow 
discharged for 2 min in a Harrick plasma cleaner (PDC-32G-2) to facilitate protein adsorption. MBP-
FUS (7 µM) -/+ TNPO1 (7 µM) was incubated with TEV protease for 90 min and subsequently diluted 
to 2 µM and deposited on the grid surface. The grid was washed twice in a drop of double distilled 
water, blotted shortly using filter paper. Fixing the grid by inverse forceps, 3 µl of 1% uranyl acetate 
were added to the grid for 30 s. After blotting, the grid was air dried for at least 30 min. Mosaics of 
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three by three images were obtained at a magnification of 60.000 using a JEOL JEM 1400-plus electron 
microscope at 120 kV (TEM Center software, JEOL). The Sight X Viewer (JEOL) and ImageJ (NIH) 
Software packages were applied for mosaic stitching. 
 
4.12 Nuclear magnetic resonance (NMR) 
All proteins / RNA samples were prepared in 20 mM Na2HPO4/NaH2PO4 pH 7.5, 75 mM NaCl, 2.5% 
glycerol, 1 mM DTT and 10% 2H2O added for the lock signal. NMR experiments were performed at 
25°C on Bruker 700 MHz spectrometer. Spectra were processed using Topspin 3.5 and Mnova 11. 
 
4.13 Isothermal Calorimetry (ITC) 
All protein samples were prepared either in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl and 2 mM Tris(2-
carboxyethyl)phosphine (TCEP) or in 50 mM Tris-HCl (pH 7.5), 1 M NaCl and 2 mM TCEP. ITC 
measurements were carried out on a MicroCal VP-ITC instrument (Microcal, Northhampton, USA) with 
36 rounds of 8 μl injections at 25 °C.  Integration of peaks corresponding to each injection, subtraction 
of the contribution of protein dilution and correction for the baseline were performed using the 
Origin-based 7.0 software provided by the manufacturer. Curve fitting was done with a standard one-
site model and gives the equilibrium binding constant (Ka), and enthalpy of the complex formation 
(ΔH). 
 
4.14 Quantification and analysis 
4.14.1 Statistics 
Statistical analyses were performed in GraphPad Prism 5. For 2-grouped analyses, for which control 
and treatment groups were handled in parallel, a paired t-test was applied. If measurements were not 
normally distributed, a non-parametric test (Mann-Whitney) was chosen. 1-way ANOVAs were applied 
to multi-group comparisons. Here, a Bonferroni post-test was applied when significance between all 
groups was analyzed, whereas a Dunnett’s multiple comparison test was applied when the significance 
of all values to a single condition was analyzed. 
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4.14.2 Image analysis 
Confocal images were acquired using LAS X (Leica), all other images were acquired in ZEN2 (Zeiss). For 
illustration of FRAP of FUS-EGFP droplets, images were displayed as heat map and processed using the 
interpolation function in ZEN2. All other images were processed using Image J/Fiji software applying 
linear enhancement for brightness and contrast. For quantitative measurements, equal exposure 
times and processing conditions for respective channels were applied to all samples within one 
experiment. For better visibility, in some figures the individual channels were displayed in artificial 
colors as indicated in the figure legends. 
 
4.14.3 Droplet quantification 
Confocal images were imported in the public-domain software Image J/Fiji (Schindelin et al., 2012) 
and a Median filter with radius 2 was applied. Huang auto threshold method providing best coverage 
of the droplet area was applied. Structures touching the edge of the image section and/or smaller 
than 0.5 µm2 were excluded from particle analysis. If required, a watershed analysis was performed. 
 
4.14.4 Quantification of MBP-FUS-EGFP in SGs 
For quantitative measurements, equal exposure times and processing conditions for respective 
channels were applied to all samples within one experiment. In Image J/Fiji, ROIs corresponding to 
SGs were identified using the wand tool by G3BP1 staining and mean fluorescence intensity in the 
EGFP channel was determined. For each condition, at least 10 cells and at least 28 SGs were analyzed. 
For display of fluorescence intensity of FUS in SGs, measured fluorescence values were log 
transformed to achieve a more balanced spread. Statistical analyses were performed in GraphPad 
Prism 5.  
 
4.14.5 Quantification of filter-binding assays 
Membranes from filter-binding assays were scanned by a FujiFilm FLA-3000 imaging machine. 
Quantification of signal intensities was carried out using the Dot Blot Analyzer macro within the Image 
J software. For binding experiments, the raw intensities of the individual dots on the nitrocellulose 
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membrane were normalized against the raw intensity measured for the highest FUS concentration. 
For outcompetition experiments, a ratio of the intensity on the nitrocellulose membrane versus the 
intensity on nitrocellulose and nylon membrane was determined. The obtained relative intensities 
were plotted against the protein concentration and fitted using the non-linear curve-fitting tool in 
Origin software.  
 
4.14.6 FRAP analysis 
Intensities of bleached areas were corrected both for bleaching due to imaging over time and 
background noise. The corresponding calculations were performed with the FIJI/ImageJ macro 
“TimeSeries Analyzer” by calculating the fluorescence intensity over time (I(t)) as follows:  
I(t) = [ROI1(t)–ROI3(t)]/[ROI2(t)–ROI3(t)] 
with ROI1 giving the averaged gray values of the bleached area, and ROI2 corresponds to the averaged 
gray values of the total droplet. ROI3 corresponded to the averaged background values. Obtained 
values were further normalized to the initial fluorescence by dividing I(t) by the mean gray value of 
the initial 4 time steps before bleaching <I(1-4)>. 
 
4.14.7 Densitometry measurements  
To determine the solubility of FUS by sedimentation analysis of TEV-cleaved MBP-FUS, densitometry 
measurements of band intensities after Sypro-Ruby staining or FUS immunoblotting of supernatant 
and pellet fractions, respectively, were performed using standard plugins in the Image J software. The 
ratio of signal intensity of the FUS bands in the supernatant and pellet was determined. The lower the 
S/P ratio the higher the degree of phase separation. 
For detailed list of used software and algorithms see appendix. 
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5 APPENDIX 
Antibodies 
Table 4: Summary of used antibodies. 
Name Source Host species 
FUS (4H11) 
Santa Cruz  
(RRID:AB_2105208) 
mouse, monoclonal 
UMA-FUS (14G1) 
D. Dormann;  
(Suarez-Calvet et al., 2016) 
rat, monoclonal 
MMA-FUS (15E11) 
D. Dormann;  
(Suarez-Calvet et al., 2016) 
rat, monoclonal 
ADMA-FUS (9G6) 
D. Dormann;  
(Dormann et al., 2012) 
rat, monoclonal 
G3BP1 
Proteintech 
(RRID:AB_2232034) 
rabbit, polyclonal 
GFP (K3-184-2) 
A. Noegel;  
(Noegel et al., 2004) 
mouse 
RFP 
Thermo  
(RRID:AB_2315269) 
rabbit, polyclonal 
TIA1 
Santa Cruz  
(AB_2201433) 
goat, polyclonal 
Alexa 555 Donkey anti-rabbit 
Thermo 
 (RRID:AB_162543) 
donkey, polyclonal 
Alexa 647 Donkey anti-rabbit 
Thermo  
(RRID:AB_2536183) 
donkey, polyclonal 
Alexa 647 Donkey anti-goat 
Thermo  
(RRID:AB_2535864) 
donkey, polyclonal 
IRDye 680RD Donkey anti-
Mouse IgG 
LI-COR  
(RRID:AB_10953628) 
donkey, polyclonal 
IRDye 680RD Goat anti-Rat IgG 
LI-COR  
(RRID:AB_10956590) 
goat, polyclonal 
IRDye 800VW Donkey anti-
Mouse IgG 
LI-COR  
(RRID:AB_621847) 
donkey, polyclonal 
 
Bacterial strains 
Table 5: Summary of used bacterial strains. 
Name Source 
BL21-Codon Plus (DE3)-RIPL Agilent Technologies 
BL21-DE3-Rosetta-LysS D. Niessing 
BL21-DE3 Rosetta C. Haass 
BL21-DE3 Agilent Technologies 
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Cell lines 
Table 6: Summary of used cell lines. 
Name Source 
HeLa P4 R. Kehlenbach, (Charneau et al., 1994) 
HeLa Kyoto I. Poser and A. Hyman 
 
Recombinant DNA 
Table 7: Summary of used recombinant DNA. 
Name Source encoded protein 
pMal-Tev-Flag-FUS-Tev-His6 
M. Ruepp; this Ph.D. thesis;  
(Hofweber et al., 2018) 
MBP-FUS-His6 WT 
pMal-Tev-FUS (WT)-EGFP-Tev-
His6 
this Ph.D. thesis;  
(Hofweber et al., 2018) 
MBP-FUS-EGFP-His6 WT 
pMal-Tev-FUS (P525L)-EGFP-
Tev-His6 
this Ph.D. thesis;  
(Hofweber et al., 2018) 
MBP-FUS-EGFP-His6 P525L 
pMal-C2-Tev-Flag-FUS-ΔRGG3-
PY-Tev-His6 
this Ph.D. thesis;  
(Hofweber et al., 2018) 
MBP-FUS-His6 ΔRGG3-PY 
pMal-C2-Tev-Flag-FUS-all-KGG-
Tev-His6 
this Ph.D. thesis;  
(Hofweber et al., 2018) 
MBP-FUS-His6 all-KGG 
pEX-A2-linker-EGFP-His6 this Ph.D. thesis  
petM11-His6-ZZ-Tev-FUS-RGG3-
PY WT 
D. Dormann;  
(Dormann et al., 2012) 
His6-Z-FUS RGG3-PY WT 
petM11-His6-ZZ-Tev-FUS-RGG3-
PY P525L 
D. Dormann;  
(Dormann et al., 2012) 
His6-Z-FUS RGG3-PY P525L 
petM11-His6-ZZ-Tev-FUS-KGG3-
PY 
this Ph.D. thesis;  
(Hofweber et al., 2018) 
His6-Z-FUS KGG3-PY 
petM11-His6-ZZ-Tev-TNPO1 
T. Madl;  
(Suarez-Calvet et al., 2016) 
 
pET28b-PRMT1 
E. Wahle;  
(Zhang and Cheng, 2003) 
His6-PRMT1 
His6-TEV in a pET-24d(+) vector A. Geerlof  
pEGFP-bimax 
D. Dormann;  
(Dormann et al., 2010) 
EGFP-bimax 
pRSV-EGFP-M9M 
S. Hutten; this Ph.D. thesis;  
(Hofweber et al., 2018) 
EGFP-M9M 
GCR2-tagRFP2-FUS WT 
S. Hutten; this Ph.D. thesis;  
(Hofweber et al., 2018) 
GCR2-tagRFP2-FUS WT 
GCR2-tagRFP2-FUS P525L 
S. Hutten; this Ph.D. thesis;  
(Hofweber et al., 2018) 
GCR2-tagRFP2-FUS P525L 
pGM3 mTauI9-28560 
D. Edbauer;  
(Orozco et al., 2012) 
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PCR primers and oligonucleotides 
Table 8: Summary of used PCR primers and oligonucleotides. 
Name Sequence 
SalI_flag_F AAAAGTCGACATGGACTACAAGGACGACGATG 
HindIII_Tev-His6- -FUS_R 
GTGCCAAGCTTTCAGTGATGATGATGATGATGGCTTTGGAAA
TACAGATTTTCATACGGCCTCTCCCTGCGATCC 
Tev_F AATTCGGCGGCGAAAATCTGTATTTCCAAAGCG 
Tev_R TCGACGCTTTGGAAATACAGATTTTCGCCGCCG 
SalI_FUS_F AAAAGTCGACATGGCCTCAAACGATTATA 
BamHI_FUS_R TTTTGGATCCATACGGCCTCTCCCT 
FUS wt-EGFP mut P525L_F AGGGAGAGGCTGTATGGATCCGGCGCACCTGGCTCA 
FUS wt-EGFP mut P525L_R TGAGCCAGGTGCGCCGGATCCATACAGCCTCTCCCT 
HindIII_FUS453X-Tev-His6_R 
TTTTAAGCTTTCAGTGATGATGATGATGATGGCTTTGGAAATA
CAGATTTTCGCCATCTGGTTTAGGGGCCTTACA 
XhoI_FUS_F AAAACTCGAGATGGCCTCAAACGATTATACCCAAC 
FUS 454_NcoI_F GATACCATGGGCCCAGGAGGGGGACCAGGTGG 
P45 AATTTAATACGACTCACTATAG 
P132 
ATTGTTTCGTGATAATGTCTCTTATTAGTTGAAAGAGATTCAG
TTATCCATCTATAGTGAGTCGTATTAAATT 
TagRFP_AgeI TTTTTACCGGTCGCCACCATGGTGTCTAAGGGCGA 
TagRFP_EcoRV_R TTTTTGATATCCATTAAGTTTGTGCCCCAGTTT 
TagRFP_SpeI TTTTTACTAGTCATGGTGTCTAAGGGCGA 
TagRFP_AgeI_R TTTTTACCGGTCCATTAAGTTTGTGCCCCAGTTT 
FUS_EcoRV_F AATTCGATATCCCATGGCCTCAAACGATTATACCCAACAAG 
FUS_BamHI_R CGGGATCCTTAATACGGCCTCTCCCTGCGATCC 
FusP525L_BamHIr TTTTTGGATCCTTAATACAGCCTCTC 
MBP_NcoI_F CGCCACCATGAA AACG 
MBPLinker_Tev_EcoRI 
GAATTCTGAAATGCCTTGGAAATACAGATTTTCCCCGAGGTTG
TTGTTATTGTATTGTT 
(UG)10 RNA UGUGUGUGUG UGUGUGUGUG 
 
Recombinant proteins 
Table 9: Summary of used recombinant proteins. 
Name Source 
AcTEV Protease Thermo 
GST-Precission Geyer 
Benzonase Nuclease Sigma 
Importin 5 D. Görlich; (Jakel et al., 2002) 
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Chemicals and reagents 
Table 10: Summary of used chemicals and reagents. 
Name Source 
S-(5′-Adenosyl)-L-methionine p-
toluenesulfonate 
Sigma 
TEM grids, carbon film coated, approx. 5-6 nm, 
400 Mesh, Cu 
Science Services 
4% Uranyl Acetate Solution Science Services 
[γ32P]ATP Hartmann Analytic 
DMEM, high glucose, GutaMAX™ supplement Thermo 
Fetal Bovine Serum, qualified, heat inactivated, 
E.U.-approved, South America Origin 
Thermo 
Fetal Bovine Serum, dialyzed, US origin Thermo 
Gentamicin (10 mg/mL) Thermo 
TurboFect™ Transfection Reagent Thermo 
Aprotinin Roth 
Leupeptin hemisulfate Roth 
Pepstatin A Roth 
Lectin from Triticum vulgaris (Wheat germ 
agglutinin, WGA) 
Sigma 
Digitonin Calbiochem 
ProLong™ Diamond Antifade Mountant Thermo 
DAPI Sigma 
Poly-L-Lysine Sigma 
Sypro-Ruby Protein Gel Stain Sigma 
 
Software and Algorithms 
Table 11: Summary of used software and algorithms. 
Name Source 
ImageJ (Fiji) NIH; (Schindelin et al., 2012) 
Image Studio Lite Li-COR 
Zen2 blue edition (lite) Zeiss 
LAS X Leica 
GraphPad Prism5 GraphPad Software, Ink 
PONDR® VL-XT 
Molecular Kinetics, Inc., Washington State 
University; WSU Research Foundation 
TEM Center Software JEOL 
Sight X Viewer Software JEOL 
Origin OriginLab 
TopSpin3.1 Bruker 
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